

```

* * * * *
FILE 'USPAT' ENTERED AT 10:13:07 ON 03 FEB 97
* * * * *
*           W E L C O M E   T O   T H E
*           U . S .   P A T E N T   T E X T   F I L E
* * * * *

```

```

=> s (crohn(w)s(w)disease) and tnf
      734 CROHN
      1406905 S

```

```

      47544 DISEASE
      686 CROHN(W)S(W)DISEASE
      1454 TNF

```

```

L1      69 (CROHN(W)S(W)DISEASE) AND TNF
=> s l1 and (treatment or treating or treat or therapy or therapeutic)
      339702 TREATMENT
      172355 TREATING
      57807 TREAT
      30268 THERAPY
      45043 THERAPEUTIC

```

```

L2      68 L1 AND (TREATMENT OR TREATING OR TREAT OR THERAPY OR THERAP
EUT
      IC)

```

```

=> s (crohn(w)s(w)disease) (p)tnf
      734 CROHN
      1406905 S

```

```

      47544 DISEASE
      1454 TNF

```

```

L3      26 (CROHN(W)S(W)DISEASE) (P)TNF
=> s l3(p)(treating or treat or therapeutic or therapy or treatment)
      172355 TREATING
      57807 TREAT
      45043 THERAPEUTIC
      30268 THERAPY
      339702 TREATMENT

```

```

L4      6 L3(P)(TREATING OR TREAT OR THERAPEUTIC OR THERAPY OR TREATM
ENT
      )

```

```

=> d l4 1-6

```

1. 5,541,219, Jul. 30, 1996, 1-Alkoxy-2-(alkoxy- or cycloalkoxy-)-4-(cyclothioalkyl- or cyclothioalkenyl-) benzenes as inhibitors of cyclic AMP phosphodiesterase and tumor necrosis factor; Garry Fenton, et al., 514/432, 431, 438, 445, 446; 549/9, 13, 28, 62, 66, 67, 78 [IMAGE AVAILABLE]

2. 5,521,315, May 28, 1996, Olefin substituted long chain compounds; Gail Underiner, et al., 546/243; 544/285; 546/242 [IMAGE AVAILABLE]

3. 5,478,827, Dec. 26, 1995, Pyrazole derivatives; Teruo Oku, et al., 514/243; 544/184 [IMAGE AVAILABLE]

4. 5,470,878, Nov. 28, 1995, Cell signaling inhibitors; John Michnick, et al., 514/558, 258, 262, 274, 299, 315, 418, 425, 529, 552, 561, 613, 617, 626, 629, 669; 544/254, 285, 301; 546/183, 243; 548/486, 556 [IMAGE AVAILABLE]

AVAILABLE]

5. 5,409,934, Apr. 25, 1995, Xanthine derivatives; David G. Smith, et al., 514/263, 826; 544/267, 268, 272 [IMAGE AVAILABLE]

6. 5,356,897, Oct. 18, 1994, 3-(heteroaryl)-pyrazololi[1,5-alpyrimidines; Teruo Oku, et al., 514/258; 544/263, 281 [IMAGE AVAILABLE]
=> d l3 1-6 kwic

US PAT NO: 5,593,992 [IMAGE AVAILABLE]

L3: 1 of 26

SUMMARY:

BSUM(6)

Excessive or unregulated **TNF** production has been implicated in mediating or exacerbating a number of diseases including rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, gouty arthritis. . . or malignancy, cachexia, secondary to acquired immune deficiency syndrome (AIDS), AIDS, ARC (AIDS related complex), keloid formation, scar tissue formation, **Crohn**'***s** **disease**, ulcerative colitis, or pyresis.

SUMMARY:

BSUM(271)

Excessive or unregulated **TNF** production has been implicated in mediating or exacerbating a number of diseases including rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, gouty arthritis. . . or malignancy, cachexia secondary to acquired immune deficiency syndrome (AIDS), AIDS, ARC (AIDS related complex), keloid formation, scar tissue formation, **Crohn**'***s** **disease**, ulcerative colitis and pyresis.

US PAT NO: 5,593,991 [IMAGE AVAILABLE]

L3: 2 of 26

SUMMARY:

BSUM(6)

Excessive or unregulated **TNF** production has been implicated in mediating or exacerbating a number of diseases including rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, gouty arthritis. . . or malignancy, cachexia, secondary to acquired immune deficiency syndrome (AIDS), AIDS, ARC (AIDS related complex), keloid formation, scar tissue formation, **Crohn**'***s** **disease**, ulcerative colitis, or pyresis.

SUMMARY:

BSUM(271)

Excessive or unregulated **TNF** production has been implicated in mediating or exacerbating a number of diseases including rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, gouty arthritis. . . or malignancy, cachexia secondary to acquired immune deficiency syndrome (AIDS), AIDS, ARC (AIDS related complex), keloid formation, scar tissue formation, **Crohn**'***s** **disease**, ulcerative coliris and pyresis.

US PAT NO: 5,591,748 [IMAGE AVAILABLE]

L3: 3 of 26

DETDESC:

DETD(82)

Badger et al. WO 92/14462 also discloses various mammalian conditions for which **TNF** is implicated in mediating or exacerbating. These conditions include: rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, gouty arthritis and other arthritic conditions; . . . reperfusion injury, graft vs. host reaction, fever and myalgias due to infection, such as influenza, keloid formation, scar tissue formation, **Crohn**'***s** **disease**, ulcerative colitis, or pyresis.

US PAT NO: 5,559,137 [IMAGE AVAILABLE]

L3: 4 of 26

SUMMARY:

BSUM(7)

Excessive or unregulated **TNF** production has been implicated in mediating or exacerbating a number of diseases including rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, gouty arthritis. . . or malignancy, cachexia, secondary to acquired immune deficiency syndrome (AIDS), AIDS, ARC (AIDS related complex), keloid formation, scar tissue formation, **Crohn**'***s** **disease**, ulcerative colitis, or pyresis.

DETDESC:

DETD(81)

Excessive or unregulated **TNF** production has been implicated in mediating or exacerbating a number of diseases including rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, gouty arthritis. . . or malignancy, cachexia secondary to acquired immune deficiency syndrome (AIDS), AIDS, ARC (AIDS related complex), keloid formation, scar tissue formation, **Crohn**'***s** **disease**, ulcerative colitis and pyresis.

US PAT NO: 5,552,438 [IMAGE AVAILABLE]

L3: 5 of 26

SUMMARY:

BSUM(9)

The compounds of this invention also inhibit the production of Tumor Necrosis Factor (**TNF**), a serum glycoprotein. Excessive or unregulated **TNF** production has been implicated in mediating or exacerbating a number of diseases including rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, gouty arthritis. . . malignancy, cachexia secondary to human acquired immune deficiency syndrome (AIDS), AIDS, ARC (AIDS related complex), keloid formation, scar tissue formation, **Crohn**'***s** **disease**, ulcerative colitis, or pyresis, in addition to a number of autoimmune diseases, such as multiple sclerosis, autoimmune diabetes and systemic. . .

US PAT NO: 5,550,132 [IMAGE AVAILABLE]

L3: 6 of 26

SUMMARY:

BSUM(9)

****Crohn**'***s** **disease**** and ulcerative colitis are chronic inflammatory bowel diseases of unknown etiology but there is circumstantial evidence that immune mechanisms play. . . lesion and that cytokines produced by lymphoid cells may be critical for the extraintestinal sequelae of the disease. In both ****Crohn**'***s** **disease**** and ulcerative colitis, activation of macrophages seems to be a key feature and increased production of the macrophage-derived cytokines ****TNF**-.alpha.**, IL-1, and IL-6 have been reported in both diseases. A recent study determined the location and tissue density of cells immunoreactive for ****TNF**-.alpha.** in intestinal specimens from 24 patients with chronic inflammatory bowel disease (15 with Crohn's, 9 with ulcerative colitis) and 11 controls (14). There was significantly increased density of ****TNF**-.alpha.** immunoreactive cells in the lamina propria of both ulcerative colitis and ****Crohn**'***s** **disease**** specimens suggesting that this degree of ****TNF**-.alpha.** production probably contributes significantly to the pathogenesis of both ****Crohn**'***s** **disease**** and ulcerative colitis by impairing the integrity of epithelial and endothelial membranes, increasing inflammatory cell recruitment, and by prothrombotic effects. . .
=> d 13 1-6 date

TITLE: Compounds L3: 1 of 26
US PAT NO: 5,593,992 DATE ISSUED: Jan. 14, 1997
[IMAGE AVAILABLE]
APPL-NO: 08/472,366 DATE FILED: Jun. 7, 1995
REL-US-DATA: Continuation-in-part of Ser. No. 369,964, Jan. 9, 1995,
which is a continuation-in-part of Ser. No. 92,733, Jul.
16, 1993, abandoned.

TITLE: Imidazole compounds, use and process of making L3: 2 of 26
US PAT NO: 5,593,991 DATE ISSUED: Jan. 14, 1997
[IMAGE AVAILABLE]
APPL-NO: 08/476,934 DATE FILED: Jun. 7, 1995
REL-US-DATA: Continuation-in-part of Ser. No. 369,964, Jan. 9, 1995,
which is a continuation-in-part of Ser. No. 92,733, Jul.
16, 1993, abandoned.

TITLE: Immunomodulatory azaspiranes L3: 3 of 26
US PAT NO: 5,591,748 DATE ISSUED: Jan. 7, 1997
[IMAGE AVAILABLE]
APPL-NO: 08/277,456 DATE FILED: Jul. 19, 1994
REL-US-DATA: Continuation-in-part of Ser. No. 981,147, Nov. 24, 1992,
abandoned, which is a continuation of Ser. No. 712,325,
Jun. 7, 1991, abandoned.

TITLE: Compounds L3: 4 of 26
US PAT NO: 5,559,137 DATE ISSUED: Sep. 24, 1996
[IMAGE AVAILABLE]
APPL-NO: 08/242,906 DATE FILED: May 16, 1994

TITLE: Compounds useful for treating allergic and inflammatory L3: 5 of 26

diseases

US PAT NO: 5,552,438 [IMAGE AVAILABLE] DATE ISSUED: Sep. 3, 1996
 APPL-NO: 08/313,094 DATE FILED: Sep. 29, 1994
 PCT-NO: PCT/US93/01991 PCT-FILED: Mar. 5, 1993
 371-DATE: Sep. 29, 1994
 102(E)-DATE: Sep. 29, 1994
 PCT-PUB-NO: WO93/19749 PCT-PUB-DATE: Oct. 14, 1993
 REL-US-DATA: Continuation-in-part of Ser. No. 968,762, Oct. 30, 1992, abandoned, which is a continuation-in-part of Ser. No. 862,030, Apr. 2, 1992, abandoned.

TITLE: Hydroxyalkylammonium-pyrimidines or purines and nucleoside derivatives, useful as inhibitors of inflammatory cytokines L3: 6 of 26

US PAT NO: 5,550,132 [IMAGE AVAILABLE] DATE ISSUED: Aug. 27, 1996
 APPL-NO: 08/264,026 DATE FILED: Jun. 22, 1994

=> d his
 (FILE 'USPAT' ENTERED AT 10:13:07 ON 03 FEB 97)
 L1 69 S (CROHN(W)S(W)DISEASE) AND TNF
 L2 68 S L1 AND (TREATMENT OR TREATING OR TREAT OR THERAPY OR THE
 RAP
 L3 26 S (CROHN(W)S(W)DISEASE) (P) TNF
 L4 6 S L3(P) (TREATING OR TREAT OR THERAPEUTIC OR THERAPY OR TRE
 ATM
 => d 14 1-6 date

TITLE: 1-Alkoxy-2-(alkoxy- or cycloalkoxy-)-4-(cyclothioalkyl- or cyclothioalkenyl-) benzenes as inhibitors of cyclic AMP phosphodiesterase and tumor necrosis factor L4: 1 of 6
 US PAT NO: 5,541,219 [IMAGE AVAILABLE] DATE ISSUED: Jul. 30, 1996
 APPL-NO: 08/295,747 DATE FILED: Nov. 3, 1994
 FRN-PR. NO: 9204808 FRN FILED: Mar. 4, 1992
 FRN-PR. CO: United Kingdom
 PCT-NO: PCT/GB93/00445 PCT-FILED: Mar. 4, 1993
 371-DATE: Nov. 3, 1994
 102(E)-DATE: Nov. 3, 1994
 PCT-PUB-NO: WO93/18024 PCT-PUB-DATE: Sep. 16, 1993

TITLE: Olefin substituted long chain compounds L4: 2 of 6
 US PAT NO: 5,521,315 [IMAGE AVAILABLE] DATE ISSUED: May 28, 1996
 APPL-NO: 08/059,697 DATE FILED: May 10, 1993
 REL-US-DATA: Continuation-in-part of Ser. No. 3,372, Jan. 12, 1993, Pat. No. 5,354,756.

TITLE: Pyrazole derivatives L4: 3 of 6
 US PAT NO: 5,478,827 [IMAGE AVAILABLE] DATE ISSUED: Dec. 26, 1995
 APPL-NO: 08/269,520 DATE FILED: Jul. 1, 1994
 FRN-PR. NO: 9119267 FRN FILED: Sep. 9, 1991
 FRN-PR. CO: United Kingdom

FRN-PR. NO: 9204464 FRN FILED: Mar. 2, 1992
FRN-PR. CO: United Kingdom
REL-US-DATA: Division of Ser. No. 931,093, Aug. 17, 1992, Pat. No.
5,356,897.

TITLE: Cell signaling inhibitors L4: 4 of 6
US PAT NO: 5,470,878
[IMAGE AVAILABLE] DATE ISSUED: Nov. 28, 1995
APPL-NO: 08/164,081 DATE FILED: Dec. 8, 1993
REL-US-DATA: Continuation-in-part of Ser. No. 40,820, Mar. 31, 1993,
abandoned.

TITLE: Xanthine derivatives L4: 5 of 6
US PAT NO: 5,409,934
[IMAGE AVAILABLE] DATE ISSUED: Apr. 25, 1995
APPL-NO: 08/078,152 DATE FILED: Jul. 7, 1993
FRN-PR. NO: 9027752 FRN FILED: Dec. 21, 1990
FRN-PR. CO: United Kingdom
FRN-PR. NO: 9027899 FRN FILED: Dec. 21, 1990
FRN-PR. CO: United Kingdom
PCT-NO: PCT/GB91/02286
PCT-FILED: Dec. 19, 1991
371-DATE: Jul. 7, 1993
102(E)-DATE: Jul. 7, 1993
PCT-PUB-DATE: Jul. 9, 1992
PCT-PUB-NO: WO/9211260

TITLE: 3-(heteroaryl)-pyrazololi[1,5-a]pyrimidines L4: 6 of 6
US PAT NO: 5,356,897
[IMAGE AVAILABLE] DATE ISSUED: Oct. 18, 1994
APPL-NO: 07/931,093 DATE FILED: Aug. 17, 1992
FRN-PR. NO: 9119267 FRN FILED: Sep. 9, 1991
FRN-PR. CO: United Kingdom
FRN-PR. NO: 9204464 FRN FILED: Mar. 2, 1992
FRN-PR. CO: United Kingdom
=> d l4 1-6 kwic

US PAT NO: 5,541,219 [IMAGE AVAILABLE] L4: 1 of 6

DETDESC:

DETD(178)

The compounds are also inhibitors of tumor necrosis factor, especially .alpha.-**TNF**. Thus, the present invention provides compounds of formula I, and compositions containing compounds of formula I, which are of use in a method for **treating** a patient suffering from, or subject to, conditions which can be ameliorated by the administration of an inhibitor of .alpha.-**TNF**. For example compounds of the present invention are useful in joint inflammation, arthritis, rheumatoid arthritis and other arthritic conditions such as rheumatoid spondylitis and osteoarthritis. Additionally, the compounds are useful in **treatment** of sepsis, septic shock, gram negative sepsis, toxic shock syndrome, acute respiratory distress syndrome, asthma and other chronic pulmonary diseases, bone resorption diseases, reperfusion injury, graft vs host reaction and allograft rejection. Furthermore, the compounds are useful in the **treatment** of infections such as viral infections and

parasitic infections, for example malaria such as cerebral malaria, fever and myalgias due. . . to AIDS or to cancer. Other disease states that may be treated with the compounds of the present invention include **Crohn's disease**, ulcerative colitis, pyresis, systemic lupus erythematosus, multiple sclerosis, type I diabetes mellitus, psoriasis, Bechet's disease, anaphylactoid purpura nephritis, chronic glomerulonephritis, inflammatory bowel disease and leukemia. A special embodiment of the **therapeutic** methods of the present invention is the **treating** of joint inflammation.

US PAT NO: 5,521,315 [IMAGE AVAILABLE]

L4: 2 of 6

DETDESC:

DETD(43)

Excessive or unregulated **TNF** (tumor necrosis factor) production is implicated in mediating or exacerbating a number of diseases including rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, . . . to infection, AIDS or malignancy, AIDS, other viral infections (e.g., CMV, influenza, adenovims, herpes family), keloid formation, scar tissue formation, **Crohn's disease**, ulcerative colitis, or pyresis. The inventive compounds or pharmaceutically acceptable salts thereof can be used in the manufacture of a medicament for the prophylactic or **therapeutic treatment** of any disease state in a human or other mammal, which is exacerbated or signaled through the present second messenger cellular phospholipid-based signaling pathway and by excessive or unregulated production of "first messenger" inflammatory cytokines such as **TNF** or IL-1. With regard to **TNF** first messenger signaling, there are several disease states in which excessive or unregulated **TNF** production by monocytes/macrophages is implicated in exacerbating or causing the disease. These include, for example, neurodegenerative diseases such as Alzheimers. . . and adult respiratory distress syndrome (Miller et al., Lancet 2(8665):712, 1989). The inventive compounds may be used topically in the **treatment** of prophylaxis of topical disease states mediated or exacerbated by excessive **TNF** or IL-1, such as viral infections (herpes or viral conjunctivitis), psoriasis, fungal or yeast infections (ringworm, athletes foot, vaginitis, dandruff, etc.) or other dermatologic hyperproliferative disorders. High **TNF** levels have been implicated in acute malaria attacks (Grau et al., N. Engl. J. Med. 320:1585, 1989), chronic pulmonary inflammatory. . .

US PAT NO: 5,478,827 [IMAGE AVAILABLE]

L4: 3 of 6

SUMMARY:

BSUM(285)

Accordingly, the new pyrazole derivatives (I) and a pharmaceutically acceptable salt thereof can be used for prophylactic and **therapeutic treatment** of IL-1 and **TNF** mediated diseases such as chronic inflammatory diseases (e.g. rheumatoid arthritis, osteoarthritis, etc.) osteoporosis, rejection by transplantation, asthma, endotoxin shock, specific. . . polychondritis, scleroderma, Wegener granulomatosis, dermatomyositis, chronic active hepatitis, myasthenia gravis, psoriasis, idiopathic sprue, autoimmune inflammatory bowel disease (e.g. ulcerative colitis, **Crohn's disease**, etc.), endocrine ophthalmopathy,

Grave's disease, sarcoidosis, multiple sclerosis, primary biliary cirrhosis, juvenile diabetes (diabetes mellitus type I), Reiter's syndrome, non. . .

US PAT NO: 5,470,878 [IMAGE AVAILABLE]

L4: 4 of 6

DETDESC:

DETD(44)

Excessive or unregulated ****TNF**** (tumor necrosis factor) production is implicated in mediating or exacerbating a number of diseases including rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, . . . to infection, AIDS or malignancy, AIDS, other viral infections (e.g., CMV, influenza, adenovirus, herpes family), keloid formation, scar tissue formation, ****Crohn**'***s** **disease****, ulcerative colitis, or pyresis. The inventive compounds or pharmaceutically acceptable salts thereof can be used in the manufacture of a medicament for the prophylactic or ****therapeutic** **treatment**** of any disease state in a human or other mammal, which is exacerbated or signaled through the present second messenger cellular phospholipid-based signaling pathway and by excessive or unregulated production of "first messenger" inflammatory cytokines such as ****TNF**** or IL-1. With regard to ****TNF**** first messenger signaling, there are several disease states in which excessive or unregulated ****TNF**** production by monocytes/macrophages is implicated in exacerbating or causing the disease. These include, for example, neurodegenerative diseases such as Alzheimers. . . and adult respiratory distress syndrome (Miller et al., Lancet (1989) 2(8665):712). The inventive compounds may be used topically in the ****treatment**** of prophylaxis of topical disease states mediated or exacerbated by excessive ****TNF**** or IL-1, such as viral infections (herpes or viral conjunctivitis), psoriasis, fungal or yeast infections (ringworm, athlete's foot, vaginitis, dandruff, etc.) or other dermatologic hyperproliferative disorders. High ****TNF**** levels have been implicated in acute malaria attacks (Grau et al., N. Engl. J. Med. (1989) 320:1585), chronic pulmonary inflammatory. . .

US PAT NO: 5,409,934 [IMAGE AVAILABLE]

L4: 5 of 6

SUMMARY:

BSUM(10)

In addition these compounds may also have potential as inhibitors of the production of tumour necrosis factor (****TNF****) and hence have potential for the ****treatment**** of human immunodeficiency virus (HIV), acute immune deficiency syndrome (AIDS), rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, gouty arthritis and other arthritic. . . to infection, such as influenza, cachexia secondary to infection or malignancy, cachexia secondary to AIDS, keloid formation, scar tissue formation, ****Crohn**'***s** **disease****, ulcerative colitis, or pyresis.

US PAT NO: 5,356,897 [IMAGE AVAILABLE]

L4: 6 of 6

DETDESC:

DETD(183)

Accordingly, the new pyrazole derivatives (I) and a pharmaceutically acceptable salt thereof can be used for prophylactic and **therapeutic** treatment of IL-1 and **TNF** mediated diseases such as chronic inflammatory diseases (e.g. rheumatoid arthritis, osteoarthritis, etc.) osteoporosis, rejection by transplantation, asthma, endotoxin shock, specific. . . polychondritis, scleroderma, Wegener granulomatosis, dermatomyositis, chronic active hepatitis, myasthenia gravis, psoriasis, idiopathic sprue, autoimmune inflammatory bowel disease (e.g. ulcerative colitis, **Crohn**'***s** **disease**, etc.), endocrine ophthalmopathy, Grave's disease, sarcoidosis, multiple sclerosis, primary biliary cirrhosis, juvenile diabetes (diabetes mellitus type I), Reiter's syndrome, non. . .

=> s l3 and (tnf(p)antibod?)

1454 TNF

21935 ANTIBOD?

316 TNF(P)ANTIBOD?

L5 8 L3 AND (TNF(P)ANTIBOD?)

=> d l5 1-8

1. 5,550,132, Aug. 27, 1996, Hydroxyalkylammonium-pyrimidines or purines and nucleoside derivatives, useful as inhibitors of inflammatory cytokines; Bradley J. Benson, et al., 514/269, 274; 544/311, 312, 313, 314 [IMAGE AVAILABLE]

2. 5,547,979, Aug. 20, 1996, TNF inhibition; Siegfried B. Christensen, IV, et al., 514/424; 548/550, 551 [IMAGE AVAILABLE]

3. 5,521,315, May 28, 1996, Olefin substituted long chain compounds; Gail Underiner, et al., 546/243; 544/285; 546/242 [IMAGE AVAILABLE]

4. 5,470,878, Nov. 28, 1995, Cell signaling inhibitors; John Michnick, et al., 514/558, 258, 262, 274, 299, 315, 418, 425, 529, 552, 561, 613, 617, 626, 629, 669; 544/254, 285, 301; 546/183, 243; 548/486, 556 [IMAGE AVAILABLE]

5. 5,420,154, May 30, 1995, TNF inhibitors; Siegfried B. Christensen, IV, et al., 514/424; 548/551 [IMAGE AVAILABLE]

6. 5,362,915, Nov. 8, 1994, Phenyl-substituted cycloalkenyl compounds useful as PDE IV inhibitors; Harald Maschler, et al., 568/20, 42, 49, 52, 329, 330, 644 [IMAGE AVAILABLE]

7. 5,317,019, May 31, 1994, Inhibition of interleukin-1 and tumor necrosis factor production by monocytes and/or macrophages; Paul E. Bender, et al., 514/224.2, 230.5, 258, 303, 333, 338, 339 [IMAGE AVAILABLE]

8. 5,169,840, Dec. 8, 1992, Diequatorially bound .beta.-1, 4 polyuronates and use of same for cytokine stimulation; Marit Otterlei, et al., 514/55; 424/85.2; 435/69.1; 514/8, 54, 908, 929; 536/2, 3, 20, 114, 123, 127 [IMAGE AVAILABLE]

=> d l5 1-8 date

L5: 1 of 8

TITLE: Hydroxyalkylammonium-pyrimidines or purines and nucleoside derivatives, useful as inhibitors of inflammatory cytokines

US PAT NO: 5,550,132

DATE ISSUED: Aug. 27, 1996

APPL-NO:	[IMAGE AVAILABLE] 08/264,026	DATE FILED:	Jun. 22, 1994
TITLE:	TNF inhibition		L5: 2 of 8
US PAT NO:	5,547,979	DATE ISSUED:	Aug. 20, 1996
APPL-NO:	[IMAGE AVAILABLE] 08/424,944	DATE FILED:	Apr. 19, 1995
REL-US-DATA:	Continuation of Ser. No. 852,180, Mar. 30, 1992, Pat. No. 5,420,154.		
TITLE:	Olefin substituted long chain compounds		L5: 3 of 8
US PAT NO:	5,521,315	DATE ISSUED:	May 28, 1996
APPL-NO:	[IMAGE AVAILABLE] 08/059,697	DATE FILED:	May 10, 1993
REL-US-DATA:	Continuation-in-part of Ser. No. 3,372, Jan. 12, 1993, Pat. No. 5,354,756.		
TITLE:	Cell signaling inhibitors		L5: 4 of 8
US PAT NO:	5,470,878	DATE ISSUED:	Nov. 28, 1995
APPL-NO:	[IMAGE AVAILABLE] 08/164,081	DATE FILED:	Dec. 8, 1993
REL-US-DATA:	Continuation-in-part of Ser. No. 40,820, Mar. 31, 1993, abandoned.		
TITLE:	TNF inhibitors		L5: 5 of 8
US PAT NO:	5,420,154	DATE ISSUED:	May 30, 1995
APPL-NO:	[IMAGE AVAILABLE] 07/852,180	DATE FILED:	Mar. 30, 1992
PCT-NO:	PCT/US91/05350	PCT-FILED:	Jul. 29, 1991
		371-DATE:	Mar. 30, 1992
PCT-PUB-NO:	WO90/15534	102(E)-DATE:	Mar. 30, 1992
REL-US-DATA:	Continuation-in-part of Ser. No. 562,761, Aug. 3, 1990, abandoned.		
TITLE:	Phenyl-substituted cycloalkenyl compounds useful as PDE IV inhibitors		L5: 6 of 8
US PAT NO:	5,362,915	DATE ISSUED:	Nov. 8, 1994
APPL-NO:	[IMAGE AVAILABLE] 07/934,546	DATE FILED:	Oct. 2, 1992
FRN-PR. NO:	9007762	FRN FILED:	Apr. 5, 1990
FRN-PR. CO:	United Kingdom		
PCT-NO:	PCT/EP91/00637	PCT-FILED:	Apr. 2, 1991
		371-DATE:	Oct. 2, 1992
PCT-PUB-NO:	WO91/15451	102(E)-DATE:	Oct. 2, 1992
		PCT-PUB-DATE:	Oct. 17, 1991
TITLE:	Inhibition of interleukin-1 and tumor necrosis factor production by monocytes and/or macrophages		L5: 7 of 8
US PAT NO:	5,317,019	DATE ISSUED:	May 31, 1994
APPL-NO:	[IMAGE AVAILABLE] 07/809,484	DATE FILED:	Dec. 12, 1991

PCT-NO: PCT/US90/03367 PCT-FILED: Jun. 13, 1990
371-DATE: Dec. 12, 1991
102(E)-DATE: Dec. 12, 1991
REL-US-DATA: Continuation-in-part of Ser. No. 365,349, Jun. 13, 1989,
abandoned.

TITLE: Diequatorially bound .beta.-1, 4 polyuronates and use of
same for cytokine stimulation L5: 8 of 8
US PAT NO: 5,169,840 DATE ISSUED: Dec. 8, 1992
[IMAGE AVAILABLE]
APPL-NO: 07/676,103 DATE FILED: Mar. 27, 1991
=> d 15 1-8 kwic

US PAT NO: 5,550,132 [IMAGE AVAILABLE] L5: 1 of 8

SUMMARY:

BSUM(6)

In addition to septic shock and cachexia, **TNF** has been implicated in the pathophysiology of rheumatoid arthritis (RA), inflammatory bowel disease (IBD), multiple sclerosis (MS) and AIDS and. . . patients. In rheumatoid arthritis, for instance, there is evidence of macrophage activation with demonstration of increased amounts of two monokines, **TNF**-.alpha. and IL-1, in the serum but even more in the synovial fluid. **TNF**-.alpha., an inducer of IL-1, is significantly elevated in rheumatoid arthritis but not in reactive arthritis. Moreover, **TNF**-.alpha. levels in RA correlate with the synovial fluid leukocyte count and with the ESR (erythrocyte sedimentation rate). **TNF** is an important mediator of immunity and inflammation and because of its biologic activities (activation of neutrophils, release of arachidonic. . . of macrophage chemotactic activating protein ([MCAP]) is one of the potential mediators in chronic arthritis. Studies have shown that monoclonal **antibody** to **TNF** can ameliorate joint disease in murine collagen-induced arthritis. In these studies, anti-**TNF** administered prior to the onset of disease significantly reduced paw swelling and histological severity of arthritis without reducing the incidence. . . arthritis or the level of circulating anti-type II collagen IgG. More relevant to human disease was the ability of the **antibody** to reduce the clinical score, paw swelling, and the histological severity of disease even when injected after the onset of. . .

SUMMARY:

BSUM(8)

Multiple . . . central nervous system (CNS). The majority of infiltrating cells at the site of demyelination are macrophages and T-cells. IL-1 and **TNF** in the CSF are detected at higher levels and more frequently in patients with active multiple sclerosis than in patients. . . inactive MS or with other neurological diseases. In a study of MS patients, Beck and colleagues found an increase of **TNF** and interferon production by peripheral blood mononuclear cells two weeks prior to disease exacerbation. Experimental allergic encephalomyelitis (EAE) is the. . . characterized demyelinating disease of the CNS in animals. EAE and MS share many characteristics. Ruddle and colleagues used a monoclonal **antibody** which neutralizes **TNF** to treat EAE in

mice. See Ruddle et al., J. Exp. Med., 1990, 172:1193-1200. The incidence and severity of EAE in the ****antibody****-treated mice were dramatically reduced and the onset of disease was delayed. Moreover, the authors reported that the preventive therapy was long-lived, extending through five months of observation. ****TNF****-.alpha. levels were measured in serum samples from 73 HIV-1 seropositive patients and in samples from two control groups. All clinical groups of HIV-1-infected patients, regardless of concurrent illness, had significantly elevated levels of both types of soluble ****TNF**** receptors (sTNFRs) and immunoreactive ****TNF****-.alpha., with the highest concentrations among the AIDS patients. These ****TNF**** parameters were significantly correlated with reduced CD4+ lymphocyte counts. The raised levels of immunoreactive ****TNF**** and sTNFRs strongly indicate activation of the ****TNF****-.alpha. system during HIV-1 infection. Levels increase with disease progression and degree of immunodeficiency. Thalidomide, a selective inhibitor of ****TNF****-.alpha. synthesis, has been shown to suppress the activation of latent HIV-1 in a monocytoid (U1) cell line. Associated with HIV-1 inhibition was a reduction in agonist-induced ****TNF****-.alpha. protein and mRNA production. The presence of thalidomide was also shown to inhibit the activation of virus in the peripheral. . . . A recent study used reverse transcriptase-polymerase chain reaction on homogenized brain tissue to correlate the relative expression of mRNA for ****TNF****-.alpha. with cognitive impairment and with neuropathologic changes in HIV infected patients. Levels of mRNA for ****TNF****-.alpha. from frontal subcortical white matter were significantly greater in patients with HIVD (HIV associated dementia) than in AIDS patients without dementia or in seronegative controls. Elevated levels of mRNA for ****TNF****-.alpha. in HIVD indicate that abnormal cytokine expression may contribute to the pathogenesis of HIVD. Pentoxifylline (PTX), a drug known to block ****TNF****-.alpha. release, was tested in a phase I/II clinical trial of HIV-seropositive patients either alone or in combination with zidovudine (ZDV).. . . after 12 weeks of PTX and ZDV compared with 8-to 9-fold greater levels in patients given either agent alone (p<0.05). ****TNF****-.alpha. levels correlated with viral load (p<0.0001) in patients given the combined drug regimen.

SUMMARY:

BSUM(9)

****Crohn**'***s**** ****disease**** and ulcerative colitis are chronic inflammatory bowel diseases of unknown etiology but there is circumstantial evidence that immune mechanisms play. . . . lesion and that cytokines produced by lymphoid cells may be critical for the extraintestinal sequelae of the disease. In both ****Crohn**'***s**** ****disease**** and ulcerative colitis, activation of macrophages seems to be a key feature and increased production of the macrophage-derived cytokines ****TNF****-.alpha., IL-1, and IL-6 have been reported in both diseases. A recent study determined the location and tissue density of cells immunoreactive for ****TNF****-.alpha. in intestinal specimens from 24 patients with chronic inflammatory bowel disease (15 with Crohn's, 9 with ulcerative colitis) and 11 controls (14). There was significantly increased density of ****TNF****-.alpha. immunoreactive cells in the lamina propria of both ulcerative colitis and ****Crohn**'***s**** ****disease**** specimens suggesting that this degree of ****TNF****-.alpha. production probably contributes significantly to the pathogenesis of both ****Crohn**'***s**** ****disease**** and ulcerative colitis by impairing the integrity of epithelial and endothelial membranes, increasing

inflammatory cell recruitment, and by prothrombotic effects. . .

US PAT NO: 5,547,979 [IMAGE AVAILABLE]

L5: 2 of 8

SUMMARY:

BSUM(4)

****TNF****, a serum glycoprotein, has been implicated in mediating or exacerbating various mammalian conditions such as rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, . . . or malignancy, cachexia, secondary to acquired immune deficiency syndrome (AIDS), AIDS, ARC (AIDS related complex), keloid formation, scar tissue formation, ****Crohn**'***s** **disease****, ulcerative colitis, or pyresis.

DETDESC:

DETD(29)

There are several disease states in which excessive or unregulated ****TNF**** production by monocytes and/or macrophages is implicated in exacerbating and/or causing the disease. These include endotoxemia and/or toxic shock syndrome. . . al., Circ. Shock 30:279-292 (1990)]; cachexia [See, Dezube et al., Lancet, 335 (8690): 662 (1990)]; Adult Respiratory Distress Syndrome where ****TNF**** concentration in excess of 12,000 pg/ml have been detected in pulmonary aspirates from ARDS patients. [See, Miller et al., Lancet 2 (8665): 712-714 (1989). Systemic infusion of recombinant ****TNF**** resulted in changes typically seen in ARDS [See, Ferrai-Baliviera et al., Arch. Surg. 124 (12): 1400-1405 (1989)]; AIDS where viral replication of latent HIV in T-cell and macrophage lines can be induced by ****TNF**** [See, Folks et al., PNAS 86:2365-2368 (1989)]. A molecular mechanism for the virus inducing activity is suggested by TNFs ability. . . which promotes HIV replication through binding to a viral regulatory gene sequence (LTR) [See, Osborn et al., PNAS 86:2336-2340 (1989)]. ****TNF**** in AIDS associated cachexia is suggested by elevated serum ****TNF**** and high levels of spontaneous ****TNF**** production in peripheral blood monocytes from patients [See, Wright et al., J. Immunol. 141 (1):99-104 (1988)]. ****TNF**** in Bone Resorption Diseases, including arthritis, wherein it has been determined that when activated, leukocytes will produce a bone-reasorbing activity, and data suggests that ****TNF****-.alpha. and ****TNF****-.beta. both contribute to this activity. [See e.g., Bertolini et al., Nature 319: 516-518 (1986) and Johnson et al., Endocrinology 124 (3): 1424-1427 (1989)]. It has been determined that ****TNF**** stimulates bone resorption and inhibits bone formation in vitro and in vivo through stimulation of osteoclast formation and activation combined with inhibition of osteoblast function. Although ****TNF**** may be involved in many bone resorption diseases, including arthritis, the most compelling link with disease is the association between production of ****TNF**** by tumor or host tissues; and malignancy associated hypercalcemia [See, Calci. Tissue Int. (US) 46 (Suppl.): S3-10 (1990)]. In Graft versus Host Reaction, increased serum ****TNF**** levels have been associated with major complication following acute allogenic bone marrow transplants [See, Holler, et al., Blood, 75 (4):1011-1016 (1990)]; cerebral malaria, which is a lethal hyperacute neurological syndrome associated with high blood levels of ****TNF**** and is the most severe complication occurring in malaria patients. A form of experimental cerebral malaria (ECM) that reproduces some features of the human disease was prevented in mice by

administration of an anti-**TNF** **antibody**. [See, Grau et al., Imm. Review 112:49-70 (1989)]. Levels of serum **TNF** correlated directly with the severity of disease and prognosis in patients with acute malaria attacks [See Grau et al., N. Engl. J. Med. 320 (24): 1586-1591 (1989)]. Another disease state in which **TNF** plays a role is the area of chronic Pulmonary Inflammatory Diseases. The deposition of silica particles leads to silicosis, a disease of progressive respiratory failure caused by a fibrotic reaction. **Antibody** to **TNF** completely blocked the silica-induced lung fibrosis in mice [See Piguet et al., Nature, 344:245-247 (1990)]. High levels of **TNF** production (in the serum and in isolated macrophages) have been demonstrated in animal models of silica and asbestos induced fibrosis. . . . 13 (3): 329-339 (1989)]. Alveolar macrophages from pulmonary sarcoidosis patients have also been found to spontaneously release massive quantities of **TNF** as compared with macrophages from normal donors [See Baughman et al., J. Lab. Clin. Med. 115 (1): 36-42 (1990)]. **TNF** is also implicated in another acute disease state such as inflammatory response which follows reperfusion, called Reperfusion Injury and is a major cause of tissue damage after loss of blood flow [See, Vedder et al., PNAS 87:2643-2646 (1990)]. **TNF** also alters the properties of endothelial cells and has various pro-coagulant activities, such as producing an increase in tissue factor. . . . protein C pathway as well as down-regulating the expression of thrombomodulin [See, Sherry et al., J. Cell Biol., 107:11269-1277 (1988)]. **TNF** also has pro-inflammatory activities which together with its early production (during the initial stage of an inflammatory event) make it. . . . in several important disorders including but not limited to, myocardial infarction, stroke and circulatory shock. Of specific importance may be **TNF**-induced expression of adhesion molecules, such as intercellular adhesion molecule (ICAM) or endothelial leukocyte adhesion molecule (ELAM) on endothelial cells [See,

US PAT NO: 5,521,315 [IMAGE AVAILABLE]

L5: 3 of 8

SUMMARY:

BSUM(15)

The caused by cytoreductive therapies; autoimmune diseases caused by a T cell response, monocyte response or a B cell response and **antibody** production; acute inflammatory disease such as septic shock or hemorrhagic shock; resistance of mesenchymal cells to tumor necrosis factor (**TNF**); chronic inflammatory disease characterized by T cell, glial, astrocyte or monocyte adhesion, migration and/or release of inflammatory stimuli and metalloproteases, therapy (e.g., cytotoxic drug or radiation); enhancing antitumor effects of nonalkylating antitumor agents; intimation in response to inflammatory stimuli (e.g., **TNF**, IL-1 and the like) characterized by production of metalloproteases or allergies due to degranulation of mast cells and basophils in. . . .

DETDESC:

DETD(43)

Excessive or unregulated **TNF** (tumor necrosis factor) production is implicated in mediating or exacerbating a number of diseases including rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, to

infection, AIDS or malignancy, AIDS, other viral infections (e.g., CMV, influenza, adenovims, herpes family), keloid formation, scar tissue formation, **Crohn**'***s** **disease**, ulcerative colitis, or pyresis. The inventive compounds or pharmaceutically acceptable salts thereof can be used in the manufacture of a . . . present second messenger cellular phospholipid-based signaling pathway and by excessive or unregulated production of "first messenger" inflammatory cytokines such as **TNF** or IL-1. With regard to **TNF** first messenger signaling, there are several disease states in which excessive or unregulated **TNF** production by monocytes/macrophages is implicated in exacerbating or causing the disease. These include, for example, neurodegenerative diseases such as Alzheimers. . . inventive compounds may be used topically in the treatment of prophylaxis of topical disease states mediated or exacerbated by excessive **TNF** or IL-1, such as viral infections (herpes or viral conjunctivitis), psoriasis, fungal or yeast infections (ringworm, athletes foot, vaginitis, dandruff, etc.) or other dermatologic hyperproliferative disorders. High **TNF** levels have been implicated in acute malaria attacks (Grau et al., N. Engl. J. Med. 320:1585, 1989), chronic pulmonary inflammatory. . .

DETDESC:

DETD(44)

The . . . said amount is sufficient to promote said activation; or (4) a method to suppress activation of monocyte/macrophage cells by endotoxin, **TNF**, IL-1 or GM-CSF stimulation and said amount is sufficient to suppress said activation; or (5) a method to enhance the . . . effect of tumor necrosis factor and said amount is sufficient to enhance said resistance; or (6) a method to suppress **antibody** production of B-cells in response to an antigen, IL-4 or CD40 ligand and said amount is sufficient to suppress said **antibody** production; or (7) a method to inhibit the proliferation of smooth muscle cells in response to growth factors capable of. . . is sufficient to enhance said resistance; or (14) a method to prevent the suppression of growth stimulatory factor production in **TNF**-treated bone marrow stromal cells and said amount is sufficient to prevent said suppression; or (15) a method to prevent the release of Mip-1.alpha. by IL-1, **TNF**, or endotoxin stimulated monocytes and macrophages; or (16) a method to prevent the release of platelet activating factor by IL-1, **TNF**, or endotoxin treated megakaryocytes, fibroblastic cells, and macrophages; or (17) a method to prevent the down-regulation of receptors for cytokines in **TNF**-treated hematopoietic progenitor cells and said amount is sufficient to prevent said down-regulation; or (18) a method to suppress the production of metalloproteases in IL-1-stimulated or **TNF**-stimulated glomerular epithelial cells or synovial cells and said amount is sufficient to enhance said production; or (19) a method to. . .

DETDESC:

DETD(67)

The . . . an activated oncogene; hematocytopenia caused by cyto-reductive therapies; autoimmune diseases caused by a T-cell response or a B-cell response and **antibody** production; septic shock; resistance of mesenchymal cells to tumor necrosis factor (**TNF**); proliferation of smooth muscle cells endothelial cells, fibroblasts and

other cell types in response to growth factors, such as PDGF-AA, . . . therapy (e.g., cytotoxic drug or radiation); enhancing antitumor effects of nonalkylating antitumor agents; allergies in response to inflammatory stimuli (e.g., **TNF**, IL-1 and the like) characterized by production of cell surface metalloproteases or by degranulation of mast cells and basophils in. . .

DETDESC:

DETD(73)

The . . . said amount is sufficient to promote said activation; or (4) a method to suppress activation of monocyte/macrophage cells by endotoxin, **TNF**, IL-1 or GM-CSF stimulation and said amount is sufficient to suppress said activation; or (5) a method to enhance. . . effect of tumor necrosis factor and said amount is sufficient to enhance said resistance; or (6) a method to suppress **antibody** production of B-cells in response to an antigen, IL-4 or CD40 ligand and said amount is sufficient to suppress said **antibody** production; or (7) a method to inhibit the proliferation of smooth muscle cells in response to growth factors capable of. . . is sufficient to enhance said resistance; or (14) a method to prevent the suppression of growth stimulatory factor production in **TNF**-treated bone marrow stromal cells and said amount is sufficient to prevent said suppression; or (15) a method to prevent the release of Mip-1.alpha. by IL-1, **TNF**, or endotoxin stimulated monocytes and macrophages; or (16) a method to prevent the release of platelet activating factor by IL-1, **TNF**, or endotoxin treated megakaryocytes, fibroblastic cells, and macrophages; or (17) a method to prevent the down-regulation of receptors for cytokines in **TNF**-treated hematopoietic progenitor cells and said amount is sufficient to prevent said down-regulation; or (18) a method to suppress the production of metalloproteases in IL-1-stimulated or **TNF**-stimulated glomerular epithelial cells or synovial cells and said amount is sufficient to enhance said production; or (19) a method to. . .

US PAT NO: 5,470,878 [IMAGE AVAILABLE]

L5: 4 of 8

DETDESC:

DETD(44)

Excessive or unregulated **TNF** (tumor necrosis factor) production is implicated in mediating or exacerbating a number of diseases including rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, . . . to infection, AIDS or malignancy, AIDS, other viral infections (e.g., CMV, influenza, adenovirus, herpes family), keloid formation, scar tissue formation, **Crohn**'***s** **disease**, ulcerative colitis, or pyresis. The inventive compounds or pharmaceutically acceptable salts thereof can be used in the manufacture of a. . . present second messenger cellular phospholipid-based signaling pathway and by excessive or unregulated production of "first messenger" inflammatory cytokines such as **TNF** or IL-1. With regard to **TNF** first messenger signaling, there are several disease states in which excessive or unregulated **TNF** production by monocytes/macrophages is implicated in exacerbating or causing the disease. These include, for example, neurodegenerative diseases such as Alzheimers. . . inventive compounds may be used topically in the treatment of prophylaxis of topical disease states mediated or

exacerbated by excessive **TNF** or IL-1, such as viral infections (herpes or viral conjunctivitis), psoriasis, fungal or yeast infections (ringworm, athlete's foot, vaginitis, dandruff, etc.) or other dermatologic hyperproliferative disorders. High **TNF** levels have been implicated in acute malaria attacks (Grau et al., N. Engl. J. Med. (1989) 320:1585), chronic pulmonary inflammatory. . .

DETDESC:

DETD(45)

The . . . or IL-2 stimulation, and said amount is sufficient to promote said activation; (3) suppress activation of monocyte/macrophage cells by endotoxin, **TNF**, IL-1 or GM-CSF stimulation and said amount is sufficient to suppress said activation; (4) suppress **antibody** production of B-cells in response to an antigen, IL-4 or CD40 ligand and said amount is sufficient to suppress said **antibody** production; (5) inhibit the proliferation of smooth muscle cells in response to growth factors capable of stimulating said proliferation and. . . or amphotericin B and said amount is sufficient to enhance said resistance; (12) prevent the release of MIP-1.alpha. by IL-1, **TNF**, or endotoxin stimulated monocytes and macrophages; (13) prevent the release of platelet activating factor by IL-1, **TNF**, or endotoxin treated megakaryocytes, fibroblastic cells, and macrophages; (14) prevent the down-regulation of receptors for cytokines in **TNF**-treated hematopoietic progenitor cells and said amount is sufficient to prevent said down-regulation; (15) suppress the production of metalloproteases in IL-1-stimulated or **TNF**-stimulated glomerular epithelial cells or synovial cells and said amount is sufficient to enhance said production; (16) enhance the resistance of. . .

DETDESC:

DETD(53)

Drug . . . fetal bovine serum, and supplemented with a stimulating agent, such as fibroblast growth factor (acidic FGF, Cell Systems, Inc.) or **TNF**. The cells are plated into wells of a microtiter plate (e.g., 5.times.10.sup.4 per well) and allowed to incubate at 37.degree.. . . (e.g., phosphate buffered saline plus 0.1% bovine serum albumin with 0.01% sodium azide) and labeled on ice with a monoclonal **antibody** ("first **antibody**") recognizing human VCAM (e.g., 1 .mu.g of a murine monoclonal **antibody** recognizing human VCAM, Genzyme). After 60 minutes on ice, the cells are washed (preferably twice) with cold wash media and incubated with an **antibody** that recognizes the first **antibody** (e.g., 1 .mu.g of goat anti-mouse IgG conjugated with phycoerythrin, CalTag, Inc.). After 30 minutes on ice, the cells are. . .

DETDESC:

DETD(73)

More . . . oncogene; hematocytopenia caused by cytoreductive therapies; autoimmune diseases caused by a T cell response or a B cell response and **antibody** production; septic shock; resistance of mesenchymal cells to tumor necrosis factor (**TNF**); proliferation of smooth muscle cells endothelial cells, fibroblasts and other cell types

in response to growth factors, such as PDGF-AA, . . . therapy (e.g., cytotoxic drug or radiation); enhancing antitumor effects of non-alkylating antitumor agents; allergies in response to inflammatory stimuli (e.g., **TNF**, IL-1 and the like) characterized by production of cell surface metalloproteases or by degranulation of mast cells and basophils in. . .

DETDESC:

DETD(85)

The . . . tumor cells, (2) suppress activation of T-cells by antigen or IL-2 stimulation (3) suppress activation of monocyte/macrophage cells by endotoxin, **TNF**, IL-1 or GM-CSF stimulation, (4) suppress **antibody** production of B-cells in response to an antigen, IL-4 or CD40 ligand, (5) inhibit the proliferation of smooth muscle cells. . . of kidney glomerular or tubular cells to cyclosporin A or amphotericin B, (12) prevent the release of MIP-1.alpha. by IL-1, **TNF**, or endotoxin stimulated monocytes and macrophages; (13) prevent the release of platelet activating factor by IL-1, **TNF**, or endotoxin treated megakaryocytes, fibroblastic cells, and macrophages; (14) prevent the down-regulation of receptors for cytokines in **TNF**-treated hematopoietic progenitor cells, (15) suppress the production of metalloproteases in IL-1-stimulated or **TNF**-stimulated glomerular epithelial cells or synovial cells, (16) enhance the resistance of gastrointestinal or pulmonary epithelial cells to cytotoxic drugs or. .

DETDESC:

DETD(221)

This . . . exemplary assay. The top panel shows a frequency histogram obtained from flow cytometric analysis of HUVEC cells stained with an **antibody** directed against VCAM and a second stem goat anti-mouse-FITC **antibody**. In the absence of **TNF**, VCAM expression on HUVEC is at a very low level. The middle panel shows a frequency histogram of cells stimulated with **TNF** for 6 hours prior to analyzing by flow cytometry. The average increase in cell fluorescence is approximately 10-fold. The bottom panel is a frequency histogram of **TNF**-stimulated cells in the presence of compound no 58. Presence of inventive compound reduced mean fluorescence by a factor of 8, compared with mean fluorescence from **TNF**-stimulated cells in the absence of compound no. 58.

US PAT NO: 5,420,154 [IMAGE AVAILABLE]

L5: 5 of 8

SUMMARY:

BSUM(4)

TNF, a serum glycoprotein, has been implicated in mediating or exacerbating various mammalian conditions such as rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, . . . or malignancy, cachexia, secondary to acquired immune deficiency syndrome (AIDS), AIDS, ARC (AIDS related complex), keloid formation, scar tissue formation, **Crohn**'***s** **disease**, ulcerative colitis, or pyresis.

DETDESC:

There are several disease states in which excessive or unregulated **TNF** production by monocytes and/or macrophages is implicated in exacerbating and/or causing the disease. These include endotoxemia and/or toxic shock syndrome. . . et al., *Circ. Shock* 30:279-292 (1990)]; cachexia [See, Dezube et al., *Lancet*, 335 (8690):662 (1990)]; Adult Respiratory Distress Syndrome where **TNF** concentration in excess of 12,000 pg/ml have been detected in pulmonary aspirates from ARDS patients. [See, Miller et al., *Lancet* 2(8665):712-714 (1989). Systemic infusion of recombinant **TNF** resulted in changes typically seen in ARDS [See, Ferrai-Baliviera et al., *Arch. Surg.* 124(12):1400-1405 (1989)]; AIDS where viral replication of latent HIV in T-cell and macrophage lines can be induced by **TNF** [See, Folks et al., *PNAS* 86:2365-2368 (1989)]. A molecular mechanism for the virus inducing activity is suggested by TNFs ability. . . which promotes HIV replication through binding to a viral regulatory gene sequence (LTR) [See, Osborn et al., *PNAS* 86:2336-2340 (1989)]. **TNF** in AIDS associated cachexia is suggested by elevated serum **TNF** and high levels of spontaneous **TNF** production in peripheral blood monocytes from patients [See, Wright et al., *J. Immunol.* 141(1):99-104 (1988)].

TNF in Bone Resorption Diseases, including arthritis, wherein it has been determined that when activated, leukocytes will produce a bone-reasorbing activity, and data suggests that **TNF**-.alpha. and **TNF**-.beta. both contribute to this activity. [See e.g., Bertolini et al., *Nature* 319:516-518 (1986) and Johnson et al., *Endocrinology* 124(3):1424-1427(1989)]. It has been determined that **TNF** stimulates bone resorption and inhibits bone formation in vitro and in vivo through stimulation of osteoclast formation and activation combined with inhibition of osteoblast function. Although **TNF** may be involved in many bone resorption diseases, including arthritis, the most compelling link with disease is the association between production of **TNF** by tumor or host tissues and malignancy associated hypercalcemia [See, Calci. *Tissue Int. (US)* 46(Suppl.):S3-10 (1990)]. In Graft versus Host Reaction, increased serum **TNF** levels have been associated with major complication following acute allogenic bone marrow transplants [See, Holler et al., *Blood*, 75(4):1011-1016(1990)]; cerebral malaria, which is a lethal hyperacute neurological syndrome associated with high blood levels of **TNF** and is the most severe complication occurring in malaria patients. A form of experimental cerebral malaria (ECM) that reproduces some features of the human disease was prevented in mice by administration of an anti-**TNF** **antibody**. [See, Grau et al., *Imm. Review* 112:49-70 (1989)]. Levels of serum **TNF** correlated directly with the severity of disease and prognosis in patients with acute malaria attacks [See Grau et al., *N. Engl. J. Med.* 320(24):1586-1591 (1989)].

Another disease state in which **TNF** plays a role is the area of chronic Pulmonary Inflammatory Diseases. The deposition of silica particles leads to silicosis, a disease of progressive respiratory failure caused by a fibrotic reaction. **Antibody** to **TNF** completely blocked the silica-induced lung fibrosis in mice [See Piguet et al., *Nature*, 344:245-247 (1990)]. High levels of **TNF** production (in the serum and in isolated macrophages) have been demonstrated in animal models of silica and asbestos induced fibrosis. . . al., *Inflammation* 13(3):329-339 (1989)]. Alveolar macrophages from pulmonary sarcoidosis patients have also been found to spontaneously release massive quantities of **TNF** as compared with macrophages from normal donors [See Baughman et al., *J. Lab. Clin. Med.* 115(1):36-42 (1990)]. **TNF** is also

implicated in another acute disease state such as the inflammatory response which follows reperfusion, called Reperfusion Injury and is a major cause of tissue damage after loss of blood flow [See, Vedder et al., PNAS 87:2643-2646 (1990)]. **TNF** also alters the properties of endothelial cells and has various pro-coagulant activities, such as producing an increase in tissue factor. . . protein C pathway as well as down-regulating the expression of thrombomodulin [See, Sherry et al., J. Cell Biol. 107:11269-1277 (1988)]. **TNF** also has pro-inflammatory activities which together with its early production (during the initial stage of an inflammatory event) make it. . . in several important disorders including but not limited to, myocardial infarction, stroke and circulatory shock. Of specific importance may be **TNF**-induced expression of adhesion molecules, such as intercellular adhesion molecule (ICAM) or endothelial leukocyte adhesion molecule (ELAM) on endothelial cells [See, . . .

US PAT NO: 5,362,915 [IMAGE AVAILABLE]

L5: 6 of 8

SUMMARY:

BSUM(22)

The compounds of this invention also inhibit production of Tumor Necrosis Factor (**TNF**), a serum glycoprotein. Excessive or unregulated **TNF** production is implicated in mediating or exacerbating a number of diseases including rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, gouty arthritis and. . . infection or malignancy, cachexia secondary to acute immune deficiency syndrome (AIDS), AIDS (ARC/AIDS related complex) keloid formation, scar tissue formation, **Crohn**'***s** **disease**, ulcerative colitis, or pyresis.

DETDESC:

DETD(98)

Levels of **TNF** were also measured using a modification of the basic sandwich ELISA assay method described in Winston et al., Current Protocols. . . 11.2.1, Ausubel et al., Ed. (1987) John Wiley and Sons, New York, USA. The ELISA employed a murine monoclonal anti-human **TNF** **antibody**, described below, as the capture **antibody** and a polyclonal rabbit anti-human **TNF**, described below, as the second **antibody**. For detection, peroxidase-conjugated goat anti-rabbit **antibody** (Boehringer Mannheim, Indianapolis, Ind., USA, Catalog#605222) was added followed by a substrate for peroxidase (1 mg/ml orthophenylenediamine with 0.1% urea peroxide). **TNF** levels in samples were calculated from a standard curve generated with recombinant human **TNF** produced in E. Coli (obtained from SmithKline Beecham Pharmaceuticals, King of Prussia, Pa., USA).

DETDESC:

DETD(99)

Section V: Production of anti-human **TNF** **antibodies**

DETDESC:

DETD(100)

* Monoclonal **antibodies** of human **TNF** were prepared from spleens of BALB/c mice immunized with recombinant human **TNF** using a modification of the method of Kohler and Millstein, Nature 256:495 (1975), the entire disclosure of which is hereby incorporated by reference. Polyclonal rabbit anti-human **TNF** **antibodies** were prepared by repeated immunization of New Zealand (NZW) rabbits with recombinant human **TNF** emulsified in complete Freund's adjuvant (DIFCO, IL., USA). Endotoxin

DETDESC:

DETD(104)

Plasma levels of **TNF** were measured using a modification of the basic sandwich ELISA method described in Winston et al., Current protocols in Molecular. . . Ausubel et al., Ed. (1987) John Wiley and Sons, New York, USA. The Elisa employed a hamster monoclonal anti-mouse **TNF** (Genzyme, Boston, Me., USA) as the capture **antibody** and a polyclonal rabbit anti-murine **TNF** (Genzyme, Boston, Me., USA) as the detecting **antibody**. **TNF** levels in mouse samples were calculated from a standard curve generated with recombinant murine **TNF** (Genzyme, Boston, Me., USA) **TNF** levels determined by ELISA correlated with levels detected by the L929 bioassay of Ruff et. al., J. Immunol, 125:1671-1677 (1980), with 1 Unit of activity in the bioassay corresponding to 70 picograms (pg) of **TNF** in the ELISA. The ELISA detected levels of **TNF** down to 25 pg/ml.

US PAT NO: 5,317,019 [IMAGE AVAILABLE]

L5: 7 of 8

SUMMARY:

BSUM(26)

Among the various mammalian conditions for which **TNF** is implicated in mediating or exacerbating rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, gouty arthritis and other arthritic conditions; sepsis, septic shock,. . . influenza, cachexia secondary to infection or malignancy, cachexia secondary to acute immune deficiency syndrome (AIDS), keloid formation, scar tissue formation, **Crohn***s** **disease**, uclerative colitis, or other inflammatory skin conditions such as pyresis.

SUMMARY:

BSUM(366)

There are several disease states in which excessive or unregulated **TNF** production by monocytes and/or macrophages is implicated in exacerbating and/or causing the disease. These include endotoxemia and/or toxic shock syndrome. . . et al., Circ. Shock 30:279-292 (1990)]; cachexia [See, Dezube et al., Lancet, 335 (8690):662 (1990)]; Adult Respiratory Distress Syndrome where **TNF** concentration in excess of 12,000 pg/ml have been detected in pulmonay aspirates from ARDS patients. [See, Millar et al., Lancet 2(8665):712-714 (1989). Systemic infusion of recombinant **TNF** resulted in changes typically seen in ARDS [See, Ferrai-Baliviera et al., Arch. Surg. 124(12):1400-1405 (1989)]; AIDS viral replication of latent HIV in T-cell and macrophage lines can be induced by **TNF** [See, Folks et al., PNAS 86:2365-2368 (1989)]. A

molecular mechanism for the virus inducing activity is suggested by TNFs ability. . . . which promotes HIV replication through binding to a viral regulatory gene sequence (LTR) [See, Osborn et al., PNAS 86:2336-2340 (1989)]. **TNF** in AIDS associated cachexia is suggested by elevated serum **TNF** and high levels of spontaneous **TNF** production in peripheral blood monocytes from patients [See, Wright et al., J. Immunol. 141(1):99-104 (1988)]. **TNF** in Bone Resorption Diseases, including arthritis, wherein it has been determined that when activated, leukocytes will produce a bone-reasorbing activity, and data suggests that **TNF**-a and **TNF**-beta. both contribute to this activity. [See e.g., Bertolini et al., Nature 319:516-518 (1986) and Johnson et al., Endocrinology 124(3):1424-1427(1489)] It has been determined that **TNF** stimulates bone resorption and inhibits bone formation in vitro and in vivo through stimulation of osteoclast formation and activation combined with inhibition of osteoblast function. Although **TNF** may be involved in may bone resorption disease, including arthritis, the most compelling link with disease is the association between production of **TNF** by tumor or host tissues and malignancy associated hypercalcemia [See, Calci. Tissue Int. (US) 46(Suppl.):S3-10 (1990)]. In Graft versus Host Reaction, increased serum **TNF** levels have been associated with major complication following acute allogenic bone marrow transplants [See, Holler et al., Blood, 75(4):1011-1016(1990)]; cerebral malaria, which is a lethal hyperacute neurological syndrome associated with high blood levels of **TNF** and is the most severe complication occuring in malaria patients. A form of experimental cerebral malaria (ECM) that reproduces some features of the human disease was prevented in mice by administration of an anti-**TNF** **antibody**. [See, Grau et al., Imm. Review 112:49-70 (1989)]. Levels of serum **TNF** correlated directly with the severity of disease and prognosis in patients with acute malaria attacks [See Grau et al., N. . . . Disease. The deposition of silica particules leads to silicosis, a disease of progressive respiratory failure caused by a fibrotic reaction. **Antibody** to **TNF** completly blocked the silica-induced lung fibrosis in mice See Piguet et al., Nature, 344:245-247 (1990)]. High levels of **TNF** production (in the serum and in isolated macrophages) have been demonstrated in animal models of silica and asbestos induced fibrosis. . . . al., Inflammation 13(3):329-339 (1989)]. Alveolar macrophages from pulmonary sarcoidosis patients have also been found to spontaneously release massive quantities of **TNF** as compared with macrophages from normal donors [See Baughman et al., J. Lab. Clin. Med. 115(1):36-42 (1990)].; **TNF** is also implicated in another acute disease state such as the inflammatory response which follows reperfusion, called Reperfusion Injury and is a major cause of tissue damage after loss of blood flow. [See, Vedder et al., PNAS 87:2643-2646 (1990)]; **TNF** also alters the properties of endothelial cells and has vanous pro-coagulant activities, such as producing an increase in tissue factor. . . . protein C pathway as well as down-regulating the expression of thrombomodulin [See, Sherry et al., J. Cell Biol. 107:11269-1277 (1988)]. **TNF** also has pro-inflammatory activities which together with its early production (during the intial stage of an inflammatory event) make it. . . . in several important disorders including but not limited to, myocardial infarction, stroke and circulatory shock. Of specific importance may be **TNF**-induced expression of adhesion molecules, such as intercellular adhesion molucule (ICAM) or endothelial leukocyte adhesion molecule (ELAM) on endothelial cells [See,

DETDESC:

DETD(72)

Plasma levels of **TNF** were measured using a modification of the basic sandwich ELISA method described in Winston et al., Current Protocols in Molecular. . . 11.2.1, Ausubel et al., Ed. (1987) John Wiley and Sons, New York, USA. The Elisa employed a hamster monoclonal anti-mouse **TNF** (Genzyme, Boston, Mass., USA) as the capture **antibody** and a polyclonal rabbit anti-murine **TNF** (Genzyme, Boston, Mass., USA) as the detecting **antibody**. **TNF** levels in rat samples were calculated from a standard curve generated with recombinant murine **TNF** (Genzyme, Boston, Mass., USA). **TNF** levels determined by ELISA correlated with levels detected by the L929 bioassay of Ruff et. al., J. Immunol. 125:1671-1677 (1980), with 1 Unit of activity in the bioassay corresponding to 70 picograms (pg) of **TNF** in the ELISA. The ELISA detected levels of **TNF** down to 25 pg/ml.

DETDESC:

DETD(81)

Levels of **TNF** were measured using a modification of the basic sandwich ELISA assay method described in Winston et al., Current Protocols in. . . 11.2.1, Ausubel et al., Ed. (1987) John Wiley and Sons, New York, USA. The Elisa employs a murine monoclonal anti-human **TNF** **antibody**, described below, as the capture **antibody** and a polyclonal rabbit anti-human **TNF**, described below, as the second **antibody**. For detection, a peroxidase-conjugated goat anti-rabbit **antibody** (Boehringer Mannheim, Indianapolis, Ind., USA, Catalog #605222) was added followed by a substrate for peroxidase (1 mg/ml orthophenylenediamine with 0.1% urea peroxide). **TNF** levels in samples were calculated from a standard curve generated with recombinant human **TNF** produced in E. Coli (obtained from SmithKline Beecham Pharmaceuticals, King of Prussia, Pa., USA).

DETDESC:

DETD(82)

Production of Anti-Human **TNF** **Antibodies**

DETDESC:

DETD(83)

Monoclonal **antibodies** to human **TNF** were prepared from spleens of BALB/c mice immunized with recombinant human **TNF** using a modification of the method of Kohler and Millstein, Nature 256:495 (1975), the entire disclosure of which is hereby incorporated by reference. Polyclonal rabbit anti-human **TNF** **antibodies** were prepared by repeated immunization of New Zealand White (NZW) rabbits with recombinant human **TNF** emulsified in complete Freund's adjuvant (DEFCO, Ill., USA).

US PAT NO: 5,169,840 [IMAGE AVAILABLE]

L5: 8 of 8

SUMMARY:

BSUM(13)

Additionally, research has demonstrated that IL-1, **TNF**, and other leukocyte derived cytokines are important, and even critical, mediators in a wide variety of inflammatory states and diseases.. . . and antiviral effects. Additionally, therapeutic compositions comprising biologically active quantities of certain cytokines and derivatives could be employed to potentiate **antibody** production in response to vaccine antigens. Also, in view of potential therapeutic utility as vaccine adjuvants and components of wound-healing. . .

DETDESC:

DETD(3)

The terms "cytokine" and "lymphokines" as used herein mean a secretory product of a leukocyte, and in particular a non-**antibody** protein released by a leukocyte on contact with antigen and which acts as an intercellular mediator of immune response. Examples. . . by macrophages, and factors that mediate secretion of oxidizing agents, such as oxygen, superoxide, hydrogen peroxide and hydroxyl radical. Specifically, **TNF**, IL-1 and IL-6 have been tested as being representative of the various cytokines which may be found.

DETDESC:

DETD(26)

TNF-.alpha. activity was determined by its cytotoxic effect on the fibrosarcoma cell line WEHI 164 clone 13, as described (Espevik T.. . . human monocytes. J. Immunol. Methods, 95:99). Dilutions of rTNF-.alpha. (rTNF-.alpha. (human) and rMuTNF-.alpha., Genentech) were included as a standard. The **TNF**-.alpha. specificity of the assay was verified by using a monoclonal **antibody** against rTNF-.alpha. which completely neutralized the recorded activity (data not shown). Results are presented as ng/ml.+-.S.E. of triplicate determinations.

DETDESC:

DETD(40)

Because IL-1, IL-6, **TNF**, and other leukocyte derived cytokines have been implicated in such a wide variety of mammalian conditions, this invention has a. . . scope of application. Among the conditions that can be treated or alleviated by the inhibition or stimulation of IL-1, IL-6, **TNF**, and other leukocyte derived cytokines are: sepsis, septic shock, endotoxic shock, gram negative sepsis, toxic shock syndrome, adult respiratory distress,. . . to infection or malignancy, cachexia secondary to AIDS, rheumatoid arthritis, gouty arthritis, osteoporosis, keloid formation, scar tissue formation, decreased appetite, **Crohn**'***s** **disease**, ulcerative colitis, fever due to central nervous system bleeding, glomerulonephritis, multiple sclerosis, Creutzfeld-Jacob disease, adverse reactions to dialysis and psoriasis.
=> d his

(FILE 'USPAT' ENTERED AT 10:13:07 ON 03 FEB 97)

L1 69 S (CROHN(W)S(W)DISEASE) AND TNF
L2 68 S L1 AND (TREATMENT OR TREATING OR TREAT OR THERAPY OR THE
RAP
L3 26 S (CROHN(W)S(W)DISEASE) (P)TNF
L4 6 S L3(P) (TREATING OR TREAT OR THERAPEUTIC OR THERAPY OR TRE

ATM
 L5 8 S L3 AND (TNF(P)ANTIBOD?)
 => s l5 and methotrexate
 2246 METHOTREXATE
 L6 0 L5 AND METHOTREXATE
 => s tn timerantibod? and methotrexate
 1454 TNF
 21935 ANTIBOD?
 316 TNF(P)ANTIBOD?
 2246 METHOTREXATE
 L7 48 TNF(P)ANTIBOD? AND METHOTREXATE
 => s l7 and crohn?
 747 CROHN?
 L8 3 L7 AND CROHN?
 => d l8 1-3

1. 5,543,503, Aug. 6, 1996, Antibodies to human IL-8 type A receptor; Anan Chuntharapai, et al., 530/388.22; 424/85.2; 530/351, 389.2 [IMAGE AVAILABLE]
2. 5,468,772, Nov. 21, 1995, Tripterinin compound and method; Ren S. Xu, et al., 514/453, 825; 549/275, 281 [IMAGE AVAILABLE]
3. 5,440,021, Aug. 8, 1995, Antibodies to human IL-8 type B receptor; Anan Chuntharapai, et al., 530/388.22; 435/240.27; 530/388.23, 389.1, 389.2 [IMAGE AVAILABLE]
 => d l8 1-3 date

L8: 1 of 3

TITLE: Antibodies to human IL-8 type A receptor
 US PAT NO: 5,543,503 DATE ISSUED: Aug. 6, 1996
 [IMAGE AVAILABLE]
 APPL-NO: 08/076,093 DATE FILED: Jun. 11, 1993
 REL-US-DATA: Continuation-in-part of Ser. No. 810,782, Dec. 19, 1991,
 abandoned, which is a continuation-in-part of Ser. No.
 677,211, Mar. 29, 1991, abandoned.

L8: 2 of 3

TITLE: Tripterinin compound and method
 US PAT NO: 5,468,772 DATE ISSUED: Nov. 21, 1995
 [IMAGE AVAILABLE]
 APPL-NO: 08/031,288 DATE FILED: Mar. 10, 1993

L8: 3 of 3

TITLE: Antibodies to human IL-8 type B receptor
 US PAT NO: 5,440,021 DATE ISSUED: Aug. 8, 1995
 [IMAGE AVAILABLE]
 APPL-NO: 08/202,056 DATE FILED: Feb. 25, 1994
 REL-US-DATA: Continuation-in-part of Ser. No. 677,211, Mar. 29, 1991,
 abandoned.
 => d l8 1-3 kwic

US PAT NO: 5,543,503 [IMAGE AVAILABLE] L8: 1 of 3

DETDESC:

DETD(27)

As . . . include T cell inflammatory responses such as inflammatory skin diseases including psoriasis; responses associated with inflammatory bowel disease (such as **Crohn**'s disease and ulcerative colitis); adult respiratory distress syndrome; dermatitis; meningitis; encephalitis; uveitic; allergic conditions such as eczema and asthma and. . .

DETDESC:

DETD(81)

Expression . . . the culture medium. Typical selection genes encode proteins that (a) confer resistance to antibiotics or other toxins, e.g. ampicillin, neomycin, **methotrexate**, or tetracycline, (b) complement auxotrophic deficiencies, or (c) supply critical nutrients not available from complex media, e.g. the gene encoding. . .

DETDESC:

DETD(84)

For . . . with the DHFR selection gene are first identified by culturing all of the transformants in a culture medium that contains **methotrexate** (Mtx), a competitive antagonist of DHFR. An appropriate host cell when wild-type DHFR is employed is the Chinese hamster ovary. . . and Chasin, Proc. Natl. Acad. Sci. USA, 77: 4216 (1980). The transformed cells are then exposed to increased levels of **methotrexate**. This leads to the synthesis of multiple copies of the DHFR gene, and, concomitantly, multiple copies of other DNA comprising. . .

DETDESC:

DETD(223)

A 77% sequence identity between IL8RoA and IL8R-B was reported by Holmes et al., supra; however, the **antibodies** herein were specific for IL8R-A. IL8R-A does not recognize IL-1, **TNF**-.alpha., MCAF, fMLP, C5.alpha., PAF, and LTB4, but does recognize two other members of the C-X-C family, namely, MGSA and NAP-2.. . . bind IL-8 equally well with a high affinity but differ in their affinity to MGSA. Murphy and Tiffany, supra. Monoclonal **antibodies** 2A4 and 9H1 block 100% of the IL-8 binding to transfected 293 cells, 35-40% of the IL-8 binding to human. . . to human neutrophils in the presence of MGSA, which presumably blocked IL-8 binding to IL8R.degree. B. Thus, the blocking monoclonal **antibodies** herein interfere with the interaction between IL-8 and IL8R-A, but not with the interaction between IL-8 and IL8R-B. Both monoclonal **antibodies** 4C8 and 6E9 showed no blocking activities in IL-8 binding to both transfected cells and human neutrophils.

US PAT NO: 5,468,772 [IMAGE AVAILABLE]

L8: 2 of 3

SUMMARY:

BSUM(53)

Rheumatoid . . . antirheumatic drugs, known as "DMARDs" (antimalarials, gold salts, penicillamine, and sulfasalazine) and immunosuppressive agents (azathioprine, chlorambucil, high dose

corticosteroids, cyclophosphamide, **methotrexate**, nitrogen mustard, 6-mercaptopurine, vincristine, hydroxyurea, and cyclosporin A). The autoimmune diseases share a common underlying pathogenesis and the need for. . .

SUMMARY:

BSUM(55)

Investigators have shown that **TNF**.alpha. (tumor necrosis factor-.alpha.) also plays a significant role in the pathology of rheumatoid arthritis (Brennan). **TNF**.alpha. increases the severity of collagen induced arthritis in animal models (Brahm) while anti-**TNF**.alpha. **antibody** administration ameliorates collagen induced arthritis (Williams; et al.). **TNF**.alpha. is increased in the serum of RA patients (Holt, et al., 1992; Altomonte, et al., 1992), and both the cytokine. . . receptors have been identified in rheumatoid synovium, at the cartilage-pannus junction (Deleuran, et al.). Serum levels of both IL-1 and **TNF**.alpha. decline in RA patients following long term administration of the disease modifying drug sulfasalazine (Danis, et al.), suggesting that the. . .

SUMMARY:

BSUM(57)

Recognition . . . these cytokines in autoimmune disease has fostered the development of a new generation of therapeutic agents. Proteins such as monoclonal **antibodies** and soluble receptors targeted against IL-1 and **TNF**.alpha. are currently being evaluated in clinical trials for the treatment RA and other autoimmune diseases. Preliminary results of administration of anti-IL-1 monoclonal **antibodies** to a small group of rheumatoid patients suggest improvement in both the clinical and laboratory manifestations of the disease (Catalano). Administration of monoclonal **antibodies** to **TNF**.alpha. has also shown encouraging early results in a group of nine patients with severe RA (Elliott).

SUMMARY:

BSUM(66)

In . . . agent. The composition includes purified tripterinin in a pharmaceutically acceptable delivery vehicle. The composition may further include cyclosporin A, azathioprine, **methotrexate** or a glucocorticoid.

SUMMARY:

BSUM(70)

In both methods above, the tripterinin compound may be administered in combination with cyclosporin A, azathioprine, **methotrexate**, or a glucocorticoid.

SUMMARY:

BSUM(71)

Also . . . by administering to the subject, a therapeutically effective amount of purified tripterinin, or tripterinin in combination with cyclosporin A, azathioprine, ****methotrexate****, or a glucocorticoid.

DETDESC:

DETD(24)

As . . . below, the tripterinin compound is also intended for use in combination with an immunosuppressive drug, such as cyclosporin A, azathioprine, ****methotrexate**** or a glucocorticoid. The invention also includes a composition containing tripterinin in combination and one of these drugs. One preferred. . .

DETDESC:

DETD(39)

The effect of tripterinin on the production of the cytokines IL-1b, IL2, IL-6, IFN.gamma., and ****TNF****.alpha. was assessed by measurement of the concentration of these cytokines in PHA stimulated human PBL cultures. Cytokine levels were measured. . . in Example 6. Briefly, assay buffer was added to each of the wells of a microtiter plate containing pre-bound anti-cytokine ****antibody****, followed by addition of standard or sample solution, diluted appropriately for the cytokine concentration measured, followed by a second reporter-labeled ****antibody**** specific against the anti-cytokine ****antibody****.

DETDESC:

DETD(46)

TABLE 2

Autoimmune Diseases	
Disease	Tissue Affected
Addison's disease	adrenal
Allergies	inflammatory cells
Asthma	bronchi
Atherosclerosis	vessel walls
Crohn 's disease	intestine
Diabetes (Type I)	pancreas
Graves' disease	thyroid
Guillain-Barre Syndrome	nerve cells
Lupus erythematosus	multiple tissues
Multiple. . .	

DETDESC:

DETD(47)

In a general treatment method, the composition of the invention, comprising tripterinin alone or in combination with cyclosporin A, azathioprine, ****methotrexate****, or a glucocorticoid, is administered in an amount sufficient to lower the serum or synovial fluid activity levels

of one. . .

DETDESC:

DETD(51)

In . . . arthritis. As above, the patient is administered a dose of tripterinin, either alone or in combination with cyclosporin A, azathioprine, ****methotrexate****, or a glucocorticoid, in an amount sufficient to lower the serum or synovial fluid activity levels of one of the. . .

DETDESC:

DETD(52)

The . . . kidney, liver, and bone marrow transplants, by administering to the patient, tripterinin or tripterinin in combination with cyclosporin A, azathioprine, ****methotrexate****, or a glucocorticoid. Initial treatment is administered perioperatively. In addition, the composition may be administered chronically to prevent graft rejection..

US PAT NO: 5,440,021 [IMAGE AVAILABLE]

L8: 3 of 3

DETDESC:

DETD(21)

As . . . chemotaxis. Examples of such disorders include inflammatory skin diseases such as psoriasis; responses associated with inflammatory bowel disease (such as ****Crohn****'s disease and ulcerative colitis); adult respiratory distress syndrome; dermatitis; meningitis; encephalitis; uveitis; autoimmune diseases such as rheumatoid arthritis, Sjorgen's syndrome, . . .

DETDESC:

DETD(52)

Expression . . . the culture medium. Typical selection genes encode proteins that (a) confer resistance to antibiotics or other toxins, e.g. ampicillin, neomycin, ****methotrexate****, or tetracycline, (b) complement auxotrophic deficiencies, or (c) supply critical nutrients not available from complex media, e.g. the gene encoding. . .

DETDESC:

DETD(55)

For . . . with the DHFR selection gene are first identified by culturing all of the transformants in a culture medium that contains ****methotrexate**** (Mtx), a competitive antagonist of DHFR. An appropriate host cell when wild-type DHFR is employed is the Chinese hamster ovary. . . and Chasin, Proc. Natl. Acad. Sci. USA, 77: 4216 (1980). The transformed cells are then exposed to increased levels of ****methotrexate****. This leads to the synthesis of multiple copies of the DHFR gene, and, concomitantly, multiple copies of other DNA comprising.

DETDESC:

DETD(187)

The 4C8, 6E9, 2A4 and 9H1 monoclonal **antibodies** recognize IL8R-A but not IL8R-B, probably because these **antibodies** bind to the N-terminal residues of IL8R-A wherein the greatest dissimilarity exists between the two IL-8 receptors. The IL-8 receptors do not recognize IL-1, **TNF**-.alpha., MCAF, fMLP, C5a, PAF, and LTB4 but do recognize two other members of the C-X-C family, namely, MGSA and NAP-2.. . .

=> e feldmann/in

E#	FILE	FREQUENCY	TERM
--	----	-----	----
E1	USPAT	1	FELDMANE, GUNA Y/IN
E2	USPAT	1	FELDMANIS, CARL J/IN
E3	USPAT	0 -->	FELDMANN/IN
E4	USPAT	1	FELDMANN KRANE, GEORG/IN
E5	USPAT	1	FELDMANN SCHLOHBOHM, GUNTHER/IN
E6	USPAT	1	FELDMANN, ANDREA/IN
E7	USPAT	1	FELDMANN, DANIEL P/IN
E8	USPAT	1	FELDMANN, ECKARD/IN
E9	USPAT	1	FELDMANN, EKKEHARD/IN
E10	USPAT	2	FELDMANN, FRANZ/IN
E11	USPAT	1	FELDMANN, FREDERICK J/IN
E12	USPAT	1	FELDMANN, FREDERICK W/IN

=> e

E13	USPAT	1	FELDMANN, FRITZ/IN
E14	USPAT	7	FELDMANN, FRITZ K/IN
E15	USPAT	1	FELDMANN, HANS HELMUT/IN
E16	USPAT	1	FELDMANN, HANS UELI/IN
E17	USPAT	3	FELDMANN, HANSUELI/IN
E18	USPAT	2	FELDMANN, HELLMUTH/IN
E19	USPAT	1	FELDMANN, HENNIG/IN
E20	USPAT	6	FELDMANN, HERMAN F/IN
E21	USPAT	22	FELDMANN, HUGO/IN
E22	USPAT	17	FELDMANN, JOACHIM/IN
E23	USPAT	3	FELDMANN, JOHN/IN
E24	USPAT	1	FELDMANN, LARRY/IN

=> e

E25	USPAT	1	FELDMANN, MANFRED/IN
E26	USPAT	1	FELDMANN, MARTIN/IN
E27	USPAT	1	FELDMANN, MARVIN H/IN
E28	USPAT	7	FELDMANN, MICHEL/IN
E29	USPAT	1	FELDMANN, PETER/IN
E30	USPAT	22	FELDMANN, RAINER/IN
E31	USPAT	4	FELDMANN, ROBERT G/IN
E32	USPAT	2	FELDMANN, ROBERT J/IN
E33	USPAT	1	FELDMANN, THOMAS B/IN
E34	USPAT	2	FELDMANN, WILHELM/IN
E35	USPAT	2	FELDMANN, WILLIAM F/IN
E36	USPAT	1	FELDMANN, WILLIAM L/IN

=>

s methotrexate(20n)(arthritis or autoimmun? or crohn?)

5065 METHOTREXATE
13501 ARTHRITIS
6443 AUTOIMMUN?
2041 CROHN?

S4 136 METHOTREXATE(20N)(ARTHRTIS OR AUTOIMMUN? OR CROHN?)
? s s4(combin?)

>>>Invalid syntax
? s s4(20n)(combin?)

136 S4
1297907 COMBIN?
S5 27 S4(20N)(COMBIN?)
? t s5/3/all

5/3/1 (Item 1 from file: 653)
DIALOG(R)File 653:US Pat.Fulltext
(c) format only 1999 Knight-Ridder Info. All rts. reserv.

01833032

Utility
PYRIDO[2,3-D]PYRIMIDINE DERIVATIVES
[ANTITUMOR AGENTS]

PATENT NO.: 4,889,859
ISSUED: December 26, 1989 (19891226)
INVENTOR(s): Taylor, Edward C., Princeton, NJ (New Jersey), US (United States of America)
Shih, Chuan, Indianapolis, IN (Indiana), US (United States of America)
ASSIGNEE(s): The Trustees of Princeton University, (A U.S. Company or Corporation), Princeton, NJ (New Jersey), US (United States of America)
[Assignee Code(s): 67901]
APPL. NO.: 7-156,908
FILED: February 05, 1988 (19880205)
FULL TEXT: 541 lines

5/3/2 (Item 2 from file: 653)
DIALOG(R)File 653:US Pat.Fulltext
(c) format only 1999 Knight-Ridder Info. All rts. reserv.

01679086

Utility
TREATMENT OF ARTHRITIS WITH 3,5-DICHLOROMETHOTREXATE
[POST ADMINISTRATION OF LEUCOVORIN TO REDUCE SIDE EFFECTS]

PATENT NO.: 4,746,662
ISSUED: May 24, 1988 (19880524)
INVENTOR(s): Kerwar, Suresh S., Ossining, NY (New York), US (United States of America)
Sloboda, Adolph E., New City, NY (New York), US (United States of America)
ASSIGNEE(s): American Cyanamid Company, (A U.S. Company or Corporation), Stamford, CT (Connecticut), US (United States of America)
[Assignee Code(s): 2888]

APPL. NO.: 7-17,286
FILED: February 20, 1987 (19870220)
FULL TEXT: 337 lines

5/3/3 (Item 1 from file: 654)
DIALOG(R)File 654:US Pat.Full.
(c) format only 1999 The Dialog Corp. All rts. reserv.

03016517

Utility
ORTHO-SUBSTITUTED AROMATIC ETHER COMPOUNDS AND THEIR USE IN PHARMACEUTICAL
COMPOSITIONS FOR PAIN RELIEF

PATENT NO.: 5,965,741
ISSUED: October 12, 1999 (19991012)
INVENTOR(s): Breault, Gloria Anne, Congleton, GB (United Kingdom)
Tucker, Howard, Macclesfield, GB (United Kingdom)
Oldfield, John, Wilmslow, GB (United Kingdom)
Warner, Peter, Macclesfield, GB (United Kingdom)
ASSIGNEE(s): Zeneca Limited, (A Non-U.S. Company or Corporation), GB
(United Kingdom)
[Assignee Code(s): 32757]
APPL. NO.: 8-793,023
FILED: February 21, 1997 (19970221)
PRIORITY: 9417532, GB (United Kingdom), August 31, 1994 (19940831)
PCT: PCT-GB95-02030 (WO 95GB2030)
Section 371 Date: February 21, 1997 (19970221)
Section 102(e) Date: February 21, 1997 (19970221)
Filing Date: August 29, 1995 (19950829)
Publication Number: WO96-06822 (WO 966822)
Publication Date: March 07, 1996 (19960307)

This application is a national stage filing under 35 U.S.C. selection 371
of PCT-GB95-02030, filed Aug. 29, 1995.

FULL TEXT: 3926 lines

5/3/4 (Item 2 from file: 654)
DIALOG(R)File 654:US Pat.Full.
(c) format only 1999 The Dialog Corp. All rts. reserv.

02983736

Utility
TREATMENT OF **AUTOIMMUNE** DISEASE USING TOLERIZATION IN
COMBINATION WITH METHOTREXATE

PATENT NO.: 5,935,577
ISSUED: August 10, 1999 (19990810)
INVENTOR(s): Weiner, Howard L., Brookline, MA (Massachusetts), US (United
States of America)
Al-Sabbagh, Ahmad, West Roxbury, MA (Massachusetts), US
(United States of America)
Nelson, Patricia A., Palo Alto, CA (California), US (United
States of America)
ASSIGNEE(s): Autoimmune Inc, (A U.S. Company or Corporation), Lexington,
MA (Massachusetts), US (United States of America)
[Assignee Code(s): 35707]
APPL. NO.: 9-12,806
FILED: January 23, 1998 (19980123)

This application claims priority pursuant to 35 U.S.C. selection 119 from
Provisional Patent Application Serial No. 60-036,722 filed Jan. 24, 1997,
the disclosure of which is hereby incorporated in its entirety.

FULL TEXT: 1367 lines

5/3/5 (Item 3 from file: 654)
DIALOG(R)File 654:US Pat.Full.
(c) format only 1999 The Dialog Corp. All rts. reserv.

02913204

Utility

TREATMENT OF ARTHROPATHIES WITH VANADATE COMPOUNDS OR ANALOGUES THEREOF

PATENT NO.: 5,871,779
ISSUED: February 16, 1999 (19990216)
INVENTOR(s): Cruz, Tony, Etobicoke, CA (Canada)
ASSIGNEE(s): Mount Sinai Hospital Corporation, (A Non-U.S. Company or Corporation), Toronto, CA (Canada)
[Assignee Code(s): 21289]
APPL. NO.: 8-662,859
FILED: June 12, 1996 (19960612)

This is a continuation-in-part of PCT International Application No. PCT-CA95-00019, filed Jan. 18, 1995, designating the United States as a continuation-in-part of United States application Ser. No. 08-181,980, filed on Jan. 14, 1994, which are incorporated by reference.

FULL TEXT: 1742 lines

5/3/6 (Item 4 from file: 654)
DIALOG(R)File 654:US Pat.Full.
(c) format only 1999 The Dialog Corp. All rts. reserv.

02910569

Utility

METHODS OF RECEPTOR MODULATION AND USES THEREFOR

[Binding to cell surface receptors and affecting their trafficking pathway for the treatment and diagnosis of disorders in warm-blooded animals]

PATENT NO.: 5,869,465
ISSUED: February 09, 1999 (19990209)
INVENTOR(s): Morgan, Jr. A. Charles, Edmonds, WA (Washington), US (United States of America)
Wilbur, D. Scott, Edmonds, WA (Washington), US (United States of America)
ASSIGNEE(s): Receptagen Corporation, (A U.S. Company or Corporation), Edmonds, WA (Washington), US (United States of America)
University of Washington, (A U.S. Company or Corporation), Seattle, WA (Washington), US (United States of America)
[Assignee Code(s): 2937; 43825]
APPL. NO.: 8-406,194
FILED: March 16, 1995 (19950316)

CROSS-REFERENCE TO RELATED APPLICATION

This application is a continuation-in-part of U.S. patent application Ser. No. 08-224,831, filed Apr. 8, 1994, now abandoned.

FULL TEXT: 2659 lines

5/3/7 (Item 5 from file: 654)
DIALOG(R)File 654:US Pat.Full.
(c) format only 1999 The Dialog Corp. All rts. reserv.

02895781

Utility

METHODS FOR INHIBITING PROLIFERATION OF TUMOR CELLS AND TUMOR GROWTH
[A 7-(substituted amino)-9-(substituted glycyloamido)-6-demethyl-6-deoxytetra-
racycline]

PATENT NO.: 5,856,315
ISSUED: January 05, 1999 (19990105)
INVENTOR(s): Backer, Joseph M., Tenafly, NJ (New Jersey), US (United States
of America)
Bohlen, Peter, Cortland Manor, NY (New York), US (United
States of America)
ASSIGNEE(s): American Cyanamid Company, (A U.S. Company or Corporation),
Madison, NJ (New Jersey), US (United States of America)
[Assignee Code(s): 2888]
APPL. NO.: -84,484
FILED: May 26, 1998 (19980526)

CROSS REFERENCE TO RELATED APPLICATION

The present application is a division of U.S. patent application Ser. No.
08-354,694, filed Dec. 13, 1994, entitled "Method of Inhibiting
Angiogenesis, Proliferation of Endothelial or Tumor Cells and Tumor
Growth".

FULL TEXT: 787 lines

5/3/8 (Item 6 from file: 654)
DIALOG(R)File 654:US Pat.Full.
(c) format only 1999 The Dialog Corp. All rts. reserv.

02881814

Utility
AROMATIC AMINO ETHERS AS PAIN RELIEVING AGENTS

PATENT NO.: 5,843,942
ISSUED: December 01, 1998 (19981201)
INVENTOR(s): Breault, Gloria Anne, Congleton, GB (United Kingdom)
Tucker, Howard, Macclesfield, GB (United Kingdom)
Oldfield, John, Wilmslow, GB (United Kingdom)
Warner, Peter, Macclesfield, GB (United Kingdom)
ASSIGNEE(s): Zeneca Limited, (A Non-U.S. Company or Corporation), GB
(United Kingdom)
[Assignee Code(s): 32757]
APPL. NO.: 8-776,275
FILED: January 24, 1997 (19970124)
PRIORITY: 9414924, GB (United Kingdom), July 25, 1994 (19940725)
9501288, GB (United Kingdom), January 24, 1995 (19950124)
PCT: PCT-GB95-01728 (WO 95GB1728)
Section 371 Date: January 24, 1997 (19970124)
Section 102(e) Date: January 24, 1997 (19970124)
Filing Date: July 21, 1995 (19950721)
Publication Number: WO96-03380 (WO 963380)
Publication Date: February 08, 1996 (19960208)
FULL TEXT: 3960 lines

5/3/9 (Item 7 from file: 654)
DIALOG(R)File 654:US Pat.Full.
(c) format only 1999 The Dialog Corp. All rts. reserv.

02881797

Utility
METHODS FOR INHIBITING ANGIOGENESIS, PROLIFERATION OF ENDOTHELIAL OR TUMOR
CELLS AND TUMOR GROWTH

PATENT NO.: 5,843,925

ISSUED: December 01, 1998 (19981201)
INVENTOR(s): Backer, Joseph M., Tenafly, NJ (New Jersey), US (United States of America)
Bohlen, Peter, Cortland Manor, NY (New York), US (United States of America)
ASSIGNEE(s): American Cyanamid Company, (A U.S. Company or Corporation),
Madison, NJ (New Jersey), US (United States of America)
[Assignee Code(s): 2888]
APPL. NO.: 8-354,694
FILED: December 13, 1994 (19941213)
FULL TEXT: 877 lines

5/3/10 (Item 8 from file: 654)
DIALOG(R)File 654:US Pat.Full.
(c) format only 1999 The Dialog Corp. All rts. reserv.

02878460

Utility
RECEPTOR MODULATING AGENTS
[Vitamin b12 dimer]

PATENT NO.: 5,840,880
ISSUED: November 24, 1998 (19981124)
INVENTOR(s): Morgan, Jr. A. Charles, Edmonds, WA (Washington), US (United States of America)
Wilbur, D. Scott, Edmonds, WA (Washington), US (United States of America)
ASSIGNEE(s): Receptagen Corporation, (A U.S. Company or Corporation),
Edmonds, WA (Washington), US (United States of America)
University of Washington, (A U.S. Company or Corporation),
Seattle, WA (Washington), US (United States of America)
[Assignee Code(s): 2937; 43825]
APPL. NO.: 8-406,191
FILED: March 16, 1995 (19950316)

CROSS-REFERENCE TO RELATED APPLICATION

This application is a continuation-in-part of U.S. patent application Ser. No. 08-224,831, filed Apr. 8, 1994, abandoned.

FULL TEXT: 2703 lines

5/3/11 (Item 9 from file: 654)
DIALOG(R)File 654:US Pat.Full.
(c) format only 1999 The Dialog Corp. All rts. reserv.

02878297

Utility
WATER SOLUBLE VITAMIN B.SUB.12 RECEPTOR MODULATING AGENTS AND METHODS
RELATED THERETO
[Targets and linkers]

PATENT NO.: 5,840,712
ISSUED: November 24, 1998 (19981124)
INVENTOR(s): Morgan, Jr. A. Charles, Mill Creek, WA (Washington), US
(United States of America)
Wilbur, D. Scott, Edmonds, WA (Washington), US (United States of America)
Pathare, Pradip M., Seattle, WA (Washington), US (United States of America)
ASSIGNEE(s): Receptagen Corporation, (A U.S. Company or Corporation),
Edmonds, WA (Washington), US (United States of America)
University of WA, (A U.S. Company or Corporation), Edmonds, WA
(Washington), US (United States of America)
[Assignee Code(s): 2937; 43825]

APPL. NO.: 8-545,151
FILED: October 19, 1995 (19951019)

This application is a continuation-in-part of PCT-US95-04404, filed Apr. 7, 1995; which application is a continuation-in-part of U.S. patent applications Ser. No. 08-406,191, Ser. No. 08-406,192, now U.S. Pat. No. 5,739,287, and Ser. No. 08-406,194, all filed Mar. 16, 1995; which in turn are continuations-in part of U.S. application Ser. No. 08-224,831, filed Apr. 8, 1994 now abandoned.

FULL TEXT: 3610 lines

5/3/12 (Item 10 from file: 654)
DIALOG(R)File 654:US Pat.Full.
(c) format only 1999 The Dialog Corp. All rts. reserv.

02871419

Utility
SUBSTITUTED ARYL AND HETEROARYL COMPOUNDS AS E-TYPE PROSTAGLANDIN
ANTAGONISTS
[Antiinflammatory agents, antiarthritic agents, analgesics treating
rheumatic disease, bone disorder, injuries]

PATENT NO.: 5,834,468
ISSUED: November 10, 1998 (19981110)
INVENTOR(s): Breault, Gloria Anne, Congleton, GB (United Kingdom)
Oldfield, John, Wilmslow, GB (United Kingdom)
Tucker, Howard, Macclesfield, GB (United Kingdom)
Warner, Peter, Macclesfield, GB (United Kingdom)
ASSIGNEE(s): Zeneca Limited, (A Non-U.S. Company or Corporation), London,
GB (United Kingdom)
[Assignee Code(s): 32757]
APPL. NO.: 8-673,878
FILED: July 02, 1996 (19960702)
PRIORITY: 9513900, GB (United Kingdom), July 7, 1995 (19950707)
9513902, GB (United Kingdom), July 7, 1995 (19950707)
9513924, GB (United Kingdom), July 7, 1995 (19950707)
9513927, GB (United Kingdom), July 7, 1995 (19950707)
951903, GB (United Kingdom), July 7, 1995 (19950707)
951923, GB (United Kingdom), July 7, 1995 (19950707)
FULL TEXT: 2658 lines

5/3/13 (Item 11 from file: 654)
DIALOG(R)File 654:US Pat.Full.
(c) format only 1999 The Dialog Corp. All rts. reserv.

02846645

Utility
ORTHO SUBSTITUTED AROMATIC COMPOUNDS USEFUL AS ANTAGONISTS OF THE PAIN
ENHANCING EFFECTS OF E-TYPE PROSTAGLANDINS
[Pain relievers]

PATENT NO.: 5,811,459
ISSUED: September 22, 1998 (19980922)
INVENTOR(s): Breault, Gloria Ann, Congleton, GB (United Kingdom)
Oldfield, John, Wilmslow, GB (United Kingdom)
Tucker, Howard, Macclesfield, GB (United Kingdom)
Warner, Peter, Macclesfield, GB (United Kingdom)
ASSIGNEE(s): Zeneca Limited, (A Non-U.S. Company or Corporation), London,
GB (United Kingdom)
[Assignee Code(s): 32757]
APPL. NO.: 8-647,977
FILED: June 04, 1996 (19960604)
PRIORITY: 9420557, GB (United Kingdom), October 12, 1994 (19941012)

PCT: PCT-GB95-02417 (WO 95GB2417)
Section 371 Date: June 04, 1996 (19960604)
Section 102(e) Date: June 04, 1996 (19960604)
Filing Date: October 12, 1995 (19951012)
Publication Number: WO96-11902 (WO 9611902)
Publication Date: April 25, 1996 (19960425)
FULL TEXT: 5986 lines

5/3/14 (Item 12 from file: 654)
DIALOG(R)File 654:US Pat.Full.
(c) format only 1999 The Dialog Corp. All rts. reserv.

02796108

Utility
BENZOYLECGONINE, ECGONINE AND ECGONIDINE DERIVATIVES

PATENT NO.: 5,763,456
ISSUED: June 09, 1998 (19980609)
INVENTOR(s): Wynn, James E., Summerville, SC (South Carolina), US (United States of America)
Somers, Lowell M., Indio, CA (California), US (United States of America)
ASSIGNEE(s): Entropin, Inc , (A U.S. Company or Corporation), Indio, CA (California), US (United States of America)
[Assignee Code(s): 35052]
APPL. NO.: 8-750,901
FILED: February 28, 1997 (19970228)
PCT: PCT-US95-07268 (WO 95US7268)
Section 371 Date: February 28, 1997 (19970228)
Section 102(e) Date: February 28, 1997 (19970228)
Filing Date: June 14, 1995 (19950614)
Publication Number: WO95-34561 (WO 9534561)
Publication Date: December 21, 1995 (19951221)

CROSS-REFERENCE

This application is a 371 of PCT-US95-07268 filed Jun. 14, 1995.

FULL TEXT: 1007 lines

5/3/15 (Item 13 from file: 654)
DIALOG(R)File 654:US Pat.Full.
(c) format only 1999 The Dialog Corp. All rts. reserv.

02770545

Utility
BIOTINYLATED COBALAMINS
[Bound also to a receptor modulating agent to impede cell surface receptor trafficking pathways by inhibiting the recycling of receptors to the cell surface; antitumor and -carcinogenic agents; leukemia]

PATENT NO.: 5,739,287
ISSUED: April 14, 1998 (19980414)
INVENTOR(s): Wilbur, D. Scott, Edmonds, WA (Washington), US (United States of America)
Pathare, Pradip M., Seattle, WA (Washington), US (United States of America)
Morgan, Jr. A. Charles, Camino Island, WA (Washington), US (United States of America)
ASSIGNEE(s): Receptagen Corp , (A U.S. Company or Corporation), Edmonds, WA (Washington), US (United States of America)
University of Washington, (A U.S. Company or Corporation), Seattle, WA (Washington), US (United States of America)
[Assignee Code(s): 2937; 43825]

APPL. NO.: 8-406,192
FILED: March 16, 1995 (19950316)

CROSS-REFERENCE TO RELATED APPLICATION

This application is a continuation-in-part of U.S. patent application Ser. No. 08-224,831, filed Apr. 8, 1994, now abandoned.

FULL TEXT: 3187 lines

5/3/16 (Item 14 from file: 654)
DIALOG(R)File 654:US Pat.Full.
(c) format only 1999 The Dialog Corp. All rts. reserv.

02713485

Utility
ANTI-RECEPTOR AND GROWTH BLOCKING ANTIBODIES TO THE VITAMIN B.SUB.12
/TRANSCOBALAMIN II RECEPTOR AND BINDING SITES
[Antagonists]

PATENT NO.: 5,688,504
ISSUED: November 18, 1997 (19971118)
INVENTOR(s): Morgan, Jr. Alton Charles, Edmonds, WA (Washington), US
(United States of America)
ASSIGNEE(s): Receptagen Corporation, (A U.S. Company or Corporation),
Edmonds, WA (Washington), US (United States of America)
[Assignee Code(s): 43825]
APPL. NO.: 8-306,504
FILED: September 13, 1994 (19940913)

CROSS-REFERENCE TO RELATED APPLICATION

This application is a continuation-in-part of pending U.S. patent application Ser. No. 07-880,540, filed May 8, 1992 now abandoned.

FULL TEXT: 1791 lines

5/3/17 (Item 15 from file: 654)
DIALOG(R)File 654:US Pat.Full.
(c) format only 1999 The Dialog Corp. All rts. reserv.

02685300

Utility
DERIVATIVES OF BENZOYLECGONINE, ECGONINE AND ECGONIDINE AND METHODS FOR
PREPARING AND USING SAME
[Immunoregulatory, neuromuscular, joint and connective tissue disorders]

PATENT NO.: 5,663,345
ISSUED: September 02, 1997 (19970902)
INVENTOR(s): Somers, Lowell M., Indio, CA (California), US (United States
of America)
Wynn, James E., Summerville, SC (South Carolina), US (United
States of America)
ASSIGNEE(s): Entropin, Inc , (A U.S. Company or Corporation), Indio, CA
(California), US (United States of America)
[Assignee Code(s): 35052]
APPL. NO.: 8-463,123
FILED: June 05, 1995 (19950605)

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a division of application Ser. No. 08-320,050, filed Oct. 7, 1994, U.S. Pat. No. 5,559,123, which is a division of Ser. No. 07-999,307, filed Dec. 31, 1992, now U.S. Pat. No. 5,376,667.

FULL TEXT: 762 lines

5/3/18 (Item 16 from file: 654)
DIALOG(R)File 654:US Pat.Full.
(c) format only 1999 The Dialog Corp. All rts. reserv.

02588867

Utility

METHODS FOR INHIBITING ANGIOGENESIS PROLIFERATION OF ENDOTHELIAL OR TUMOR
CELLS AND TUMOR GROWTH
[Administering substituted 6-demethyl-6-deoxytetracycline]

PATENT NO.: 5,574,026
ISSUED: November 12, 1996 (19961112)
INVENTOR(s): Backer, Joseph M., Tenaflly, NJ (New Jersey), US (United States
of America)
Bohlen, Peter, Cortland Manor, NY (New York), US (United
States of America)
Sum, Phaik-Eng, Pomona, NY (New York), US (United States of
America)
ASSIGNEE(s): American Cyanamid Company, (A U.S. Company or Corporation),
Madison, NJ (New Jersey), US (United States of America)
[Assignee Code(s): 2888]
APPL. NO.: 8-355,392
FILED: December 13, 1994 (19941213)
FULL TEXT: 795 lines

5/3/19 (Item 17 from file: 654)
DIALOG(R)File 654:US Pat.Full.
(c) format only 1999 The Dialog Corp. All rts. reserv.

02581908

Utility

METHOD FOR INHIBITING ANGIOGENESIS, PROLIFERATION OF ENDOTHELIAL OR TUMOR
CELLS AND TUMOR GROWTH

PATENT NO.: 5,567,693
ISSUED: October 22, 1996 (19961022)
INVENTOR(s): Backer, Joseph M., Tenaflly, NJ (New Jersey), US (United States
of America)
Bohlen, Peter, Cortland Manor, NY (New York), US (United
States of America)
Sum, Phaik-Eng, Pomona, NY (New York), US (United States of
America)
ASSIGNEE(s): American Cyanamid Company, (A U.S. Company or Corporation),
Madison, NJ (New Jersey), US (United States of America)
[Assignee Code(s): 2888]
APPL. NO.: 8-354,688
FILED: December 13, 1994 (19941213)
FULL TEXT: 921 lines

5/3/20 (Item 18 from file: 654)
DIALOG(R)File 654:US Pat.Full.
(c) format only 1999 The Dialog Corp. All rts. reserv.

02576926

Utility

METHODS FOR INHIBITING ANGIOGENESIS, PROLIFERATION OF ENDOTHELIAL OR TUMOR
CELLS AND TUMOR GROWTH
[Administering 9-((substituted glycy)amido)-6-demethyl-6-deoxytetracycline
derivative]

PATENT NO.: 5,563,130

ISSUED: October 08, 1996 (19961008)
INVENTOR(s): Backer, Joseph M., Tenaflly, NJ (New Jersey), US (United States of America)
Bohlen, Peter, Cortland Manor, NY (New York), US (United States of America)
ASSIGNEE(s): American Cyanamid Company, (A U.S. Company or Corporation),
Madison, NJ (New Jersey), US (United States of America)
[Assignee Code(s): 2888]
APPL. NO.: 8-355,371
FILED: December 13, 1994 (19941213)
FULL TEXT: 714 lines

5/3/21 (Item 19 from file: 654)
DIALOG(R)File 654:US Pat.Full.
(c) format only 1999 The Dialog Corp. All rts. reserv.

02572490

Utility
DERIVATIVES OF BENZOYLECGONINE, ECGONINE AND ECGONIDINE AND METHODS FOR PREPARING AND USING SAME
[Treatment of disorders of neuromusclular system, joints connective tissues, myocardial ischemia, antiinflammatory agents, analgesics]

PATENT NO.: 5,559,123
ISSUED: September 24, 1996 (19960924)
INVENTOR(s): Somers, Lowell M., Indio, CA (California), US (United States of America)
Wynn, James E., Summerville, SC (South Carolina), US (United States of America)
ASSIGNEE(s): Entropin, Inc, (A U.S. Company or Corporation), Indio, CA (California), US (United States of America)
[Assignee Code(s): 35052]
APPL. NO.: 8-320,050
FILED: October 07, 1994 (19941007)

CROSS-REFERENCE TO RELATED APPLICATION

This application is a divisional of application Ser. No. 07-999,307, filed Dec. 31, 1992, U.S. Pat. No. 5,376,667.

FULL TEXT: 836 lines

5/3/22 (Item 20 from file: 654)
DIALOG(R)File 654:US Pat.Full.
(c) format only 1999 The Dialog Corp. All rts. reserv.

02547990

Utility
ANTIINFLAMMATORY AND ANTINEOPLASTIC 5-DEAZAAMINOPTERINS AND 5,10-DIDEAZAAMINOPTERINS

PATENT NO.: 5,536,724
ISSUED: July 16, 1996 (19960716)
INVENTOR(s): DeGraw, Joseph I., Sunnyvale, CA (California), US (United States of America)
Colwell, William T., Menlo Park, CA (California), US (United States of America)
Sirotnak, Francis M., New York, NY (New York), US (United States of America)
Smith, R. Lane, Palo Alto, CA (California), US (United States of America)
Piper, James R., Birmingham, AL (Alabama), US (United States of America)
ASSIGNEE(s): Sloan-Kettering Institute, (A U.S. Company or Corporation), New York, NY (New York), US (United States of America)

SRI International, (A U.S. Company or Corporation), Menlo Park
, CA (California), US (United States of America)
[Assignee Code(s): 1305; 2630]
EXTRA INFO: Assignment transaction [Reassigned], recorded August 26,
1997 (19970826)
Assignment transaction [Reassigned], recorded April 9,
1998 (19980409)
APPL. NO.: 8-140,793
FILED: October 21, 1993 (19931021)

This application is a continuation-in-part of the U.S. patent application for "Novel Antiinflammatory and Antineoplastic 10-Deazaaminopterins", Ser. No. 08-090,750, U.S. Pat. No. 5,354,751 filed on Jul. 12, 1993 which is a continuation-in-part of the PCT application U.S. Ser. No. 93-03965 filed on Apr. 28, 1993 entitled "Deazaaminopterins for Treatment of Inflammation", which is a continuation-in-part of the U.S. patent application for "Process for Preparing 10-Deazaaminopterins and 5,10- and 8,10-Dideazaaminopterins from Pteric Dicarboxylic Acid Diesters", Ser. No. 08-028,431 filed on Mar. 9, 1993 U.S. Pat. No. 5,374,726 and of the U.S. patent application for "Heteroaroyl-10-Deazaaminopterins and 5,10-Dideazaaminopterins for Treatment of Inflammation", Ser. No. 08-008,919 filed on Jan. 26, 1993 abandoned and of the U.S. patent application for "Heteroaroyl-10-deazaaminopterins for Treatment of Inflammation", Ser. No. 07-938,105 filed on Aug. 31, 1992 abandoned and of the U.S. patent application for "10-Alkenyl and 10-Alkynyl-10-Deazaaminopterins," Ser. No. 07-845,407 abandoned filed on Mar. 3, 1992, and of the U.S. patent application for "5-Deazaaminopterins and 5,10-Dideazaaminopterins for Treatment of Inflammation, Ser. No. 07-875,779 filed on Apr. 29, 1992 abandoned.

FULL TEXT: 2372 lines

5/3/23 (Item 21 from file: 654)
DIALOG(R)File 654:US Pat.Full.
(c) format only 1999 The Dialog Corp. All rts. reserv.

02535783

Utility
COVALENTLY COUPLED BENZOYLECGONINE ECGONINE AND ECGONIDINE
[Alleviating symptoms of autoimmune diseases, neuromuscular disorders, joint disorders, connective tissue disorders, circulatory disorders, pain]

PATENT NO.: 5,525,613
ISSUED: June 11, 1996 (19960611)
INVENTOR(s): Wynn, James E., Summerville, SC (South Carolina), US (United States of America)
Somers, Lowell M., Indio, CA (California), US (United States of America)
ASSIGNEE(s): Entropin, Inc, (A U.S. Company or Corporation), Indio, CA (California), US (United States of America)
[Assignee Code(s): 35052]
APPL. NO.: 8-260,054
FILED: June 16, 1994 (19940616)
FULL TEXT: 968 lines

5/3/24 (Item 22 from file: 654)
DIALOG(R)File 654:US Pat.Full.
(c) format only 1999 The Dialog Corp. All rts. reserv.

02472845

Utility
TRIPTERININ COMPOUND AND METHOD
[Immunosuppressive compounds for treatment of arthritis]

PATENT NO.: 5,468,772
ISSUED: November 21, 1995 (19951121)
INVENTOR(s): Xu, Ren S., Palo Alto, CA (California), US (United States of America)
Wiedmann, Tien W., Stanford, CA (California), US (United States of America)
ASSIGNEE(s): Pharmagenesis, Inc, (A U.S. Company or Corporation), Palo Alto, CA (California), US (United States of America)
[Assignee Code(s): 37461]
APPL. NO.: 8-31,288
FILED: March 10, 1993 (19930310)
FULL TEXT: 819 lines

5/3/25 (Item 23 from file: 654)
DIALOG(R)File 654:US Pat.Full.
(c) format only 1999 The Dialog Corp. All rts. reserv.

02370237

Utility
DERIVATIVES OF BENZOYLECGONINE, ECGONINE AND THEIR MULTIPLE PHARMACOLOGICAL PROPERTIES
[Immunoregulatory, neuromuscular disorders, pain]

PATENT NO.: 5,376,667
ISSUED: December 27, 1994 (19941227)
INVENTOR(s): Somers, Lowell M., Indio, CA (California), US (United States of America)
Wynn, James E., Summerville, SC (South Carolina), US (United States of America)
ASSIGNEE(s): Entropin, Inc, (A U.S. Company or Corporation), Indio, CA (California), US (United States of America)
[Assignee Code(s): 35052]
APPL. NO.: 7-999,307
FILED: December 31, 1992 (19921231)
FULL TEXT: 838 lines

5/3/26 (Item 24 from file: 654)
DIALOG(R)File 654:US Pat.Full.
(c) format only 1999 The Dialog Corp. All rts. reserv.

02345901

Utility
HETEROAROYL 10-DEAZAAMINO-PTERINE COMPOUNDS AND USE FOR RHEUMATOID ARTHRITIS
[Antiinflammatory agents, leukemia]

PATENT NO.: 5,354,751
ISSUED: October 11, 1994 (19941011)
INVENTOR(s): DeGraw, Joseph I., Sunnyvale, CA (California), US (United States of America)
Colwell, William T., Menlo Park, CA (California), US (United States of America)
Sirotnak, Francis M., New York, NY (New York), US (United States of America)
Smith, R. Lane, Palo Alto, CA (California), US (United States of America)
Piper, James R., Birmingham, AL (Alabama), US (United States of America)
ASSIGNEE(s): SRI International, (A U.S. Company or Corporation), Menlo Park, CA (California), US (United States of America)
[Assignee Code(s): 2630]
EXTRA INFO: Assignment transaction [Reassigned], recorded August 26, 1997 (19970826)

Assignment transaction [Reassigned], recorded April 9,
1998 (19980409)
APPL. NO.: 8-90,750
FILED: July 12, 1993 (19930712)

This application is a continuation-in-part of the U.S. patent application for "Process for Preparing 10-Deazaaminopterin and 5,10- and 8,10-Dideazaaminopterin from Pteric Dicarboxylic Acid Diesters" Ser. No. 08-028,431 pending filed on Mar. 9, 1993 and of the U.S. patent application for "Heteroaroyl-10-Deazaaminopterin and 5,10-Dideazaaminopterin for Treatment of Inflammation" Ser. No. 08-008,919 pending filed on Jan. 26, 1993 and of the U.S. patent application for "Heteroaroyl-10-deazaaminopterin for Treatment of Inflammation" Ser. No. 07-938,105 filed on Aug. 31, 1992 now abandoned and of the U.S. patent application for "10-Alkenyl and 10-Alkynyl-10-Deazaaminopterin," Ser. No. 07-845,407 filed on Mar. 3, 1992, now abandoned and of the U.S. patent application for "5-Deazaaminopterin and 5,10-Dideazaaminopterin for Treatment of Inflammation, Ser.No. 07-875,779 filed on Apr. 29, 1992, now abandoned.

FULL TEXT: 1695 lines

5/3/27 (Item 25 from file: 654)
DIALOG(R)File 654:US Pat.Full.
(c) format only 1999 The Dialog Corp. All rts. reserv.

01987553

Utility

10-DEAZAAMINOPTERIN: A NEW ARTHRITIS REMITTIVE DRUG
[10-Deazaaminopterin: a new arthritis remittive drug]

PATENT NO.: 5,030,634
ISSUED: July 09, 1991 (19910709)
INVENTOR(s): Krumdieck, Carlos L., 3408 Welford Cir., Birmingham, AL
(Alabama), US (United States of America), 35226
Castaneda, Oswaldo, Apartment 2713, Clinica Anglo Americana,
Lima, PE (Peru)
Alarcon, Graciela, 1221 Rumson Dr., Birmingham, AL (Alabama),
US (United States of America), 35226
Koopman, William J., 452-H Wildwood La., Helena, AL (Alabama),
US (United States of America), 35080
Nair, Madhavan G., 7005 Charleston Oaks Dr., Mobile, AL
(Alabama), US (United States of America), 36695
[Assignee Code(s): 68000]
EXTRA INFO: Expired, effective July 9, 1999 (19990709), recorded in O.G.
of September 7, 1999 (19990907)
APPL. NO.: 7-500,911
FILED: March 29, 1990 (19900329)
FULL TEXT: 347 lines
? t s5/k/4,26,27

5/K/4 (Item 2 from file: 654)
DIALOG(R)File 654:(c) format only 1999 The Dialog Corp. All rts. reserv.

TREATMENT OF **AUTOIMMUNE** DISEASE USING TOLERIZATION IN
COMBINATION WITH **METHOTREXATE**

ABSTRACT

A **combination** of a mucosally administrable bystander antigen and an orally, enterally, or parenterally administrable **methotrexate** is employed to make a pharmaceutical formulation and to treat or prevent **autoimmune** disease. The amounts of bystander antigen and **methotrexate** are effective in **combination** to suppress **autoimmune** response associated with the **autoimmune** disease

...autoantigens or bystanders antigens.

None of these applications, however, describes any form of tolerization in **combination** with methotrexate therapy. Also, prior to the present invention, it was not known whether **methotrexate**, which inhibits cell division, would inhibit cells involved in mediating mucosal tolerance in the treatment of **autoimmune** disease.

One object of the invention is to allow administration of less toxic amounts of **methotrexate** in the treatment of **autoimmune** diseases.

An additional object is to allow administration of **methotrexate** in more frequent administrations in order to reduce the amount that is administered at one...

...OF THE INVENTION

In one embodiment, the present invention relates to a method for treating **autoimmune** disease. The method involves mucosally administering a bystander antigen. The method also involves orally, enterally, or parenterally administering **methotrexate**. The amounts of bystander antigen and **methotrexate** are effective in **combination** to suppress **autoimmune** response associated with the **autoimmune** disease.

In another embodiment, the present invention relates to a pharmaceutical **combination** for oral or enteral administration to treat **autoimmune** disease. The **combination** comprises **methotrexate** and a bystander antigen, the amounts of the bystander antigen and **methotrexate** being effective in **combination** to suppress **autoimmune** response associated with the **autoimmune** disease.

In another embodiment, the present invention relates to a method for treating **autoimmune** disease. The method involves mucosally administering an autoantigen. The method also involves orally, enterally, or parenterally administering **methotrexate**. The amounts of autoantigen and **methotrexate** are effective in **combination** to suppress **autoimmune** response associated with the disease.

In another embodiment, the present invention relates to a pharmaceutical **combination** for oral or enteral administration to treat **autoimmune** disease. The **combination** comprises **methotrexate** and an autoantigen, the amounts of the autoantigen and **methotrexate** being effective in **combination** to suppress **autoimmune** response associated with the **autoimmune** disease.
...of each treatment separately.

In one embodiment, the present invention allows a lower amount of **methotrexate** to be administered for treatment of **autoimmune** disease than would otherwise be necessary (a suboptimal dose). This is highly advantageous because of **methotrexate**'s high toxicity. Thus, for example, the suppressive effect of administering a **combination** of methotrexate and MBP has been found to be more effective than the effect of ...interfere with this benefit of mucosal tolerization.

In addition, it has been determined that the **combination** of methotrexate and tolerizing agent can be frequently administered at lower doses per administration. While **methotrexate** is normally administered once a week in a high dose to treat **autoimmune** disease, the **combination** of the invention has been found to be effective when administered three times a week... is one observed by a clinician of ordinary skill in the field of a particular **autoimmune** disease.)

When **combined** with **methotrexate** treatment, the dosage of

bystander antigen (or autoantigen) may equal that ...have been used if the bystander antigen (or autoantigen) was administered alone, except that the **combination** is more effective in abating **autoimmune** reaction.

Where the dosage of **methotrexate** is as high as that where **methotrexate** is used alone, the **combination** with a bystander antigen or autoantigen can result in enhanced suppressive effects. Alternately, a sub... the information disclosed herein and well known information concerning administration of bystander antigens, autoantigens, and **methotrexate**. Routine variation of dosages, **combinations**, and duration of treatment is performed under circumstances wherein the severity of **autoimmune** reaction can be measured. Useful dosage and administration parameters are those that result in reduction...dose of **methotrexate** can be administered than is optimal, but, as a result of the **combination** with MBP, a suppressive effect is achieved that is similar to that of an optimal dose of **methotrexate** alone. In addition, the **combination** eliminates the rebound effect associated with **methotrexate** administration alone.

EXAMPLE 3

Suppression of Collagen Induced **Arthritis** in Mice with a **Combination** of **Methotrexate** and Tolerizing Agent

DBA/J1 mice were orally dosed once a day for 5 consecutive...
...that is, or is derived from, a component specific to the organ or tissue under **autoimmune** attack; and

(b) orally, enterally, or parenterally administering **methotrexate**;

wherein the amounts of said bystander antigen and **methotrexate** are effective in **combination** to suppress **autoimmune** response associated with said disease.

2. The method of claim 1 wherein said bystander antigen and said **methotrexate** are more effective in suppressing said response in **combination** compared to the suppressive effects achieved by administering each alone.

3. The method of claim...of a composition comprising MBP; and

(b) orally, enterally, or parenterally administering an amount of **methotrexate**;

wherein the amounts of said composition and **methotrexate** are effective in **combination** in suppressing **autoimmune** response associated with said disease.

16. The method of claim 15 wherein said composition comprises...
...method of claim 18 wherein said composition is bovine myelin.

20. A method for treating **autoimmune** disease comprising:

(a) mucosally administering an autoantigen; and

(b) orally, enterally, or parenterally administering **methotrexate**;

wherein the amounts of said autoantigen and **methotrexate** are effective in **combination** to suppress **autoimmune** response associated with said disease.

21. The method of claim 20 wherein said disease is...

... a bystander antigen, wherein the amounts of said bystander antigen and **methotrexate** are effective in **combination** to suppress **autoimmune** response associated with said disease.

23. A pharmaceutical formulation for oral or enteral administration to treat **autoimmune** disease, said formulation comprising **methotrexate** and an autoantigen, wherein the amounts of said

autoantigen and **methotrexate** are effective in **combination** to suppress **autoimmune** response associated with said disease.

5/K/26 (Item 24 from file: 654)
DIALOG(R)File 654:(c) format only 1999 The Dialog Corp. All rts. reserv.

... and despite therapies including disease-modifying antirheumatic drugs such as gold complexes, penicillamine, antimalarials, and **methotrexate** often require surgical joint replacement. In some patients with intractable rheumatoid **arthritis**, administration of immunosuppressive agents including azathioprine, **methotrexate**, cyclophosphamide, and **combinations** of these drugs have been proven beneficial. However, the actual or potential side effects of...

5/K/27 (Item 25 from file: 654)
DIALOG(R)File 654:(c) format only 1999 The Dialog Corp. All rts. reserv.

... The results established that 10-deazaaminopterin is at least equally effective in all respects to **methotrexate** in the treatment of rheumatoid **arthritis**, and clearly superior to **methotrexate** in controlling pain, joint stiffness and in improving grip strength. **Combined** with the low frequency of toxicity and unexpectedly high attrition rate make 10-deazaaminopterin a superior drug than **methotrexate** in the treatment of rheumatoid **arthritis** in humans.

In accordance with the foregoing disclosure it has been determined that rheumatoid **arthritis** can be ameliorated in humans by the administration of 10-deazaaminopterin.

10-deazaaminopterin can be...

ENTER PASSWORD:

□p58093fe

Welcome to DIALOG

Dialog leel 99.07.29D

Lat logoff: 19no99 11:38:22

Logon file001 20no99 17:37:15

ANNOUNCEMENT ***** ANNOUNCEMENT ***** ANNOUNCEMENT

NEW

***Kompa Mexico (File 586)

***Market Gide Compan Financial (File 100)

***Frot & Sllian Market Engineering (File 767)

RELOADED

***CLAIMS(r)/U.S. Patent (File 340,341,942)

***Gale Grop PROMT (File 16, 160)

***Gale Grop F&S Index (File 18)

***RAPRA (File 323)

***Gale Grop New Prodct Annoncement (File 621)

REMOVED

***The Colmb Dipatch (File 495)

***A-V Online (File 46)

>>> Enter BEGIN HOMEBASE for Dialog Annoncement <<<

>>> of new databae, price change, etc. <<<

□dialog

* * *

* * *

File 1:ERIC 1966-1999/Oct

(c) format only 1999 The Dialog Corporation

*File 1: File has been reloaded. See HELP NEWS 1.

Limits of /ED and /EJ currently not working.

Set Items Description

--- -----

? b 410

>>>'IALOG' not recognized as set or accession number

? set hi ;set hi

20nov99 17:37:21 User208760 Session D1351.1

\$0.33 0.102 DialUnits File1

\$0.33 Estimated cost File1

\$0.05 TYMNET

\$0.38 Estimated cost this search

\$0.38 Estimated total session cost 0.102 DialUnits

File 410:Chronolog(R) 1981-1999 Sep/Oct

(c) 1999 The Dialog Corporation plc

Set Items Description

--- -----

?

HILIGHT set on as ''

HILIGHT set on as ''

? begin 652,653,654

20nov99 17:37:34 User208760 Session D1351.2

\$0.00 0.049 DialUnits File410
\$0.00 Estimated cost File410
\$0.01 TYMNET
\$0.01 Estimated cost this search
\$0.39 Estimated total session cost 0.150 DialUnits

SYSTEM:OS - DIALOG OneSearch

File 652:US Patents Fulltext 1971-1979

(c) format only 1999 The Dialog Corp.

*File 652: Reassignment data now current through 07/09/99

Reexamination, extension, expiration, reinstatement updated weekly.

File 653:US Pat.Fulltext 1980-1989

(c) format only 1999 Knight-Ridder Info

*File 653: Reassignment data now current through 07/09/99.

Reexamination, extension, expiration, reinstatement updated weekly.

File 654:US Pat.Full. 1990-1999/Nov 16

(c) format only 1999 The Dialog Corp.

*File 654: Reassignment data current through 07/09/99.

Set Items Description

--- -----

? e au=le

Ref	Items	Index-term
E1	1	AU=LDERS
E2	1	AU=LDERS WERNER M
E3	3123	*AU=LE
E4	1	AU=LE AN
E5	18	AU=LE AN V
E6	2	AU=LE AN VAN
E7	1	AU=LE ANDREW D
E8	1	AU=LE ANDREW D T
E9	3	AU=LE ANH
E10	2	AU=LE ANH H
E11	1	AU=LE ANH V
E12	1	AU=LE BAIGUE JACQUES L

Enter P or PAGE for more

? e au=le junming

Ref	Items	Index-term
E1	5	AU=LE JOHANNES
E2	1	AU=LE JOHN O
E3	4	*AU=LE JUNMING
E4	1	AU=LE K ALLEN
E5	1	AU=LE KHA
E6	1	AU=LE KHA H
E7	24	AU=LE KHAC BI
E8	1	AU=LE KHAI M
E9	1	AU=LE KHANH T
E10	1	AU=LE KIM C
E11	1	AU=LE KIM CHI
E12	1	AU=LE KIM-CHI

Enter P or PAGE for more

? s e3

S1 4 AU="LE JUNMING"

? t s1/3/all

1/3/1 (Item 1 from file: 653)

DIALOG(R)File 653:US Pat.Fulltext
(c) format only 1999 Knight-Ridder Info. All rts. reserv.

01592794

Utility

IMMUNOASSAY FOR BIOLOGICALLY ACTIVE HUMAN INTERFERON-GAMMA EMPLOYING UNIQUE
MONOCLONAL ANTIBODIES

PATENT NO.: 4,666,865

ISSUED: May 19, 1987 (19870519)

INVENTOR(s): Chang, Tse W., Paoli, PA (Pennsylvania), US (United States of
America)

Kung, Patrick C., Villanova, PA (Pennsylvania), US (United
States of America)

Le, Junming, New York, NY (New York), US (United States of
America)

Liu, Victor, Malvern, PA (Pennsylvania), US (United States of
America)

Vilcek, Jan, New York, NY (New York), US (United States of
America)

ASSIGNEE(s): Centocor, Inc , (A U.S. Company or Corporation), Malvern, PA
(Pennsylvania), US (United States of America)
[Assignee Code(s): 12273]

EXTRA INFO: Assignment transaction [Reassigned], recorded November 10,
1998 (19981110)

Expired, effective May 24, 1995 (19950524), recorded in O.G.
of August 1, 1995 (19950801)

APPL. NO.: 6-570,353

FILED: January 13, 1984 (19840113)

FULL TEXT: 1152 lines

1/3/2 (Item 1 from file: 654)

DIALOG(R)File 654:US Pat.Full.

(c) format only 1999 The Dialog Corp. All rts. reserv.

02966750

Utility

METHODS OF TREATING TNF.ALPHA.-MEDIATED DISEASE USING CHIMERIC ANTI-TNF
ANTIBODIES

PATENT NO.: 5,919,452

ISSUED: July 06, 1999 (19990706)

INVENTOR(s): Le, Junming, Jackson Heights, NY (New York), US (United
States of America)

Vilcek, Jan, New York, NY (New York), US (United States of
America)

Dadonna, Peter, Palo Alto, CA (California), US (United States
of America)

Ghrayeb, John, Thorndale, PA (Pennsylvania), US (United States
of America)

Knight, David, Berwyn, PA (Pennsylvania), US (United States of
America)

Seigal, Scott, Westborough, MA (Massachusetts), US (United
States of America)

ASSIGNEE(s): Centocor, Inc , (A U.S. Company or Corporation), Malvern, PA
(Pennsylvania), US (United States of America)
New York University, (A U.S. Company or Corporation), New York
, NY (New York), US (United States of America)
[Assignee Code(s): 12273; 59449]

APPL. NO.: 8-192,861

FILED: February 04, 1994 (19940204)

This application is a continuation-in-part of each of U.S. application
Ser. No. 08-010,406, filed Jan. 29, 1993 now abandoned; and U.S.
application Ser. No. 08-013,413, filed Feb. 2, 1993, now abandoned, which

is a continuation-in-part of U.S. application Ser. No. 07-943,852, filed Sep. 11, 1992, now abandoned, which is a continuation-in-part of U.S. application Ser. No. 07-853,606, filed Mar. 18, 1992, now abandoned, which is a continuation-in-part of U.S. application Ser. No. 07-670,827 filed Mar. 18, 1991, now abandoned. Each of the above applications are entirely incorporated herein by reference.

FULL TEXT: 5413 lines

1/3/3 (Item 2 from file: 654)
DIALOG(R)File 654:US Pat.Full.
(c) format only 1999 The Dialog Corp. All rts. reserv.

02724381

Utility

METHODS OF TREATING RHEUMATOID ARTHRITIS USING CHIMERIC ANTI-TNF ANTIBODIES
[Administering chimeric antibody comprising non-human variable region or tumor necrosis factor antigen-binding portion thereof and human constant region]

PATENT NO.: 5,698,195
ISSUED: December 16, 1997 (19971216)
INVENTOR(s): **Le**, Junming, Jackson Heights, NY (New York), US (United States of America)
Vilcek, Jan, New York, NY (New York), US (United States of America)
Daddona, Peter, Menlo Park, CA (California), US (United States of America)
Ghrayeb, John, Thorndale, PA (Pennsylvania), US (United States of America)
Knight, David, Berwyn, PA (Pennsylvania), US (United States of America)
Siegel, Scott, Westborough, MA (Massachusetts), US (United States of America)
ASSIGNEE(s): Centocor, Inc , (A U.S. Company or Corporation), Malvern, PA (Pennsylvania), US (United States of America)
New York University Medical Center, (A U.S. Company or Corporation), New York, NY (New York), US (United States of America)
[Assignee Code(s): 12273; 35102]
EXTRA INFO: Assignment transaction [Reassigned], recorded December 28, 1998 (19981228)
APPL. NO.: 8-324,799
FILED: October 18, 1994 (19941018)

RELATED APPLICATIONS

This application is a continuation-in-part of each of U.S. application Ser. No. 08-192,102, filed Feb. 4, 1994, U.S. application Ser. No. 08-192,061, filed Feb. 4, 1994, now abandoned, and U.S. application Ser. No. 08-192,093, filed Feb. 4, 1994, now abandoned, which are all continuations-in-part of each of U.S. application Ser. No. 08-010,406, filed Jan. 29, 1993, now abandoned, and U.S. application Ser. No. 08-013,413, filed Feb. 2, 1993, now abandoned, which is a continuation-in-part of U.S. application Ser. No. 07-943,852, filed Sep. 11, 1992, now abandoned, which is a continuation-in-part of U.S. application Ser. No. 07-853,606, filed Mar. 18, 1992, now abandoned, which is a continuation-in-part of U.S. application Ser. No. 07-670,827, filed Mar. 18, 1991, now abandoned. Each of the above non-abandoned applications are entirely incorporated herein by reference.

FULL TEXT: 6239 lines

1/3/4 (Item 3 from file: 654)

DIALOG(R)File 654:US Pat.Full.
(c) format only 1999 The Dialog Corp. All rts. reserv.

02677406

Utility

METHODS OF TREATING TNF-.ALPHA.-MEDIATED CROHN'S DISEASE USING CHIMERIC
ANTI-TNF ANTIBODIES
[Human tumor necrosis factor antibodies]

PATENT NO.: 5,656,272

ISSUED: August 12, 1997 (19970812)

INVENTOR(s): **Le**, Junming, Jackson Heights, NY (New York), US (United
States of America)
Vilcek, Jan, New York, NY (New York), US (United States of
America)
Dadonna, Peter, Palo Alto, CA (California), US (United States
of America)
Ghrayeb, John, Thorndale, PA (Pennsylvania), US (United States
of America)
Knight, David, Berwyn, PA (Pennsylvania), US (United States of
America)
Siegel, Scott A., Westborough, MA (Massachusetts), US (United
States of America)

ASSIGNEE(s): Centocor, Inc, (A U.S. Company or Corporation), Malvern, PA
(Pennsylvania), US (United States of America)
New York University Medical Center, (A U.S. Company or
Corporation), New York, NY (New York), US (United States of
America)
[Assignee Code(s): 12273; 35102]

EXTRA INFO: Assignment transaction [Reassigned], recorded December 28,
1998 (19981228)

APPL. NO.: 8-192,102

FILED: February 04, 1994 (19940204)

This application is a continuation-in-part of each of U.S. application
Ser. No. 08-010,406, filed Jan. 29, 1993, now abandoned, and U.S.
application Ser. No. 08-013,413, filed Feb. 2, 1993, now abandoned, which
is a continuation-in-part of U.S. application Ser. No. 07-943,852, filed
Sep. 11, 1992, now abandoned, which is a continuation-in-part of U.S.
application Ser. No. 07-853,606, filed Mar. 18, 1992, now abandoned, which
is a continuation-in-part of U.S. application Ser. No. 07-670,827, filed
Mar. 18, 1991, now abandoned. Each of the above non-abandoned applications
is entirely incorporated herein by reference.

FULL TEXT: 5309 lines

? s s1 and methotrexate

4 S1
5065 METHOTREXATE
S2 3 S1 AND METHOTREXATE
? t s2/3/all

2/3/1 (Item 1 from file: 654)

DIALOG(R)File 654:US Pat.Full.

(c) format only 1999 The Dialog Corp. All rts. reserv.

02966750

Utility

METHODS OF TREATING TNF.ALPHA.-MEDIATED DISEASE USING CHIMERIC ANTI-TNF
ANTIBODIES

PATENT NO.: 5,919,452

ISSUED: July 06, 1999 (19990706)

INVENTOR(s): **Le**, Junming, Jackson Heights, NY (New York), US (United
States of America)

Vilcek, Jan, New York, NY (New York), US (United States of America)
Dadonna, Peter, Palo Alto, CA (California), US (United States of America)
Ghrayeb, John, Thorndale, PA (Pennsylvania), US (United States of America)
Knight, David, Berwyn, PA (Pennsylvania), US (United States of America)
Seigal, Scott, Westborough, MA (Massachusetts), US (United States of America)
ASSIGNEE(s): Centocor, Inc , (A U.S. Company or Corporation), Malvern, PA (Pennsylvania), US (United States of America)
New York University, (A U.S. Company or Corporation), New York , NY (New York), US (United States of America)
[Assignee Code(s): 12273; 59449]
APPL. NO.: 8-192,861
FILED: February 04, 1994 (19940204)

This application is a continuation-in-part of each of U.S. application Ser. No. 08-010,406, filed Jan. 29, 1993 now abandoned; and U.S. application Ser. No. 08-013,413, filed Feb. 2, 1993, now abandoned, which is a continuation-in-part of U.S. application Ser. No. 07-943,852, filed Sep. 11, 1992, now abandoned, which is a continuation-in-part of U.S. application Ser. No. 07-853,606, filed Mar. 18, 1992, now abandoned, which is a continuation-in-part of U.S. application Ser. No. 07-670,827 filed Mar. 18, 1991, now abandoned. Each of the above applications are entirely incorporated herein by reference.

FULL TEXT: 5413 lines

2/3/2 (Item 2 from file: 654)
DIALOG(R)File 654:US Pat.Full.
(c) format only 1999 The Dialog Corp. All rts. reserv.

02724381

Utility

METHODS OF TREATING RHEUMATOID ARTHRITIS USING CHIMERIC ANTI-TNF ANTIBODIES
[Administering chimeric antibody comprising non-human variable region or tumor necrosis factor antigen-binding portion thereof and human constant region]

PATENT NO.: 5,698,195
ISSUED: December 16, 1997 (19971216)
INVENTOR(s): Le, Junming, Jackson Heights, NY (New York), US (United States of America)
Vilcek, Jan, New York, NY (New York), US (United States of America)
Daddona, Peter, Menlo Park, CA (California), US (United States of America)
Ghrayeb, John, Thorndale, PA (Pennsylvania), US (United States of America)
Knight, David, Berwyn, PA (Pennsylvania), US (United States of America)
Siegel, Scott, Westborough, MA (Massachusetts), US (United States of America)
ASSIGNEE(s): Centocor, Inc , (A U.S. Company or Corporation), Malvern, PA (Pennsylvania), US (United States of America)
New York University Medical Center, (A U.S. Company or Corporation), New York, NY (New York), US (United States of America)
[Assignee Code(s): 12273; 35102]
EXTRA INFO: Assignment transaction [Reassigned], recorded December 28, 1998 (19981228)
APPL. NO.: 8-324,799
FILED: October 18, 1994 (19941018)

RELATED APPLICATIONS

This application is a continuation-in-part of each of U.S. application Ser. No. 08-192,102, filed Feb. 4, 1994, U.S. application Ser. No. 08-192,061, filed Feb. 4, 1994, now abandoned, and U.S. application Ser. No. 08-192,093, filed Feb. 4, 1994, now abandoned, which are all continuations-in-part of each of U.S. application Ser. No. 08-010,406, filed Jan. 29, 1993, now abandoned, and U.S. application Ser. No. 08-013,413, filed Feb. 2, 1993, now abandoned, which is a continuation-in-part of U.S. application Ser. No. 07-943,852, filed Sep. 11, 1992, now abandoned, which is a continuation-in-part of U.S. application Ser. No. 07-853,606, filed Mar. 18, 1992, now abandoned, which is a continuation-in-part of U.S. application Ser. No. 07-670,827, filed Mar. 18, 1991, now abandoned. Each of the above non-abandoned applications are entirely incorporated herein by reference.

FULL TEXT: 6239 lines

2/3/3 (Item 3 from file: 654)
DIALOG(R)File 654:US Pat.Full.
(c) format only 1999 The Dialog Corp. All rts. reserv.

02677406

Utility
METHODS OF TREATING TNF-.ALPHA.-MEDIATED CROHN'S DISEASE USING CHIMERIC ANTI-TNF ANTIBODIES
[Human tumor necrosis factor antibodies]

PATENT NO.: 5,656,272
ISSUED: August 12, 1997 (19970812)
INVENTOR(s): Le, Junming, Jackson Heights, NY (New York), US (United States of America)
Vilcek, Jan, New York, NY (New York), US (United States of America)
Dadonna, Peter, Palo Alto, CA (California), US (United States of America)
Ghrayeb, John, Thorndale, PA (Pennsylvania), US (United States of America)
Knight, David, Berwyn, PA (Pennsylvania), US (United States of America)
Siegel, Scott A., Westborough, MA (Massachusetts), US (United States of America)
ASSIGNEE(s): Centocor, Inc, (A U.S. Company or Corporation), Malvern, PA (Pennsylvania), US (United States of America)
New York University Medical Center, (A U.S. Company or Corporation), New York, NY (New York), US (United States of America)
[Assignee Code(s): 12273; 35102]
EXTRA INFO: Assignment transaction [Reassigned], recorded December 28, 1998 (19981228)
APPL. NO.: 8-192,102
FILED: February 04, 1994 (19940204)

This application is a continuation-in-part of each of U.S. application Ser. No. 08-010,406, filed Jan. 29, 1993, now abandoned, and U.S. application Ser. No. 08-013,413, filed Feb. 2, 1993, now abandoned, which is a continuation-in-part of U.S. application Ser. No. 07-943,852, filed Sep. 11, 1992, now abandoned, which is a continuation-in-part of U.S. application Ser. No. 07-853,606, filed Mar. 18, 1992, now abandoned, which is a continuation-in-part of U.S. application Ser. No. 07-670,827, filed Mar. 18, 1991, now abandoned. Each of the above non-abandoned applications is entirely incorporated herein by reference.

FULL TEXT: 5309 lines

? t s3/k/all

>>>Set 3 does not exist

? t s2/k/all

2/K/1 (Item 1 from file: 654)

DIALOG(R)File 654:(c) format only 1999 The Dialog Corp. All rts. reserv.

INVENTOR(s): **Le**, Junming...

... and subsequently used for in vivo therapy include, but are not limited to, daunorubicin, doxorubicin, **methotrexate**, and Mitomycin C. Cytotoxic drugs interfere with critical cellular processes including DNA, RNA, and protein...and subsequently used for in vivo therapy include, but are not limited to, daunorubicin, doxorubicin, **methotrexate**, and Mitomycin C. Cytotoxic drugs interfere with critical cellular processes including DNA, RNA, and protein...

2/K/2 (Item 2 from file: 654)

DIALOG(R)File 654:(c) format only 1999 The Dialog Corp. All rts. reserv.

INVENTOR(s): **Le**, Junming...

... and subsequently used for in vivo therapy include, but are not limited to, daunorubicin, doxorubicin, **methotrexate**, and Mitomycin C. Cytotoxic drugs interfere with critical cellular processes including DNA, RNA, and protein...and subsequently used for in vivo therapy include, but are not limited to, daunorubicin, doxorubicin, **methotrexate**, and Mitomycin C. Cytotoxic drugs interfere with critical cellular processes including DNA, RNA, and proteinSal = Sulphasalazine;

DP = Dpenicillamine;

Myo = Myocrisin;

Aur = auranofin;

MTX = **methotrexate**;

Aza = azathioprine;

Chl = hydroxychloroquine.

**Pred = prednisolone (dosage/day);

Para = paracetamol;

Ind = indomethacin;

Ibu = ibuprofen;

Cod...

2/K/3 (Item 3 from file: 654)

DIALOG(R)File 654:(c) format only 1999 The Dialog Corp. All rts. reserv.

INVENTOR(s): **Le**, Junming...

... and subsequently used for in vivo therapy include, but are not limited to, daunorubicin, doxorubicin, **methotrexate**, and Mitomycin C. Cytotoxic drugs interfere with critical cellular processes including DNA, RNA, and protein...and subsequently used for in vivo therapy include, but are not limited to, daunorubicin, doxorubicin, **methotrexate**, and Mitomycin C. Cytotoxic drugs interfere with critical cellular processes including DNA, RNA, and proteinSal = Sulphasalazine; DP = Dpenicillamine; Myo = Myocrisin; Aur =

auranofin; MTX = **methotrexate**; Aza = azathioprine; Chl = hydroxychloroquine.

**Pred = prednisolone (dosage/day); Para = paracetamol; Ind = indomethacin; Ibuibuprofen; Cod = codeine...

?s s1 and (inflammat? or autoimmun?)

426 S1
349367 INFLAMMAT?
99100 AUTOIMMUN?

S4 116 S1 AND (INFLAMMAT? OR AUTOIMMUN?)

?rd s4

>>>Duplicate detection is not supported for File 351.

>>>Records from unsupported files will be retained in the RD set.

...examined 50 records (50)

...examined 50 records (100)

...completed examining records

S5 93 RD S4 (unique items)

?s (s3 or s5) and review?

108 S3
93 S5
1929787 REVIEW?

S6 39 (S3 OR S5) AND REVIEW?

?rd s6

>>>Duplicate detection is not supported for File 351.

>>>Records from unsupported files will be retained in the RD set.

...completed examining records

S7 39 RD S6 (unique items)

?t s7/3/all

7/3/1 (Item 1 from file: 72)

DIALOG(R)File 72:EMBASE

(c) 1997 Elsevier Science B.V. All rts. reserv.

10166244 EMBASE No: 96338065

Cytokine-suppressive anti-inflammatory drugs. Status of development in rheumatoid arthritis

Huizinga T.W.J.; Breedveld F.C.

Department of Rheumatology, University Hospital, Postbus 9600, 2300 RC Leiden Netherlands

Clinical Immunotherapeutics (New Zealand) , 1996, 6/5 (395-404) CODEN: CIMME ISSN: 1172-7039

LANGUAGES: English SUMMARY LANGUAGES: English

7/3/2 (Item 2 from file: 72)

DIALOG(R)File 72:EMBASE

(c) 1997 Elsevier Science B.V. All rts. reserv.

9994652 EMBASE No: 96160387

Recent developments in the treatment of encephalomyelitis

Liu X.; Mashour G.A.; Kurtz A.

Georgetown University, Department of Neurosurgery, 3970 Reservoir Road, Washington, DC 20007 USA

Expert Opinion on Therapeutic Patents (United Kingdom) , 1996, 6/5 (457-470) CODEN: EOTPE ISSN: 1354-3776

LANGUAGES: English SUMMARY LANGUAGES: English

7/3/3 (Item 3 from file: 72)

DIALOG(R)File 72:EMBASE

(c) 1997 Elsevier Science B.V. All rts. reserv.

9986735 EMBASE No: 96146574

The immunological network: Novel approaches to the treatment of Crohn's disease

Davidson B.; Nielsen O.H.; Vainer B.; Kirman I.

Department of Gastroenterology F, Glostrup Hospital, University of Copenhagen, Nordre Ringvej, DK-2600 Glostrup Denmark

Expert Opinion on Investigational Drugs (United Kingdom) , 1996, 5/5 (555-564) CODEN: EOIDE ISSN: 1354-3784

LANGUAGES: English SUMMARY LANGUAGES: English

7/3/4 (Item 4 from file: 72)

DIALOG(R)File 72:EMBASE

(c) 1997 Elsevier Science B.V. All rts. reserv.

9979333 EMBASE No: 96166734

Experimental immunotherapies for multiple sclerosis

Martin R.; McFarland H.

Neuroimmunology Branch, Natl Inst Neurological Disord Stroke, National Institutes of Health, Bethesda, MD 20892 USA

Springer Seminars in Immunopathology (Germany) , 1996, 18/1 (1-24)

CODEN: SSIMD ISSN: 0344-4325

LANGUAGES: English SUMMARY LANGUAGES: English

7/3/5 (Item 5 from file: 72)

DIALOG(R)File 72:EMBASE

(c) 1997 Elsevier Science B.V. All rts. reserv.

9937049 EMBASE No: 96122714

Cicatricial pemphigoid: Diagnosis and treatment

Quan Dong Nguyen; Foster C.S.

Department of Ophthalmology, Massachusetts Eye and Ear Infirmary, Harvard Medical School, 243 Charles Street, Boston, MA 02114 USA

International Ophthalmology Clinics (USA) , 1996, 36/1 (41-60) CODEN: IOPCA ISSN: 0020-8167

LANGUAGES: English SUMMARY LANGUAGES: English

7/3/6 (Item 6 from file: 72)

DIALOG(R)File 72:EMBASE

(c) 1997 Elsevier Science B.V. All rts. reserv.

9898715 EMBASE No: 96066151

Effects of antirheumatic agents on cytokines

Barrera P.; Boerbooms A.M.T.; Van De Putte L.B.A.; Van Der Meer J.W.M.

Department of Rheumatology, University Hospital, PO Box 9101, 6500 HM Nijmegen Netherlands

Seminars in Arthritis and Rheumatism (USA) , 1996, 25/4 (234-253)

CODEN: SAHRB ISSN: 0049-0172

LANGUAGES: English SUMMARY LANGUAGES: English

begin 55,72,154,399,351

03feb97 15:01:21 User208760 Session D736.1

\$0.09 0.003 Hrs File1
\$0.09 Estimated cost File1
\$0.09 Estimated cost this search
\$0.09 Estimated total session cost 0.003 Hrs.

SYSTEM:OS - DIALOG OneSearch

File 55:BIOSIS PREVIEWS(R) 1985-1997/Feb W1

(c) 1997 BIOSIS

*File 55: "KWIC format pricing will change effective 1/1/97.

See HELP RATES 055 to see new prices."

File 72:EMBASE 1985-1997/Jan W4

(c) 1997 Elsevier Science B.V.

*File 72: "KWIC format pricing will change effective 1/1/97.

See HELP RATES 072 to see new prices."

File 154:MEDLINE(R) 1985-1997/Mar W4

(c) format only 1997 Knight-Ridder Info

*File 154: "KWIC format pricing will change effective 1/1/97. See HELP
RATES 154 to see new prices." MEDLINE updates delayed. See HELP DELAY 154.

File 399:CA SEARCH(R) 1967-1996/UD=12605

(c) 1997 American Chemical Society

*File 399: Use is subject to the terms of your user/customer agreement.
For format prices, including formats 6 & 8, see HELP RATES 399.

File 351:DERWENT WPI 1981-1996/UD=9704;UA=9701;UM=9645

(c) 1997 Derwent Info Ltd

*File 351: *** See revised HELP NEWS351 message for new information
regarding the reload and Alert profiles. ***

Set Items Description

--- -----

?s methotrexate and (tnf or tumor(w)necrosis(w)factor?)

Processing

53587 METHOTREXATE

55060 TNF

726104 TUMOR

190783 NECROSIS

2080027 FACTOR?

96826 TUMOR(W)NECROSIS(W)FACTOR?

S1 426 METHOTREXATE AND (TNF OR TUMOR(W)NECROSIS(W)FACTOR?)

?s s1 and (crohn? or arthritis)

426 S1

23664 CROHN?.

134379 ARTHRITIS

S2 145 S1 AND (CROHN? OR ARTHRITIS)

?rd s2

>>>Duplicate detection is not supported for File 351.

>>>Records from unsupported files will be retained in the RD set.

...examined 50 records (50)

...examined 50 records (100)

...completed examining records

S3 108 RD S2 (unique items)

7/3/7 (Item 7 from file: 72)

DIALOG(R)File 72:EMBASE

(c) 1997 Elsevier Science B.V. All rts. reserv.

9860716 EMBASE No: 96044870

Inhibitors of haemopoiesis and their potential clinical relevance

Parker A.N.; Pragnell I.B.

Beatson Institute Cancer Research, Gartcube Estate, Switchback Road,
Bearsden, Glasgow G61 1BD United Kingdom

Blood Reviews (United Kingdom) , 1995, 9/4 (226-233) CODEN: BLORE
ISSN: 0268-960X

LANGUAGES: English SUMMARY LANGUAGES: English

7/3/8 (Item 8 from file: 72)

DIALOG(R)File 72:EMBASE

(c) 1997 Elsevier Science B.V. All rts. reserv.

9851158 EMBASE No: 96032527

Maintenance strategies in Crohn's disease

Sachar D.B.

Division of Gastroenterology, Mount Sinai Medical Center, Mount Sinai
School of Medicine, New York, NY USA

Hospital Practice (USA) , 1996, 31/1 (99-106) CODEN: HOPRB ISSN:
8750-2836

LANGUAGES: English SUMMARY LANGUAGES: English

7/3/9 (Item 9 from file: 72)

DIALOG(R)File 72:EMBASE

(c) 1997 Elsevier Science B.V. All rts. reserv.

9787618 EMBASE No: 95351542

Combination therapy

Borignini M.J.; Paulus H.E.

Division of Rheumatology, UCLA School of Medicine, 32-48 Rehabilitation,
1000 Veterans Avenue, Los Angeles, CA 90024 USA

Bailliere's Clinical Rheumatology (United Kingdom) , 1995, 9/4 (689-710)
CODEN: BCRHE ISSN: 0950-3579

LANGUAGES: English SUMMARY LANGUAGES: English

7/3/10 (Item 10 from file: 72)

DIALOG(R)File 72:EMBASE

(c) 1997 Elsevier Science B.V. All rts. reserv.

9782760 EMBASE No: 95334809

A review on the strategies for the development and application of new
anti-arthritis agents

Lewis A.J.; Keft A.F.

Wyeth Ayerst Research, Princeton, NJ USA

Immunopharmacology and Immunotoxicology (USA) , 1995, 17/4 (607-663)
CODEN: IITOE ISSN: 0892-3973

LANGUAGES: English

7/3/11 (Item 11 from file: 72)

DIALOG(R)File 72:EMBASE

(c) 1997 Elsevier Science B.V. All rts. reserv.

9774097 EMBASE No: 95326680

Rheumatology update - Part II

UPDATE RHEUMATOLOGIE - TEIL II

Hein G.; Bolwin R.; Brauer R.; Eidner T.; Franke S.; Oezlner P.; Sprott H.

Klinik fur Innere Medizin IV, Klinikum, Friedrich-Schiller-Universitat,
D-07740 Jena Germany

Medizinische Klinik (Germany) , 1995, 90/5 (294-302) CODEN: MEKLA

ISSN: 0723-5003

LANGUAGES: German

7/3/12 (Item 12 from file: 72)

DIALOG(R)File 72:EMBASE

(c) 1997 Elsevier Science B.V. All rts. reserv.

9716625 EMBASE No: 95273067

Juvenile rheumatoid arthritis and spondyloarthropathies

Lindsley C.B.

Department of Pediatrics, University of Kansas Medical Center, 3901
Rainbow Boulevard, Kansas City, KS 66160-7330 USA

Current Opinion in Rheumatology (USA) , 1995, 7/5 (425-429) CODEN: CORHE

ISSN: 1040-8711

LANGUAGES: English SUMMARY LANGUAGES: English

7/3/13 (Item 13 from file: 72)

DIALOG(R)File 72:EMBASE

(c) 1997 Elsevier Science B.V. All rts. reserv.

9675733 EMBASE No: 95227193

Etiopathogenesis of reactive arthritis and ankylosing spondylitis

Careless D.J.; Inman R.D.

Toronto Hospital Arthritis Centre, 399 Bathurst Street, Toronto, Ont. M5T
2S8 Canada

Current Opinion in Rheumatology (USA) , 1995, 7/4 (290-298) CODEN: CORHE

ISSN: 1040-8711

LANGUAGES: English SUMMARY LANGUAGES: English

7/3/14 (Item 14 from file: 72)

DIALOG(R)File 72:EMBASE

(c) 1997 Elsevier Science B.V. All rts. reserv.

9658135 EMBASE No: 95213487

Biological therapies: A novel approach to the treatment of autoimmune
disease

Fox D.A.

Division of Rheumatology, Department of Internal Medicine, Univ. of
Michigan Medical Center, Ann Arbor, MI 48109-0358 USA

American Journal of Medicine (USA) , 1995, 99/1 (82-88) CODEN: AJMEA

ISSN: 0002-9343

LANGUAGES: English SUMMARY LANGUAGES: English

7/3/15 (Item 15 from file: 72)
DIALOG(R)File 72:EMBASE
(c) 1997 Elsevier Science B.V. All rts. reserv.

9629778 EMBASE No: 95188270
Thalidomide: Rationale for renewed use in immunological disorders
Schuler U.; Ehninger G.
Medizinische Klinik I, Fetscherstrasse 74, 01307 Dresden Germany
Drug Safety (New Zealand) , 1995, 12/6 (364-369) CODEN: DRSAE ISSN:
0114-5916
LANGUAGES: English SUMMARY LANGUAGES: English

7/3/16 (Item 16 from file: 72)
DIALOG(R)File 72:EMBASE
(c) 1997 Elsevier Science B.V. All rts. reserv.

9588949 EMBASE No: 95153573
Cell adhesion molecules in rheumatoid arthritis
Haskard D.O.
Department of Medicine, Royal Postgraduate Medical School, Hammersmith
Hospital, Du Cane Road, W12 ONN London United Kingdom
Current Opinion in Rheumatology (USA) , 1995, 7/3 (229-234) CODEN: CORHE
ISSN: 1040-8711
LANGUAGES: English SUMMARY LANGUAGES: English

7/3/17 (Item 17 from file: 72)
DIALOG(R)File 72:EMBASE
(c) 1997 Elsevier Science B.V. All rts. reserv.

9588943 EMBASE No: 95153567
Biologic agents in the treatment of inflammatory rheumatic diseases
Kalden J.R.; Manger B.
Department of Internal Medicine III, Clin. Immunology/Rheumatology Inst.,
University of Erlangen-Nuremberg, Krankenhausstr 12, D-91054 Erlangen
Germany
Current Opinion in Rheumatology (USA) , 1995, 7/3 (191-197) CODEN: CORHE
ISSN: 1040-8711
LANGUAGES: English SUMMARY LANGUAGES: English

7/3/18 (Item 18 from file: 72)
DIALOG(R)File 72:EMBASE
(c) 1997 Elsevier Science B.V. All rts. reserv.

9588940 EMBASE No: 95153564
Disease-modifying antirheumatic drugs, including methotrexate, gold,
antimalarials, and D-penicillamine
Conaghan P.G.; Brooks P.
University of New South Wales, St. Vincent's Hospital, Victoria Street,
Darlinghurst, NSW 2010 Australia
Current Opinion in Rheumatology (USA) , 1995, 7/3 (167-173) CODEN: CORHE
ISSN: 1040-8711
LANGUAGES: English SUMMARY LANGUAGES: English

7/3/19 (Item 19 from file: 72)

DIALOG(R)File 72:EMBASE

(c) 1997 Elsevier Science B.V. All rts. reserv.

9537654 EMBASE No: 95106038

Signal transduction pathways in epidermal proliferation and cutaneous inflammation

Van Ruissen F.; Van de Kerkhof P.C.M.; Schalkwijk J.

Department of Dermatology, University Hospital Nijmegen, PO Box 9101, 6500 HB Nijmegen Netherlands

Clinics in Dermatology (USA), 1995, 13/2 (161-190) CODEN: CLDEE

ISSN: 0738-081X

LANGUAGES: English

7/3/20 (Item 20 from file: 72)

DIALOG(R)File 72:EMBASE

(c) 1997 Elsevier Science B.V. All rts. reserv.

9495670 EMBASE No: 95064067

Pulmonary involvement in rheumatoid arthritis

Anaya J.-M.; Diethelm L.; Ortiz L.A.; Gutierrez M.; Citera G.; Welsh R.A.; Espinoza L.R.

Division of Clinical Immunology, UTHSC, 7703 Floyd Curl Dr, San Antonio, TX 78284-7874 USA

Seminars in Arthritis and Rheumatism (USA), 1995, 24/4 (242-254)

CODEN: SAHRB ISSN: 0049-0172

LANGUAGES: English SUMMARY LANGUAGES: English

7/3/21 (Item 21 from file: 72)

DIALOG(R)File 72:EMBASE

(c) 1997 Elsevier Science B.V. All rts. reserv.

9490525 EMBASE No: 95062493

Therapy for multiple sclerosis

Weiner H.L.; Hohol M.J.; Khoury S.J.; Dawson D.M.; Hafler D.A.

221 Longwood Ave., Boston, MA 02115 USA

NEUROL. CLIN. (USA), 1995, 13/1 (173-196) CODEN: NECLE ISSN: 0733-8619

LANGUAGES: English SUMMARY LANGUAGES: English

7/3/22 (Item 22 from file: 72)

DIALOG(R)File 72:EMBASE

(c) 1997 Elsevier Science B.V. All rts. reserv.

9477163 EMBASE No: 95049183

Novel drug therapies in inflammatory bowel disease

Debinski H.S.; Kamm M.A.

St Mark's Hospital, City Road, London EC1V 2PS United Kingdom

EUR. J. GASTROENTEROL. HEPATOL. (United Kingdom), 1995, 7/2 (169-182)

CODEN: EJJGHE ISSN: 0954-691X

LANGUAGES: English SUMMARY LANGUAGES: English

7/3/23 (Item 23 from file: 72)

DIALOG(R)File 72:EMBASE

(c) 1997 Elsevier Science B.V. All rts. reserv.

9476519 EMBASE No: 95048253
Advances in understanding and novel therapeutic targets in inflammatory arthritis
FitzGerald O.
Department of Rheumatology, St Vincents Hospital, Dublin 4 Ireland
IR. J. MED. SCI. (Ireland) , 1995, 164/1 (4-11) CODEN: IJMSA ISSN:
0021-1265
LANGUAGES: English

7/3/24 (Item 24 from file: 72)
DIALOG(R)File 72:EMBASE
(c) 1997 Elsevier Science B.V. All rts. reserv.

9305445 EMBASE No: 94253153
Pediatric rheumatic diseases
Warren R.W.; Perez M.D.; Wilking A.P.; Myones B.L.
Department of Pediatrics, Baylor College of Medicine, One Baylor Plaza,
Houston, TX 77030 USA
PEDIATR. CLIN. NORTH AM. (USA) , 1994, 41/4 (783-818) CODEN: PCNAA
ISSN: 0031-3955
LANGUAGES: English SUMMARY LANGUAGES: English

7/3/25 (Item 25 from file: 72)
DIALOG(R)File 72:EMBASE
(c) 1997 Elsevier Science B.V. All rts. reserv.

9084440 EMBASE No: 94014905
The current and future therapy strategies of rheumatoid arthritis (RA)
GEGENWARTIGE UND ZUKUNFTIGE THERAPIESTRATEGIEN DER RHEUMATOIDEN ARTHRITIS
(RA)
Schacht E.
Hauptabteilung Med. Wissenschaften, E. Tosse und Co. GmbH,
Friedrich-Ebert-Damm 101, 22047 Hamburg Germany
Z. RHEUMATOL. (Germany) , 1993, 52/6 (365-382) CODEN: ZRHMB ISSN:
0340-1855
LANGUAGES: German SUMMARY LANGUAGES: German; English

7/3/26 (Item 26 from file: 72)
DIALOG(R)File 72:EMBASE
(c) 1997 Elsevier Science B.V. All rts. reserv.

9071836 EMBASE No: 94010175
Myositis and myopathies: Editorial overview
Kagen L.J.
Department of Medicine, Hospital for Special Surgery, 535 East 70th
Street, New York, NY 10021 USA
CURR. OPIN. RHEUMATOL. (USA) , 1993, 5/6 (691-694) CODEN: CORHE ISSN:
1040-8711
LANGUAGES: English

7/3/27 (Item 27 from file: 72)
DIALOG(R)File 72:EMBASE
(c) 1997 Elsevier Science B.V. All rts. reserv.

8985535 EMBASE No: 93289267
Interleukin-1 receptor antagonist
Arend W.P.
Division of Rheumatology, Department of Medicine, Colorado Univ. Health
Sciences Ctr., Denver, CO 80262 USA
ADV. IMMUNOL. (USA) , 1993; 54/- (167-227) CODEN: ADIMA ISSN:
0065-2776
LANGUAGES: English SUMMARY LANGUAGES: English

7/3/28 (Item 28 from file: 72)
DIALOG(R)File 72:EMBASE
(c) 1997 Elsevier Science B.V. All rts. reserv.

8982997 EMBASE No: 93284230
Future aspects of new therapeutic possibilities of rheumatic diseases
NEUE THERAPEUTISCHE MOGLICHKEITEN. ZUKUNFTSASPEKTE
Rubbert A.; Burmester G.-R.
Inst. fur Klin. Immunol./Rheumatol., Medizinische Klinik III, Universitat
Erlangen-Nurnberg, Krankenhausstrasse 12, D-91054 Erlangen Germany
INTERNIST (Germany) , 1993, 34/9 (841-851) CODEN: INTEA ISSN:
0020-9554 ADONIS ORDER NUMBER: 002095549300127M
LANGUAGES: German SUMMARY LANGUAGES: German

7/3/29 (Item 29 from file: 72)
DIALOG(R)File 72:EMBASE
(c) 1997 Elsevier Science B.V. All rts. reserv.

8872009 EMBASE No: 93175822
Rheumatoid arthritis: New science, new treatment
Miller-Blair D.J.; Robbins D.L.
Kaiser-Permanente Medical Center, South Sacramento, CA USA
GERIATRICS (USA) , 1993, 48/6 (28-38) CODEN: GERIA ISSN: 0016-867X
LANGUAGES: English SUMMARY LANGUAGES: English

7/3/30 (Item 30 from file: 72)
DIALOG(R)File 72:EMBASE
(c) 1997 Elsevier Science B.V. All rts. reserv.

8852420 EMBASE No: 93156138
The role of cytokines in psoriatic inflammation
DIE ROLLE VON ZYTOKINEN FUR DIE PATHOGENESE DER PSORIASIS
Kapp A.
Funktionsbereich Allergologie, Hautklinik, Albert-Ludwigs-Universitat,
Hauptstrasse 7, W-7800 Freiburg Germany
HAUTARZT (Germany) , 1993, 44/4 (201-207) CODEN: HAUTA ISSN: 0017-8470
LANGUAGES: German SUMMARY LANGUAGES: German; English

7/3/31 (Item 31 from file: 72)
DIALOG(R)File 72:EMBASE
(c) 1997 Elsevier Science B.V. All rts. reserv.

8831742 EMBASE No: 93135727
Therapeutic applications of photopheresis

Roòk A.H.; Cohen J.H.; Lessin S.R.; Vowels B.R.
Department of Dermatology, Hospital University of Pennsylvania, 3400
Spruce Street, Philadelphia, PA 19104 USA
DERMATOL. CLIN. (USA) , 1993, 11/2 (339-347) CODEN: DRMCD ISSN:
0733-8635
LANGUAGES: English SUMMARY LANGUAGES: English

7/3/32 (Item 32 from file: 72)
DIALOG(R)File 72:EMBASE
(c) 1997 Elsevier Science B.V. All rts. reserv.

8809709 EMBASE No: 93110017
Immunosuppressive therapy for autoimmune diseases
Hoffman G.S.
Cleveland Clinic Foundation, 9500 Euclid Ave, Cleveland, OH 44195 USA
ANN. ALLERGY (USA) , 1993, 70/4 (263-274) CODEN: ANAEA ISSN: 0003-4738
LANGUAGES: English

7/3/33 (Item 33 from file: 72)
DIALOG(R)File 72:EMBASE
(c) 1997 Elsevier Science B.V. All rts. reserv.

8807982 EMBASE No: 93111770
Acute and chronic graft-versus-host disease
Vogelsang G.B.
Johns Hopkins Oncology Center, 600 North Wolfe Street, Baltimore, MD
21287-8985 USA
CURR. OPIN. ONCOL. (USA) , 1993, 5/2 (276-281) CODEN: CUOOE ISSN:
1040-8746
LANGUAGES: English SUMMARY LANGUAGES: English

7/3/34 (Item 34 from file: 72)
DIALOG(R)File 72:EMBASE
(c) 1997 Elsevier Science B.V. All rts. reserv.

8730141 EMBASE No: 93034093
Wegener's granulomatosis
Hoffman G.S.
Rheumatic/Immunologic Diseases Dept., Cleveland Clinic Foundation, 9500
Euclid Avenue, Cleveland, OH 44195 USA
CURR. OPIN. RHEUMATOL. (USA) , 1993, 5/1 (11-17) CODEN: CORHE ISSN:
1040-8711
LANGUAGES: English SUMMARY LANGUAGES: English

7/3/35 (Item 35 from file: 72)
DIALOG(R)File 72:EMBASE
(c) 1997 Elsevier Science B.V. All rts. reserv.

8675094 EMBASE No: 92355604
Use of monoclonal antibodies in vivo as a therapeutic strategy for
alloimmune or autoimmune reactivity: The Besancon experience
Herve P.; Racadot E.; Wendling D.; Rumbach L.; Tiberghien P.; Cahn J.Y.;
Flesch M.; Wijdenes J.
Centre Reg. de Transfusion Sanguine, 1 Boulevard Fleming, 25020 Besancon

France

IMMUNOL. REV. (Denmark) , 1992, -/129 (31-55) CODEN: IMRED ISSN:
0105-2896 ADONIS ORDER NUMBER: 010528969200043S
LANGUAGES: English

7/3/36 (Item 36 from file: 72)

DIALOG(R)File 72:EMBASE

(c) 1997 Elsevier Science B.V. All rts. reserv.

8621094 EMBASE No: 92297268

Is there a disease-modifying drug for juvenile chronic arthritis?

Rooney M.

Molecular Rheumatology Section, MRC Clinical Research Centre, Watford
Road, Harrow, Middlesex HA1 3UJ United Kingdom

BR. J. RHEUMATOL. (United Kingdom) , 1992, 31/9 (635-641) CODEN: BJRHD
ISSN: 0263-7103

LANGUAGES: English

7/3/37 (Item 37 from file: 72)

DIALOG(R)File 72:EMBASE

(c) 1997 Elsevier Science B.V. All rts. reserv.

8574752 EMBASE No: 92250773

Supportive care in marrow transplantation

Bensinger W.I.

Clinical Research Division, Fred Hutchinson Cancer Research Ctr., 1124
Columbia Street, Seattle, WA 98104 USA

CURR. OPIN. ONCOL. (USA) , 1992, 4/4 (614-623) CODEN: CUOOE ISSN:
1040-8746

LANGUAGES: English SUMMARY LANGUAGES: English

7/3/38 (Item 38 from file: 72)

DIALOG(R)File 72:EMBASE

(c) 1997 Elsevier Science B.V. All rts. reserv.

8355207 EMBASE No: 92020818

Interaction(s) between essential fatty acids, eicosanoids, cytokines,
growth factors and free radicals: Relevance to new therapeutic strategies
in rheumatoid arthritis and other collagen vascular diseases

Das U.N.

Department of Medicine, Nizam's Institute of Medical Sciences, Hyderabad
500482 India

PROSTAGLANDINS LEUKOTRIENES ESSENT. FATTY ACIDS (United Kingdom) , 1991,
44/4 (201-210) CODEN: PLEAE ISSN: 0952-3278 ADONIS ORDER NUMBER:
095232789100121B

LANGUAGES: English SUMMARY LANGUAGES: English

7/3/39 (Item 39 from file: 72)

DIALOG(R)File 72:EMBASE

(c) 1997 Elsevier Science B.V. All rts. reserv.

7923223 EMBASE No: 90357842

Development of angiogenesis inhibitors for clinical applications

Maione T.E.; Sharpe R.J.

Repligen Corporation, One Kendall Square, Cambridge, MA 02139 USA
TRENDS PHARMACOL. SCI. (United Kingdom) , 1990, 11/11 (457-461) CODEN:
TPHSD ISSN: 0165-6147
LANGUAGES: English
?ds

Set	Items	Description
S1	426	METHOTREXATE AND (TNF OR TUMOR(W) NECROSIS(W) FACTOR?)
S2	145	S1 AND (CROHN? OR ARTHRITIS)
S3	108	RD S2 (unique items)
S4	116	S1 AND (INFLAMMAT? OR AUTOIMMUN?)
S5	93	RD S4 (unique items)
S6	39	(S3 OR S5) AND REVIEW?
S7	39	RD S6 (unique items)

?s s3 and py=1991

108 S3
2377597 PY=1991

S8 10 S3 AND PY=1991

?rd s8

>>>Duplicate detection is not supported for File 351.

>>>Records from unsupported files will be retained in the RD set.

...completed examining records

S9 10 RD S8 (unique items)

?t s9/7/all

9/7/1 (Item 1 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)
(c) 1997 BIOSIS. All rts. reserv.

9538308 BIOSIS Number: 94043308

THE EFFECT OF SLOW-ACTING ANTI-RHEUMATIC DRUGS SAARDS AND COMBINATIONS OF
SAARDS ON MONOKINE PRODUCTION IN-VITRO

DANIS V A; FRANIC G M; BROOKS P M

KOLLING INST., ROYAL NORTH SHORE HOSP., ST. LEONARDS, NSW 2065, AUST.

DRUGS EXP CLIN RES 17 (12). 1991. 549-554. CODEN: DECRD

Full Journal Title: Drugs under Experimental and Clinical Research

Language: ENGLISH

The mode of action of slow-acting anti-rheumatic drugs (SAARDS) is complex but may often include effects of cytokine (interleukin-1, IL-1, and tumour necrosis factor, TNF) production by monocytes/macrophages. Different SAARDS. May have variable effects on cytokine production in vitro depending on the concentration of drug, the presence of other SAARDS and individual variation. The gold compounds gold sodium thiomalate (GST) and auranofin (AF) had a bimodal effect on cytokine production. High concentrations of GST (> 1 .mu.g/ml) weakly inhibited IL-1-.beta. secretion (without affecting IL-1-.alpha. or TNF secretion and without affecting cell-associated IL-1-.alpha. and IL-1-.beta. accumulation), and although AF (> 100 ng/ml) inhibited cytokine production it did so at concentrations near to the toxic range for the drug (> 200 ng/ml). GST and AF when used in combination inhibited cytokine production in a synergistic manner even at concentrations that would potentiate cytokine production if used individually. Hydroxychloroquine (HCQ) and sulfasalazine (SAP) were two other inhibitory SAARDS which acted synergistically in combination.

Combination of HCQ and SAP with gold drugs gave variable results. D-penicillamine (D-pen) and methotrexate (MTX) were two SAARDs that generally did not affect cytokine production individually or in combination with other SAARDs. These results suggest that combination SAARD therapy may more effectively target excessive cytokine production, which is a hallmark of rheumatoid arthritis.

9/7/2 (Item 2 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)
(c) 1997 BIOSIS. All rts. reserv.

8785193 BIOSIS Number: 42010193
EFFECTS OF A WEEKLY DOSES OF METHOTREXATE ON IL-1 TNF AND IL-6 IN
PATIENTS WITH RHEUMATOID ARTHRITIS
BARRERA P; JANSSEN E M; BOERBOOMS A M T; VAN DE PUTTE L B A; SAUERWEIN R
W; VAN DER MEER J W M
UNIV. HOSPITAL NIJMEGEN, POSTBOX 9101, NETHERLANDS.
THIRD INTERNATIONAL WORKSHOP ON CYTOKINES, STRESA, ITALY, NOVEMBER 10-14,
1991. CYTOKINE 3 (5). 1991. 504. CODEN: CYTIE
Language: ENGLISH

9/7/3 (Item 3 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)
(c) 1997 BIOSIS. All rts. reserv.

8339671 BIOSIS Number: 41023671
IMMUNOLOGY OF INFLAMMATORY BOWEL DISEASE SUMMARY OF THE PROCEEDINGS OF
THE SUBCOMMITTEE ON IMMUNOSUPPRESSIVE USE IN IBD
MARKOWITZ J; DAUM F; COHEN S A; GLASSMAN M; HOLMES R D; PICCOLI D; ROSSI
T M; TREEM W R; ULSHEN M H; WINTER H S
DEP. PEDIATRICS, NORTH SHORE UNIV. HOSP., CORNELL UNIV. MED. COLL., 300
COMMUNITY DR., MANHASSET, N.Y. 11030, USA.
J PEDIATR GASTROENTEROL NUTR 12 (4). 1991. 411-423. CODEN: JPGND
Full Journal Title: Journal of Pediatric Gastroenterology and Nutrition
Language: ENGLISH

9/7/4 (Item 4 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)
(c) 1997 BIOSIS. All rts. reserv.

8209483 BIOSIS Number: 91130483
INCREASED TNF-ALPHA SECRETION BY ALVEOLAR MACROPHAGES FROM PATIENTS WITH
RHEUMATOID ARTHRITIS
GOSSET P; PEREZ T; LASSALLE P; DUQUESNOY B; FARRE J M; TONNEL A B; CAPRON
A
CENTRE IMMUNOLOGIE BIOLOGIE PARASITAIRE, UNITE MIXTE INSERM 167, CNRS
624, BP 245, INSTITUT PASTEUR, 59019 LILLE CEDEX, FR.
AM REV RESPIR DIS 143 (3). 1991. 593-597. CODEN: ARDSB
Full Journal Title: American Review of Respiratory Disease
Language: ENGLISH

Tumor necrosis factor .alpha. (TNF) and interleukin-1 (IL-1) production
by alveolar macrophages (AM) was evaluated in 17 rheumatoid arthritis (RA)
patients without interstitial disease (ILD, Group 1) and 14 RA patients
with clinical ILD (Group 2) in comparison with 10 control subjects. AM
after recovery by bronchoalveolar lavage were selected by adherence, and

then supernatants were collected after 3 or 24 h of culture. Results showed no modification of IL-1 synthesis in either group of RA patients. Spontaneous TNF production was significantly increased in Group 2 (2.5 \pm 0.5 ng/ml) as well as in Group 1 (2.4 \pm 0.4 ng/ml) compared with control subjects (0.43 \pm 0.1 ng/ml, $p < 0.001$). In addition, AM from patients untreated or treated exclusively by nonsteroidal antiinflammatory drugs produced similar levels of TNF, whereas those receiving corticosteroids, second-line drugs (such as sulfasalazine, aurothiomalate, and methotrexate), or the combination of both therapy regimens released significantly less TNF. Interestingly, TNF was not different in both groups, but Group 2 had a markedly increased ratio of local immune complex to albumin in bronchoalveolar lavage fluid (0.47 \pm 0.12 versus 0.07 \pm 0.02 in Group 1; $p < 0.002$). TNF thus appears an additional component of RA subclinical alveolitis in RA, but its prognostic value and its precise role in lung damage remain to be determined. Development of ILD requires certainly complex interactions of synergistic factors, possibly including local immune complexes detected in BAL fluids.

9/7/5 (Item 1 from file: 72)

DIALOG(R) File 72:EMBASE

(c) 1997 Elsevier Science B.V. All rts. reserv.

8355207 EMBASE No: 92020818

Interaction(s) between essential fatty acids, eicosanoids, cytokines, growth factors and free radicals: Relevance to new therapeutic strategies in rheumatoid arthritis and other collagen vascular diseases

Das U.N.

Department of Medicine, Nizam's Institute of Medical Sciences, Hyderabad 500482 India

PROSTAGLANDINS LEUKOTRIENES ESSENT. FATTY ACIDS (United Kingdom) , 1991, 44/4 (201-210) CODEN: PLEAE ISSN: 0952-3278 ADONIS ORDER NUMBER: 095232789100121B

LANGUAGES: English SUMMARY LANGUAGES: English

Eicosanoids, lymphokines, and free radicals are known to participate in the pathogenesis of inflammation. Tumour necrosis factor (TNF), interleukin-1 and 6 (IL-1 and IL-6) and colony stimulating factor-1 (CSF-1) are secreted mainly by activated macrophages, whereas T-cells secrete IL-2, IL-3, IL-4 and interferon-gamma (IFN-gamma). In addition, activated macrophages and lymphocytes can also produce eicosanoids and free radicals which have potent pro-inflammatory actions. Eicosanoids, lymphokines, and free radicals can modulate the immune response, cell proliferation, stimulate collagenase and proteases secretion and induce bone resorption; events which are known to be associated with various collagen vascular diseases. On the other hand transforming growth factor-beta (TGF-beta) produced by synovial tissue, platelets and lymphocytes can inhibit collagenase production, suppress T-cell and NK-cell proliferation and activation and block free radical generation and seems to be of benefit in rheumatoid arthritis. Drugs such as cyclosporine, 1,25-dihydroxycholecalciferol and pentoxifylline can block lymphokine and TNF production and thus, may inhibit the inflammatory process. Essential fatty acids, the precursors of eicosanoids, are suppressors of T-cell proliferation, IL-1, IL-2 and TNF production and have been shown to be of benefit in rheumatoid arthritis, systemic lupus erythematosus and glomerulonephritis. Thus, the interactions between essential fatty acids, eicosanoids, lymphokines, TGF-beta and free radicals suggest that new therapeutic strategies can be devised to modify the course of collagen vascular diseases.

9/7/6 (Item 2 from file: 72)
DIALOG(R)File 72:EMBASE
(c) 1997 Elsevier Science B.V. All rts. reserv.

8344235 EMBASE No: 92021049
Cytokines and drugs workshop
Hom J.T.; Simon P.L.
Lilly Research Laboratories, Indianapolis IN 46285 USA
AGENTS ACTIONS (Switzerland) , 1991, 35/SUPPL. (147-150) CODEN: AGACB
ISSN: 0065-4299
LANGUAGES: English

9/7/7 (Item 3 from file: 72)
DIALOG(R)File 72:EMBASE
(c) 1997 Elsevier Science B.V. All rts. reserv.

8124745 EMBASE No: 91154846
Synovial angiogenesis
Liote F.
Clinique de Rhumatologie, Centre Viggo Petersen, 6, Rue Guy-Patin, 75010
Paris France
REV. RHUM. MAL. OSTEO-ARTICULAIRES (France) , 1991, 58/3 BIS (51-59S)
CODEN: RRMOA ISSN: 0035-2659
LANGUAGES: French

Synovial angiogenesis, the formation of new capillaries from pre-existent capillaries, is a constant feature of synovial inflammation. Strictly regulated, it normally disappears after recovery from the acute episode. However it may persist during chronic synovial inflammation and then participates in pannus development in RA. This is the result of biochemical events which have contributed to breakdown of the extracellular matrix and cartilage in association with activation or secretion into this micro-environment of angiogenic factors. Relations with immuno-competent cells (lymphocytes and monocytes) suggest that this final common pathway may be partially dependent upon stimulation by the antigen. The development of treatment aimed at inhibiting angiogenesis could offer additional therapeutic hope in rheumatoid arthritis.

9/7/8 (Item 4 from file: 72)
DIALOG(R)File 72:EMBASE
(c) 1997 Elsevier Science B.V. All rts. reserv.

8108738 EMBASE No: 91137004
Osteoporosis associated with rheumatoid arthritis: Pathogenesis and management
Joffe I.; Epstein S.
Division of Endocrinology and Metabolism, Albert Einstein Medical Center,
5401 Old York Rd, Philadelphia, PA 19141 USA
SEMIN. ARTHRITIS RHEUM. (USA) , 1991, 20/4 (256-272) CODEN: SAHRB
ISSN: 0049-0172
LANGUAGES: English

Rheumatoid arthritis is associated with both localized and generalized osteoporosis. Localized osteoporosis can be considered to be caused by local disease mechanisms, including the generation of factors from activation of the cytokine pathway. The etiology of generalized osteoporosis has been difficult to elucidate, particularly because of the

lack of sensitive techniques to measure bone mineral density. The introduction of single- and dual-photon absorptiometry and quantitative computed tomography has allowed more accurate assessment of bone mineral density. In general, bone mineral density loss at appendicular sites does not correlate well with axial bone density loss. Corticosteroid treatment exaggerates the development of osteoporosis in up to 40% of patients with rheumatoid arthritis. Sex hormone status, physical activity, disease duration, and functional class are all significant predictors for the development of osteoporosis. Current therapy for prevention and treatment is based largely on theoretical considerations. Physical activity should be encouraged once acute joint inflammation has settled. Postmenopausal women and amenorrheic premenopausal women will benefit from cyclical estrogen replacement. Patients with low serum 1,25-dihydroxy vitamin D3 levels, and males with low serum testosterone levels, are candidates for replacement therapy with the appropriate hormones. In patients who are receiving corticosteroids the dose should be limited, and oral calcium supplements are of benefit. The use of the newer corticosteroid deflazacort, and disease-modifying immunosuppressive drugs, are discussed. Other therapeutic options which should be considered, although published trials are scarce, are calcitonin and the diphosphonates. Further studies are awaited concerning the optimum prevention and treatment of osteoporosis associated with rheumatoid arthritis. For the present, management should be based on theoretical considerations. The introduction of dual-energy X-ray absorptiometry for measuring bone mineral density represents a significant improvement over the older techniques, and will assist in future clinical trials. Inhibitors of the cytokine pathway, or the products stemming from activation of this pathway, need to be evaluated in the treatment of osteoporosis associated with rheumatoid arthritis.

9/7/9 (Item 5 from file: 72)
DIALOG(R)File 72:EMBASE
(c) 1997 Elsevier Science B.V. All rts. reserv.

8041608 EMBASE No: 91071603

The effects of some anti-arthritic drugs and cytokines on the shape and function of rodent macrophages

Haynes D.R.; Whitehouse M.W.; Vernon-Roberts B.

Department of Pathology, University of Adelaide, GPO Box 498, Adelaide, SA 5001 Australia

INT. J. EXP. PATHOL. (United Kingdom) , 1991, 72/1 (9-22) CODEN: IJEPE
ISSN: 0959-9673 ADONIS ORDER NUMBER: 095996739100002R

LANGUAGES: English

Non-steroidal antiinflammatory drugs (NSAID) enhanced the spreading of mouse and rat peritoneal macrophages attached to either plastic or glass. This was probably due to drug inhibition of prostaglandin E2 (PGE2) production since spreading was also inhibited by adding exogenous PGE2. Corticosteroids (dexamethasone, cortisol and prednisolone) and some immunosuppressants (6-mercaptopurine, methotrexate, but not cyclosporin-A) also enhanced in-vitro spreading of murine peritoneal macrophages. Some recombinant cytokines (human tumour necrosis factor alpha and beta, murine tumour necrosis factor alpha, and murine interferon gamma, but not human interferon gamma) also enhanced the spreading of mouse peritoneal macrophages in vitro. Scanning electron microscopy revealed significant differences in morphology of cells induced to spread by these drugs and cytokines. NSAID treatment also enhanced macrophage clumping in vitro, indicating that cell spreading may play an important role in the resolution of inflammatory processes and/or the formation of multinucleated giant

cells.

9/7/10 (Item 1 from file: 154)
DIALOG(R)File 154:MEDLINE(R)
(c) format only 1997 Knight-Ridder Info. All rts. reserv.

08101632 92239632

Angiogenesis and its inhibition: potential new therapies in oncology and non-neoplastic diseases.

Billington DC

Institut de Recherches Servier, Suresnes, France.

Drug Des Discov (SWITZERLAND) Nov 1991, 8 (1) p3-35, ISSN 1055-9612

Journal Code: A5B

Languages: ENGLISH

Document type: JOURNAL ARTICLE; REVIEW; REVIEW, TUTORIAL

To summarise the key points: The ability to mount an angiogenic response is probably present in all tissues, and stimulation of endothelial cells by any one of a wide variety of factors initiates a cascade of events leading to angiogenesis. In most tissues the overall lack of angiogenesis in normal situations probably results from the interaction of a complex series of multifactorial systems, each of which maintained in a state of balance between stimulation and inhibition. An imbalance in any one of these systems, for example by an increase in the concentration of a growth factor, may lead to angiogenesis. Inhibition of angiogenic stimuli is unlikely to be effective as an approach to new angiostatic drugs, given the multiple stimulatory pathways available. Tumour cells for example may induce angiogenesis via release of numerous growth factors, prostaglandins etc, and by their attraction of inflammatory cells which in turn release multiple angiogenic stimuli. Inhibitory modulation of many of the individual steps of capillary growth which occur following an angiogenic stimulus can block the angiogenic response. This leads to the expectation that an effective inhibitor of a single key step in this cascade would be able to completely suppress angiogenesis. Inappropriate angiogenesis is an important factor in many diseases including cancer and arthritis. In particular angiogenesis is an absolute requirement for neoplastic growth of solid tumours, and the establishment of secondary growths. There is also a strong link between induction of angiogenesis by a tumour and its ability to metastasise. Several drugs with proven clinical effects in diseases involving angiogenesis have recently been found to be angiogenesis inhibitors, and this may be their primary mechanism of action. In particular the activities of methotrexate and gold compounds in arthritis, and alpha-interferon and medroxyprogesterone in cancer therapy may be due to inhibition of angiogenesis. In animal models, treatment with angiogenesis inhibitors has proven anti-tumour effects in vivo, and can both reduce metastases and lead to regression of the primary growth by necrosis following capillary retraction. In man the success of alpha-interferon and TNF alpha in AIDS related Kaposi's sarcoma may be due to inhibition of angiogenesis. Interferon has also been successfully used to treat pulmonary hemangiomatosis, in which angiogenesis in the lung may be the pathogenic basis of the disease. (33 Refs.)

?ds

Set	Items	Description
S1	426	METHOTREXATE AND (TNF OR TUMOR(W) NECROSIS(W) FACTOR?)
S2	145	S1 AND (CROHN? OR ARTHRITIS)
S3	108	RD S2 (unique items)

S4 116 S1 AND (INFLAMMAT? OR AUTOIMMUN?)
S5 93 RD S4 (unique items)
S6 39 (S3 OR S5) AND REVIEW?
S7 39 RD S6 (unique items)
S8 10 S3 AND PY=1991
S9 10 RD S8 (unique items)
?t s3/3/all

3/3/1 (Item 1 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)
(c) 1997 BIOSIS. All rts. reserv.

13290905 BIOSIS Number: 99290905
In vitro and in vivo biological activities of a novel nonpolyglutamable anti-folate, MX-68
Mihara M; Urakawa K; Takagi N; Moriya Y; Takeda Y
Fuji-Gotemba Res. Laboratories, Chugai Pharm. Co. Ltd., 135 Komakado 1-chome, Gotemba-shi, Shizuoka 412, Japan
Immunopharmacology 35 (1). 1996. 41-46.
Full Journal Title: Immunopharmacology
ISSN: 0162-3109
Language: ENGLISH
Print Number: Biological Abstracts Vol. 103 Iss. 001 Ref. 006377

3/3/2 (Item 2 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)
(c) 1997 BIOSIS. All rts. reserv.

13224258 BIOSIS Number: 99224258
Anti-TNF-alpha monoclonal antibody (mAb) treatment of rheumatoid arthritis (RA) patients with active disease on methotrexate (MTX): Results of open label, repeated dose administration following a single dose double-blind, placebo controlled trial
Kavanaugh A F; Cush J J; St Clair E W; McCune W J; Braakman T A J; Nichols L A; Lipsky P E
Univ. Texas, Southwestern Med. Cent., Dallas, TX 75235, USA
Arthritis & Rheumatism 39 (9 SUPPL.). 1996. S244.
Full Journal Title: 60th National Scientific Meeting of the American College of Rheumatology and the 31st National Scientific Meeting of the Association of Rheumatology Health Professionals, Orlando, Florida, USA, October 18-22, 1996. Arthritis & Rheumatism
ISSN: 0004-3591
Language: ENGLISH
Document Type: CONFERENCE PAPER
Print Number: Biological Abstracts/RRM Vol. 048 Iss. 011 Ref. 203379

3/3/3 (Item 3 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)
(c) 1997 BIOSIS. All rts. reserv.

13223538 BIOSIS Number: 99223538
Anti-TNF-alpha monoclonal antibody (mAb) treatment of rheumatoid arthritis (RA) patients with active disease on methotrexate (MTX); results of a double-blind, placebo controlled multicenter trial
Kavanaugh A F; Cush J J; St Clair E W; McCune W J; Braakman T A J;

Nichols L A; Lipsky P E

Univ. Texas, Southwestern Medical Sch., Dallas, TX 75235, USA

Arthritis & Rheumatism 39 (9 SUPPL.). 1996. S123.

Full Journal Title: 60th National Scientific Meeting of the American College of Rheumatology and the 31st National Scientific Meeting of the Association of Rheumatology Health Professionals, Orlando, Florida, USA, October 18-22, 1996. Arthritis & Rheumatism

ISSN: 0004-3591

Language: ENGLISH

Document Type: CONFERENCE PAPER

Print Number: Biological Abstracts/RRM Vol. 048 Iss. 011 Ref. 202659

3/3/4 (Item 4 from file: 55)

DIALOG(R)File 55:BIOSIS PREVIEWS(R)

(c) 1997 BIOSIS. All rts. reserv.

13223416 BIOSIS Number: 99223416

Methotrexate (MTX) treatment reduces inflammatory cell numbers and expression of monokines and adhesion molecules in synovial tissue of patients with rheumatoid arthritis (RA)

Dolhain R J E M; Tak P P; Dijkmans B A C; De Kuiper P; Breedveld F C; Miltenburg A M M

Dep. Rheumatol., Univ. Hosp., Leiden, Netherlands

Arthritis & Rheumatism 39 (9 SUPPL.). 1996. S102.

Full Journal Title: 60th National Scientific Meeting of the American College of Rheumatology and the 31st National Scientific Meeting of the Association of Rheumatology Health Professionals, Orlando, Florida, USA, October 18-22, 1996. Arthritis & Rheumatism

ISSN: 0004-3591

Language: ENGLISH

Document Type: CONFERENCE PAPER

Print Number: Biological Abstracts/RRM Vol. 048 Iss. 011 Ref. 202537

3/3/5 (Item 5 from file: 55)

DIALOG(R)File 55:BIOSIS PREVIEWS(R)

(c) 1997 BIOSIS. All rts. reserv.

13195603 BIOSIS Number: 99195603

Interleukin 1 (IL-1) receptor antagonist, soluble tumor necrosis factor receptors, IL-1-beta, and IL-8-markers of remission in rheumatoid arthritis during treatment with methotrexate

Seitz M; Loetscher P; Dewald B; Towbin H; Rordorf C; Gallati H; Gerber N J

Dep. Rheumatol., Univ. Hosp., Inselspital, CH-3010 Berne, Switzerland

Journal of Rheumatology 23 (9). 1996. 1512-1516.

Full Journal Title: Journal of Rheumatology

ISSN: 0315-162X

Language: ENGLISH

Print Number: Biological Abstracts Vol. 102 Iss. 009 Ref. 127610

3/3/6 (Item 6 from file: 55)

DIALOG(R)File 55:BIOSIS PREVIEWS(R)

(c) 1997 BIOSIS. All rts. reserv.

13129832 BIOSIS Number: 99129832

Protein metabolism in rheumatoid arthritis and aging: Effects of muscle strength training and tumor necrosis factor alpha

Rall L C; Rosen C J; Dolnikowski G; Hartman W J; Lundgren N; Abad L W; Dinarello C A; Roubenoff R

Tufts Univ., 711 Washington St., Boston, MA 02111, USA

Arthritis & Rheumatism 39 (7). 1996. 1115-1124.

Full Journal Title: Arthritis & Rheumatism

ISSN: 0004-3591

Language: ENGLISH

Print Number: Biological Abstracts Vol. 102 Iss. 006 Ref. 077963

3/3/7 (Item 7 from file: 55)

DIALOG(R)File 55:BIOSIS PREVIEWS(R)

(c) 1997 BIOSIS. All rts. reserv.

12173087 BIOSIS Number: 98773087

Inflammatory bowel disease (IBD): Therapeutic actualities

Florent C H

Hopital Saint Antoine, Paris, France

Acta Endoscopica 25 (5 SUPPL.). 1995. 571-574.

Full Journal Title: Acta Endoscopica

ISSN: 0240-642X

Language: FRENCH ENGLISH

Print Number: Biological Abstracts Vol. 101 Iss. 010 Ref. 140279

3/3/8 (Item 8 from file: 55)

DIALOG(R)File 55:BIOSIS PREVIEWS(R)

(c) 1997 BIOSIS. All rts. reserv.

12122694 BIOSIS Number: 98722694

Nitric oxide: An important articular free radical

Murrell G A C; Dolan M M; Jang D; Szabo C; Warren R F; Hannafin J A

Dep. Orthopaedic Surg., St. George Hosp., Kogarah, Sydney, NSW 2217, Australia

Journal of Bone and Joint Surgery American Volume 78 (2). 1996. 265-274.

Full Journal Title: Journal of Bone and Joint Surgery American Volume

ISSN: 0021-9355

Language: ENGLISH

Print Number: Biological Abstracts Vol. 101 Iss. 008 Ref. 106969

3/3/9 (Item 9 from file: 55)

DIALOG(R)File 55:BIOSIS PREVIEWS(R)

(c) 1997 BIOSIS. All rts. reserv.

12080296 BIOSIS Number: 98680296

Trends in rheumatoid arthritis research

Emilie D; Russo-Marie F

INSERM U. 322, 22 rue Mechain, 75014 Paris, France

M-S (Medecine Sciences) 11 (11). 1995. 1577-1580.

Full Journal Title: M-S (Medecine Sciences)

ISSN: 0767-0974

Language: FRENCH

Print Number: Biological Abstracts Vol. 101 Iss. 006 Ref. 080577

3/3/10 (Item 10 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)
(c) 1997 BIOSIS. All rts. reserv.

12038433 BIOSIS Number: 98638433
Auranofin inhibits the induction of interleukin 1-beta and tumor necrosis factor alpha mRNA in macrophages
Bondeson J; Sundler R
Dep. Cell Mol. Biol., Lund University, PO Box 94, S-221 00 Lund, Sweden
Biochemical Pharmacology 50 (11). 1995. 1753-1759.
Full Journal Title: Biochemical Pharmacology
ISSN: 0006-2952
Language: ENGLISH
Print Number: Biological Abstracts Vol. 101 Iss. 004 Ref. 054178

3/3/11 (Item 11 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)
(c) 1997 BIOSIS. All rts. reserv.

11990492 BIOSIS Number: 98590492
Therapy of chronic inflammatory bowel
Levy P
Strasbourg, France
Acta Endoscopica 25 (2 SUPPL.). 1995. 219-222.
Full Journal Title: Acta Endoscopica
ISSN: 0240-642X
Language: FRENCH
Document Type: MEETING REPORT
Print Number: Biological Abstracts Vol. 101 Iss. 002 Ref. 018197

3/3/12 (Item 12 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)
(c) 1997 BIOSIS. All rts. reserv.

11936107 BIOSIS Number: 98536107
Direct stimulation of cytokines IL-1-beta, TNF-alpha, IL-6, IL-2, IFN-gamma and GM-CSF in whole blood: Role of methotrexate and aurothiopropionol sulfonate sodium
Kaye O; Zangerle P F; Vrindts Y; Lopez M; Meulemans R J; De Groote D; Malaise M G
Rheumatol., Univ. Liege, Liege, Belgium
Arthritis & Rheumatism 38 (9 SUPPL.). 1995. S370.
Full Journal Title: 59th National Scientific Meeting of the American College of Rheumatology and the 30th National Scientific Meeting of the Association of Rheumatology Health Professionals, San Francisco, California, USA, October 21-26, 1995. Arthritis & Rheumatism
ISSN: 0004-3591
Language: ENGLISH
Document Type: CONFERENCE PAPER
Print Number: Biological Abstracts/RRM Vol. 047 Iss. 012 Ref. 205982

3/3/13 (Item 13 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)
(c) 1997 BIOSIS. All rts. reserv.

11935586 BIOSIS Number: 98535586

High dose intravenous immunoglobulin (IVIg) in severe refractory rheumatoid arthritis (RA): No evidence for efficacy

Maksymowych W P; Avina-Zubieta A; Luong M; Russell A S

Dep. Med., Univ. Alberta, Edmonton, Alberta, Canada

Arthritis & Rheumatism 38 (9 SUPPL.). 1995. S283.

Full Journal Title: 59th National Scientific Meeting of the American College of Rheumatology and the 30th National Scientific Meeting of the Association of Rheumatology Health Professionals, San Francisco, California, USA, October 21-26, 1995. Arthritis & Rheumatism

ISSN: 0004-3591

Language: ENGLISH

Document Type: CONFERENCE PAPER

Print Number: Biological Abstracts/RRM Vol. 047 Iss. 012 Ref. 205461

3/3/14 (Item 14 from file: 55)

DIALOG(R)File 55:BIOSIS PREVIEWS(R)

(c) 1997 BIOSIS. All rts. reserv.

11935486 BIOSIS Number: 98535486

Suppression of tumor necrosis factor (TNF) and TNF-mediated effector mechanisms by methotrexate (MTX) in patients with rheumatoid arthritis

Fenner H; Zueger S; Taylor D; Sander O; Herborn G; Rau R

Swiss Fed. Inst. Technol., CH-8057 Zurich, Switzerland

Arthritis & Rheumatism 38 (9 SUPPL.). 1995. S266.

Full Journal Title: 59th National Scientific Meeting of the American College of Rheumatology and the 30th National Scientific Meeting of the Association of Rheumatology Health Professionals, San Francisco, California, USA, October 21-26, 1995. Arthritis & Rheumatism

ISSN: 0004-3591

Language: ENGLISH

Document Type: CONFERENCE PAPER

Print Number: Biological Abstracts/RRM Vol. 047 Iss. 012 Ref. 205361

3/3/15 (Item 15 from file: 55)

DIALOG(R)File 55:BIOSIS PREVIEWS(R)

(c) 1997 BIOSIS. All rts. reserv.

11935485 BIOSIS Number: 98535485

Tumor necrosis factor alpha (TNF) blockade enhances methotrexate (MTX) response in patients with rheumatoid arthritis (RA)

Sander O; Herborn G; Rau R

Rheumatol. Unit, Evangelisches Krankenhaus, D-40882 Ratingen, Germany

Arthritis & Rheumatism 38 (9 SUPPL.). 1995. S266.

Full Journal Title: 59th National Scientific Meeting of the American College of Rheumatology and the 30th National Scientific Meeting of the Association of Rheumatology Health Professionals, San Francisco, California, USA, October 21-26, 1995. Arthritis & Rheumatism

ISSN: 0004-3591

Language: ENGLISH

Document Type: CONFERENCE PAPER

Print Number: Biological Abstracts/RRM Vol. 047 Iss. 012 Ref. 205360

3/3/16 (Item 16 from file: 55)

DIALOG(R)File 55:BIOSIS PREVIEWS(R)

(c) 1997 BIOSIS. All rts. reserv.

11922319 BIOSIS Number: 98522319

Effect of methotrexate alone or in combination with sulphasalazine on the production and circulating concentrations of cytokines and their antagonists: Longitudinal evaluation in patients with rheumatoid arthritis

Barrera P; Haagsma C J; Boerbooms A M T; Van Riel P L C M; Borm G F; Van De Putte L B A; Van Der Meer J W M

Dep. Rheumatol., University Hospital Nijmegen, PO Box 9101, 6500 HB Nijmegen, Netherlands

British Journal of Rheumatology 34 (8). 1995. 747-755.

Full Journal Title: British Journal of Rheumatology

ISSN: 0263-7103

Language: ENGLISH

Print Number: Biological Abstracts Vol. 100 Iss. 011 Ref. 173176



3/3/17 (Item 17 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)
(c) 1997 BIOSIS. All rts. reserv.

11873246 BIOSIS Number: 98473246

Methotrexate action in rheumatoid arthritis: Stimulation of cytokine inhibitor and inhibition of chemokine production by peripheral blood mononuclear cells

Seitz M; Loetscher P; Dewald B; Towbin H; Rordorf C; Gallati H; Baggiolini M; Gerber N J

Div. Rheumatol., Univ. Hosp., Inselspital, CH-3010 Bern, Switzerland

British Journal of Rheumatology 34 (7). 1995. 602-609.

Full Journal Title: British Journal of Rheumatology

ISSN: 0263-7103

Language: ENGLISH

Print Number: Biological Abstracts Vol. 100 Iss. 009 Ref. 139303

3/3/18 (Item 18 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)
(c) 1997 BIOSIS. All rts. reserv.

11857705 BIOSIS Number: 98457705

The antiinflammatory effects of an adenosine kinase inhibitor are mediated by adenosine

Cronstein B N; Naime D; Firestein G

New York Univ. Med. Cent., New York, NY, USA

Arthritis & Rheumatism 38 (8). 1995. 1040-1045.

Full Journal Title: Arthritis & Rheumatism

ISSN: 0004-3591

Language: ENGLISH

Print Number: Biological Abstracts Vol. 100 Iss. 008 Ref. 123762

3/3/19 (Item 19 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)
(c) 1997 BIOSIS. All rts. reserv.

11799630 BIOSIS Number: 98399630

Effect of disease modifying anti-rheumatic (DMARD) drugs on in vitro cytokine production by peripheral blood mononuclear cells of rheumatoid

arthritis (RA)

Yadav R H; Misra R M; Naik S

Dep. Immunol., SGPGIMS, Raebareli Road, Lucknow, India

0 (0). 1995. 798.

Full Journal Title: 9TH INTERNATIONAL CONGRESS OF IMMUNOLOGY. The 9th International Congress of Immunology; Meeting Sponsored by the American Association of Immunologists and the International Union of Immunological Societies, San Francisco, California, USA, July 23-29, 1995. 311p. 9th International Congress of Immunology: San Francisco, California, USA.

ISSN: *****

Language: ENGLISH

Document Type: CONFERENCE PROCEEDINGS

Print Number: Biological Abstracts/RRM Vol. 047 Iss. 009 Ref. 162033

3/3/20 (Item 20 from file: 55)

DIALOG(R)File 55:BIOSIS PREVIEWS(R)

(c) 1997 BIOSIS. All rts. reserv.

11729019 BIOSIS Number: 98329019

Autoimmunity, nutrition and old age

Florez-Tascon Sixto F J; Goya J; Sanchez-Escribano F; Serrano S; Garay J

Lab. MEGALAB, C/Alfonso XII 42, Madrid, Spain

Geriatrka (Madrid) 11 (1). 1995. 18-20, 22-24, 26-27.

Full Journal Title: Geriatrka (Madrid)

ISSN: 0212-9744

Language: SPANISH

Print Number: Biological Abstracts Vol. 100 Iss. 003 Ref. 036743

3/3/21 (Item 21 from file: 55)

DIALOG(R)File 55:BIOSIS PREVIEWS(R)

(c) 1997 BIOSIS. All rts. reserv.

11717879 BIOSIS Number: 98317879

Every-other-week methotrexate in patients with rheumatoid arthritis: A double-blind, placebo-controlled prospective study

Kremer J M; Davies J M S; Rynes R I; Fink S; Lawrence D A; Petrillo G F; Mullaly P M

Div. Rheumatol., Albany Med. Coll., 47 New Scotland Ave., Albany, NY 12208, USA

Arthritis & Rheumatism 38 (5). 1995. 601-607.

Full Journal Title: Arthritis & Rheumatism

ISSN: 0004-3591

Language: ENGLISH

Print Number: Biological Abstracts Vol. 100 Iss. 002 Ref. 025603

3/3/22 (Item 22 from file: 55)

DIALOG(R)File 55:BIOSIS PREVIEWS(R)

(c) 1997 BIOSIS. All rts. reserv.

11545087 BIOSIS Number: 98145087

Rheumatoid arthritis treated with tenidap and piroxicam: Clinical associations with cytokine modulation by tenidap

Littman B H; Drury C E; Zimmerer R O; Stack C B; Law C G

Central Res. Div., Pfizer Inc., Eastern Point Road, Groton, CT 06340, USA

Arthritis & Rheumatism 38 (1). 1995. 29-37.

Full Journal Title: Arthritis & Rheumatism

ISSN: 0004-3591

Language: ENGLISH

Print Number: Biological Abstracts Vol. 099 Iss. 007 Ref. 101644

3/3/23 (Item 23 from file: 55)

DIALOG(R)File 55:BIOSIS PREVIEWS(R)

(c) 1997 BIOSIS. All rts. reserv.

11482204 BIOSIS Number: 98082204

Circulating concentrations and production of cytokines and soluble receptors in rheumatoid arthritis patients: Effects of a single dose methotrexate

Barrera P; Boerbooms A M T; Demacker P N M; Van De Putte L B A; Gallati H ; Van Der Meer J W M

Dep. Rheumatol., Univ. Hosp., Nijmegen, Netherlands

British Journal of Rheumatology 33 (11). 1994. 1017-1024.

Full Journal Title: British Journal of Rheumatology

ISSN: 0263-7103

Language: ENGLISH

Print Number: Biological Abstracts Vol. 099 Iss. 004 Ref. 052614

3/3/24 (Item 24 from file: 55)

DIALOG(R)File 55:BIOSIS PREVIEWS(R)

(c) 1997 BIOSIS. All rts. reserv.

10945560 BIOSIS Number: 97145560

Serum levels of interleukin-6 and tumour-necrosis-factor-alpha are not correlated to disease activity in patients with rheumatoid arthritis after treatment with low-dose methotrexate

Wascher T C; Hermann J; Brezinschek R; Brezinschek H P; Wilders-Trusching M; Rainer F; Krejs G J

Dep. Med., Auenbruggerpl. 15, A-8036 Graz, AUS

European Journal of Clinical Investigation 24 (1). 1994. 73-75.

Full Journal Title: European Journal of Clinical Investigation

ISSN: 0014-2972

Language: ENGLISH

Print Number: Biological Abstracts Vol. 097 Iss. 007 Ref. 095435

3/3/25 (Item 25 from file: 55)

DIALOG(R)File 55:BIOSIS PREVIEWS(R)

(c) 1997 BIOSIS. All rts. reserv.

10842177 BIOSIS Number: 97042177

Elevated levels of TNF in the joints of adjuvant arthritic rats

Smith-Oliver T; Noel L S; Stimpson S S; Yarnall D P; Connolly K M

Dep. Immunology, Glaxo Res. Inst., Five Moore Drive, Research Triangle Park, NC 27709, USA

Cytokine 5 (4). 1993. 298-304.

Full Journal Title: Cytokine

ISSN: 1043-4666

Language: ENGLISH

Print Number: Biological Abstracts Vol. 097 Iss. 003 Ref. 026524

3/3/26 (Item 26 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)
(c) 1997 BIOSIS. All rts. reserv.

10822136 BIOSIS Number: 97022136

Methotrexate (MTX) therapy is associated with a reduction of TNF-alpha (TNF-a) an soluble TNF receptor (TNF-R) levels in serum of patients with psoriatic arthritis (PA) but not with rheumatoid arthritis (RA)

Leeb B F; Studnicka-Benke A; Steiner G; Smolen J S

Second Dep. Med., Lainz Hospital, Vienna, AUS

Arthritis and Rheumatism 36 (9 SUPPL.). 1993. A80.

Full Journal Title: 57th Annual Scientific Meeting of the American College of Rheumatology, San Antonio, Texas, USA, November 7-11, 1993.

Arthritis and Rheumatism

ISSN: 0004-3591

Language: ENGLISH

Document Type: CONFERENCE PAPER

3/3/27 (Item 27 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)
(c) 1997 BIOSIS. All rts. reserv.

10499899 BIOSIS Number: 96099899

CIRCULATING SOLUBLE TUMOR NECROSIS FACTOR RECEPTORS INTERLEUKIN-2 RECEPTORS TUMOR NECROSIS FACTOR ALPHA AND INTERLEUKIN-6 LEVELS IN RHEUMATOID ARTHRITIS LONGITUDINAL EVALUATION DURING METHOTREXATE AND AZATHIOPRINE THERAPY

BARRERA P; BOERBOOMS A M T; JANSSEN E M; SAUERWEIN R W; GALLATI H; MULDER J; DE BOO T; DEMACKER P N M; VAN DER PUTTE L B A; VAN DER MEER J W M

DEP. RHEUMATOL. INTERNAL MED., UNIV. HOSP. NIJMEGEN, P.O. BOX 9101, 6500 HB NIJMEGEN, NETHERLANDS.

ARTHRITIS RHEUM 36 (8). 1993. 1070-1079. CODEN: ARHEA

Full Journal Title: Arthritis and Rheumatism

Language: ENGLISH

3/3/28 (Item 28 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)
(c) 1997 BIOSIS. All rts. reserv.

9766686 BIOSIS Number: 44016686

EFFECT OF METHOTREXATE PHOSPHOLIPID CONJUGATES UPON MEDIATOR RELEASE BY MACROPHAGES

WILLIAMS A S; AMOS N; TOPLEY M; WILLIAMS B D

DEP. RHEUMATOL., UNIV. HOSP., CARDIFF CF4 4XN, UK.

56TH ANNUAL SCIENTIFIC MEETING OF THE AMERICAN COLLEGE OF RHEUMATOLOGY, ATLANTA, GEORGIA, USA, OCTOBER 11-15, 1992. ARTHRITIS RHEUM 35 (9 SUPPL.). 1992. S309. CODEN: ARHEA

Language: ENGLISH

Document Type: CONFERENCE PAPER

3/3/29 (Item 29 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)
(c) 1997 BIOSIS. All rts. reserv.

9766676 BIOSIS Number: 44016676

METHOTREXATE AND AZATHIOPRINE THERAPY FOR RHEUMATOID ARTHRITIS EFFECTS ON
CIRCULATING CYTOKINES

BARRERA P; JANSSEN E M; SAUERWEIN R W; BOERBOOMS A M T; VAN DE PUTTE L B
A; VAN DER MEER J W M

DEP. RHEUMATOL. INTERNAL MED., UNIV. HOSP. NIJMEGEN, NETH.

56TH ANNUAL SCIENTIFIC MEETING OF THE AMERICAN COLLEGE OF RHEUMATOLOGY,
ATLANTA, GEORGIA, USA, OCTOBER 11-15, 1992. ARTHRITIS RHEUM 35 (9 SUPPL.).
1992. S307. CODEN: ARHEA

Language: ENGLISH

Document Type: CONFERENCE PAPER

3/3/30 (Item 30 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)
(c) 1997 BIOSIS. All rts. reserv.

9538308 BIOSIS Number: 94043308

THE EFFECT OF SLOW-ACTING ANTI-RHEUMATIC DRUGS SAARDS AND COMBINATIONS OF
SAARDS ON MONOKINE PRODUCTION IN-VITRO

DANIS V A; FRANIC G M; BROOKS P M

KOLLING INST., ROYAL NORTH SHORE HOSP., ST. LEONARDS, NSW 2065, AUST.

DRUGS EXP CLIN RES 17 (12). 1991. 549-554. CODEN: DECRD

Full Journal Title: Drugs under Experimental and Clinical Research

Language: ENGLISH

3/3/31 (Item 31 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)
(c) 1997 BIOSIS. All rts. reserv.

8785193 BIOSIS Number: 42010193

EFFECTS OF A WEEKLY DOSES OF METHOTREXATE ON IL-1 TNF AND IL-6 IN
PATIENTS WITH RHEUMATOID ARTHRITIS

BARRERA P; JANSSEN E M; BOERBOOMS A M T; VAN DE PUTTE L B A; SAUERWEIN R
W; VAN DER MEER J W M

UNIV. HOSPITAL NIJMEGEN, POSTBOX 9101, NETHERLANDS.

THIRD INTERNATIONAL WORKSHOP ON CYTOKINES, STRESA, ITALY, NOVEMBER 10-14,
1991. CYTOKINE 3 (5). 1991. 504. CODEN: CYTIE

Language: ENGLISH

Document Type: CONFERENCE PAPER

3/3/32 (Item 32 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)
(c) 1997 BIOSIS. All rts. reserv.

8339671 BIOSIS Number: 41023671

IMMUNOLOGY OF INFLAMMATORY BOWEL DISEASE SUMMARY OF THE PROCEEDINGS OF
THE SUBCOMMITTEE ON IMMUNOSUPPRESSIVE USE IN IBD

MARKOWITZ J; DAUM F; COHEN S A; GLASSMAN M; HOLMES R D; PICCOLI D; ROSSI
T M; TREEM W R; ULSHEN M H; WINTER H S

DEP. PEDIATRICS, NORTH SHORE UNIV. HOSP., CORNELL UNIV. MED. COLL., 300
COMMUNITY DR., MANHASSET, N.Y. 11030, USA.

J PEDIATR GASTROENTEROL NUTR 12 (4). 1991. 411-423. CODEN: JPGND

Full Journal Title: Journal of Pediatric Gastroenterology and Nutrition

Language: ENGLISH

Document Type: CONFERENCE PROCEEDINGS

3/3/33 (Item 33 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)
(c) 1997 BIOSIS. All rts. reserv.

8209483 BIOSIS Number: 91130483
INCREASED TNF-ALPHA SECRETION BY ALVEOLAR MACROPHAGES FROM PATIENTS WITH
RHEUMATOID ARTHRITIS
GOSSET P; PEREZ T; LASSALLE P; DUQUESNOY B; FARRE J M; TONNEL A B; CAPRON
A
CENTRE IMMUNOLOGIE BIOLOGIE PARASITAIRE, UNITE MIXTE INSERM 167, CNRS
624, BP 245, INSTITUT PASTEUR, 59019 LILLE CEDEX, FR.
AM REV RESPIR DIS 143 (3). 1991. 593-597. CODEN: ARDSB
Full Journal Title: American Review of Respiratory Disease
Language: ENGLISH

3/3/34 (Item 34 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)
(c) 1997 BIOSIS. All rts. reserv.

7832820 BIOSIS Number: 40033820
METHOTREXATE MECHANISM OF ACTION IN RHEUMATOID ARTHRITIS
SEGAL R; YARON M; TARTAKOVSKY B
DEP. RHEUMATOLOGY, ICHILOV HOSP., TEL-AVIV 64239, ISRAEL.
SEMIN ARTHRITIS RHEUM 20 (3). 1990. 190-200. CODEN: SAHRB
Full Journal Title: Seminars in Arthritis and Rheumatism
Language: ENGLISH

3/3/35 (Item 35 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)
(c) 1997 BIOSIS. All rts. reserv.

6872115 BIOSIS Number: 37066494
EFFECTS OF TUMOR NECROSIS FACTOR AND COMBINATION CYCLOSPORIN
A-METHOTREXATE THERAPY ON COLLAGEN ARTHRITIS
BRAHN E; BANQUERIGO M L C; LIU D Y
UCLA SCH. MED., LOS ANGELES, CALIF. 90024, USA.
53RD ANNUAL SCIENTIFIC MEETING OF THE AMERICAN COLLEGE OF RHEUMATOLOGY,
CINCINNATI, OHIO, USA, JUNE 12-17, 1989. ARTHRITIS RHEUM 32 (4 SUPPL.).
1989. S133. CODEN: ARHEA
Language: ENGLISH
Document Type: CONFERENCE PAPER

3/3/36 (Item 1 from file: 72)
DIALOG(R)File 72:EMBASE
(c) 1997 Elsevier Science B.V. All rts. reserv.

10166244 EMBASE No: 96338065
Cytokine-suppressive anti-inflammatory drugs. Status of development in
rheumatoid arthritis
Huizinga T.W.J.; Breedveld F.C.
Department of Rheumatology, University Hospital, Postbus 9600, 2300 RC
Leiden Netherlands
Clinical Immunotherapeutics (New Zealand) , 1996, 6/5 (395-404) CODEN:
CIMME ISSN: 1172-7039

LANGUAGES: English SUMMARY LANGUAGES: English

3/3/37 (Item 2 from file: 72)
DIALOG(R)File 72:EMBASE
(c) 1997 Elsevier Science B.V. All rts. reserv.

10150490 EMBASE No: 96328822
Effects of disease modifying antirheumatic drugs (DMARDs) and DEX on
IL-1beta and IL-6 production by IL-1beta stimulated synovial culture cells
Koda M.; Yoshino S.; Nakamura H.; Asano G.
Department of Joint Diseases, Nippon Medical School, First Hospital,
3-3-5 Iidabashi, Chiyoda-ku, Tokyo 102 Japan
Journal of Nippon Medical School (Japan) , 1996, 63/5 (419-423) CODEN:
NIDZA ISSN: 0048-0444
LANGUAGES: Japanese SUMMARY LANGUAGES: English

3/3/38 (Item 3 from file: 72)
DIALOG(R)File 72:EMBASE
(c) 1997 Elsevier Science B.V. All rts. reserv.

10135749 EMBASE No: 96313827
The effects of immunosuppressive agents on cytokines
Elson C.O.
Div. Gastroenterology/Hepatology, Department of Medicine, University of
Alabama, UAB Station, Birmingham, AL 35294-0007 USA
Alimentary Pharmacology and Therapeutics, Supplement (United Kingdom) ,
1996, 10/2 (100-105) CODEN: ATSLE ISSN: 0953-0673
LANGUAGES: English SUMMARY LANGUAGES: English

3/3/39 (Item 4 from file: 72)
DIALOG(R)File 72:EMBASE
(c) 1997 Elsevier Science B.V. All rts. reserv.

10004727 EMBASE No: 96173159
Combination regimens for rheumatoid arthritis
ASSOCIATION DES TRAITEMENTS DE FOND DANS LA POLYARTHRITE RHUMATOIDE
Bologna C.; Sany J.
Service d'Immuno-Rhumatologie, Federation de Rhumatologie, Hopital
Lapeyronie, F 34295 Montpellier Cedex 5 France
Presse Medicale (France) , 1996, 25/19 (876-878) CODEN: PRMEE ISSN:
0755-4982
LANGUAGES: French SUMMARY LANGUAGES: English

3/3/40 (Item 5 from file: 72)
DIALOG(R)File 72:EMBASE
(c) 1997 Elsevier Science B.V. All rts. reserv.

9986735 EMBASE No: 96146574
The immunological network: Novel approaches to the treatment of Crohn's
disease
Davidsen B.; Nielsen O.H.; Vainer B.; Kirman I.
Department of Gastroenterology F, Glostrup Hospital, University of
Copenhagen, Nordre Ringvej, DK-2600 Glostrup Denmark
Expert Opinion on Investigational Drugs (United Kingdom) , 1996, 5/5

(555-564) CODEN: EOIDE ISSN: 1354-3784
LANGUAGES: English SUMMARY LANGUAGES: English
t s5/3/all

3/3/41 (Item 6 from file: 72)
DIALOG(R)File 72:EMBASE
(c) 1997 Elsevier Science B.V. All rts. reserv.

9979913 EMBASE No: 96135284
Treatment of rheumatoid arthritis
THERAPIE DER RHEUMATOIDEN ARTHRITIS
Sieper J.; Braun J.
Abt. fur Allg. Innere Med./Nephrol., Universitatsklin. Benjamin Franklin,
Hindenburgdamm 30, 12200 Berlin Germany
Deutsche Medizinische Wochenschrift (Germany) , 1996, 121/17 (563-567)
CODEN: DMWOA ISSN: 0012-0472
LANGUAGES: German

3/3/42 (Item 7 from file: 72)
DIALOG(R)File 72:EMBASE
(c) 1997 Elsevier Science B.V. All rts. reserv.

9979809 EMBASE No: 96148902
Different cytokine profiles in the synovial fluid of patients with
osteoarthritis, rheumatoid arthritis and seronegative spondylarthropathies
Schlaak J.F.; Pfers I.; Meyer Zum Buschenfelde K.-H.; Marker-Hermann E.
1. Med. Klinik, University of Mainz, Langenbeckstrasse 1, 55101 Mainz
Germany
Clinical and Experimental Rheumatology (Italy) , 1996, 14/2 (155-162)
CODEN: CERHD ISSN: 0392-856X
LANGUAGES: English SUMMARY LANGUAGES: English

3/3/43 (Item 8 from file: 72)
DIALOG(R)File 72:EMBASE
(c) 1997 Elsevier Science B.V. All rts. reserv.

9916826 EMBASE No: 96086319
Management of osteoarthritis and rheumatoid arthritis: Prospects and
possibilities
Blackburn Jr. W.D.
Division of Immunology/Rheumatology, University of Alabama, Birmingham,
AL 35233 USA
American Journal of Medicine (USA) , 1996, 100/2 A (2A24S-2A30S) CODEN:
AJMEA ISSN: 0002-9343
LANGUAGES: English SUMMARY LANGUAGES: English

3/3/44 (Item 9 from file: 72)
DIALOG(R)File 72:EMBASE
(c) 1997 Elsevier Science B.V. All rts. reserv.

9916740 EMBASE No: 96085529
The future use of biologic therapies in combination for the treatment of
rheumatoid arthritis
Strand V.

546-29th Street, San Francisco, CA 94131 USA
Journal of Rheumatology (Canada) , 1996, 23/SUPPL. 44 (91-96) CODEN:
JRHUA ISSN: 0315-162X
LANGUAGES: English SUMMARY LANGUAGES: English

3/3/45 (Item 10 from file: 72)
DIALOG(R)File 72:EMBASE
(c) 1997 Elsevier Science B.V. All rts. reserv.

9898715 EMBASE No: 96066151
Effects of antirheumatic agents on cytokines
Barrera P.; Boerbooms A.M.T.; Van De Putte L.B.A.; Van Der Meer J.W.M.
Department of Rheumatology, University Hospital, PO Box 9101, 6500 HM
Nijmegen Netherlands
Seminars in Arthritis and Rheumatism (USA) , 1996, 25/4 (234-253)
CODEN: SAHRB ISSN: 0049-0172
LANGUAGES: English SUMMARY LANGUAGES: English

3/3/46 (Item 11 from file: 72)
DIALOG(R)File 72:EMBASE
(c) 1997 Elsevier Science B.V. All rts. reserv.

9885852 EMBASE No: 96063084
Macrophage activation syndrome in systemic juvenile rheumatoid arthritis
successfully treated with cyclosporine
Ravelli A.; De Benedetti F.; Viola S.; Martini A.
Clinica Pediatrica, IRCCS S. Matteo, Università di Pavia, P.le Golgi (2),
27100 Pavia Italy
Journal of Pediatrics (USA) , 1996, 128/2 (275-278) CODEN: JOPDA
ISSN: 0022-3476
LANGUAGES: English SUMMARY LANGUAGES: English

3/3/47 (Item 12 from file: 72)
DIALOG(R)File 72:EMBASE
(c) 1997 Elsevier Science B.V. All rts. reserv.

9878018 EMBASE No: 96043628
Crohn's disease
MALADIE DE CROHN
Guyot J.; Hess J.; Fasel J.
Division de Gastro-Enterologie, CHUV, 1011 Lausanne Switzerland
Medecine et Hygiene (Switzerland) , 1996, 54/2102 (196-198) CODEN: MEHGA
ISSN: 0025-6749
LANGUAGES: French SUMMARY LANGUAGES: English; French

3/3/48 (Item 13 from file: 72)
DIALOG(R)File 72:EMBASE
(c) 1997 Elsevier Science B.V. All rts. reserv.

9851158 EMBASE No: 96032527
Maintenance strategies in Crohn's disease
Sachar D.B.
Division of Gastroenterology, Mount Sinai Medical Center, Mount Sinai
School of Medicine, New York, NY USA

Hospital Practice (USA) , 1996, 31/1 (99-106) CODEN: HOPRB ISSN: 8750-2836

LANGUAGES: English SUMMARY LANGUAGES: English

3/3/49 (Item 14 from file: 72)

DIALOG(R)File 72:EMBASE

(c) 1997 Elsevier Science B.V. All rts. reserv.

9832395 EMBASE No: 96009693

Angiogenesis

Swerlick R.A.

Department of Dermatology, Emory University, WMB 5014, Atlanta, GA 30322 USA

Journal of Dermatology (Japan) , 1995, 22/11 (845-852) CODEN: JDMYA
ISSN: 0385-2407

LANGUAGES: English SUMMARY LANGUAGES: English

3/3/50 (Item 15 from file: 72)

DIALOG(R)File 72:EMBASE

(c) 1997 Elsevier Science B.V. All rts. reserv.

9796263 EMBASE No: 95319838

The treatment of Crohn's disease

THERAPEUTIQUE DES MICI

Levy P.

France

Acta Endoscopica (France) , 1995, 25/2 SUPPL. I (219-222) CODEN: AENDDD
ISSN: 0240-642X

LANGUAGES: French

3/3/51 (Item 16 from file: 72)

DIALOG(R)File 72:EMBASE

(c) 1997 Elsevier Science B.V. All rts. reserv.

9787618 EMBASE No: 95351542

Combination therapy

Borigini M.J.; Paulus H.E.

Division of Rheumatology, UCLA School of Medicine, 32-48 Rehabilitation, 1000 Veterans Avenue, Los Angeles, CA 90024 USA

Bailliere's Clinical Rheumatology (United Kingdom) , 1995, 9/4 (689-710)
CODEN: BCRHE ISSN: 0950-3579

LANGUAGES: English SUMMARY LANGUAGES: English

3/3/52 (Item 17 from file: 72)

DIALOG(R)File 72:EMBASE

(c) 1997 Elsevier Science B.V. All rts. reserv.

9782760 EMBASE No: 95334809

A review on the strategies for the development and application of new anti-arthritic agents

Lewis A.J.; Keft A.F.

Wyeth Ayerst Research, Princeton, NJ USA

Immunopharmacology and Immunotoxicology (USA) , 1995, 17/4 (607-663)
CODEN: IITOE ISSN: 0892-3973

LANGUAGES: English

3/3/53 (Item 18 from file: 72)
DIALOG(R)File 72:EMBASE
(c) 1997 Elsevier Science B.V. All rts. reserv.

9774097 EMBASE No: 95326680
Rheumatology update - Part II
UPDATE RHEUMATOLOGIE - TEIL II
Hein G.; Bolwin R.; Brauer R.; Eidner T.; Franke S.; Oezlner P.; Sprott H.
Klinik für Innere Medizin IV, Klinikum, Friedrich-Schiller-Universität,
D-07740 Jena Germany
Medizinische Klinik (Germany) , 1995, 90/5 (294-302) CODEN: MEKLA
ISSN: 0723-5003
LANGUAGES: German

3/3/54 (Item 19 from file: 72)
DIALOG(R)File 72:EMBASE
(c) 1997 Elsevier Science B.V. All rts. reserv.

9772322 EMBASE No: 95329534
New IBD markers: Definition of disease heterogeneity
Targan S.R.
Cedars Sinai Medical Centre, Inflammatory Bowel Disease Centre, 8700
Beverly Boulevard, Los Angeles, CA 90048 USA
Canadian Journal of Gastroenterology (Canada) , 1995, 9/6 (301-304)
CODEN: CJGAE ISSN: 0835-7900
LANGUAGES: English SUMMARY LANGUAGES: English; French

3/3/55 (Item 20 from file: 72)
DIALOG(R)File 72:EMBASE
(c) 1997 Elsevier Science B.V. All rts. reserv.

9716625 EMBASE No: 95273067
Juvenile rheumatoid arthritis and spondyloarthropathies
Lindsley C.B.
Department of Pediatrics, University of Kansas Medical Center, 3901
Rainbow Boulevard, Kansas City, KS 66160-7330 USA
Current Opinion in Rheumatology (USA) , 1995, 7/5 (425-429) CODEN: CORHE
ISSN: 1040-8711
LANGUAGES: English SUMMARY LANGUAGES: English

3/3/56 (Item 21 from file: 72)
DIALOG(R)File 72:EMBASE
(c) 1997 Elsevier Science B.V. All rts. reserv.

9697977 EMBASE No: 95246937
Effects of high-dose fish oil on rheumatoid arthritis after stopping
nonsteroidal antiinflammatory drugs: Clinical and immune correlates
Kremer J.M.; Lawrence D.A.; Petrillo G.F.; Litts L.L.; Mullaly P.M.;
Rynes R.I.; Stocker R.P.; Parhami N.; Greenstein N.S.; Fuchs B.R.; Mathur
A.; Robinson D.R.; Sperling R.I.; Bigaouette J.
Division of Rheumatology, Albany Medical College, New Scotland Avenue,

Albany, NY 12208 USA
. Arthritis and Rheumatism (USA) , 1995, 38/8 (1107-1114) CODEN: ARHEA
ISSN: 0004-3591
LANGUAGES: English SUMMARY LANGUAGES: English

3/3/57 (Item 22 from file: 72)
DIALOG(R)File 72:EMBASE
(c) 1997 Elsevier Science B.V. All rts. reserv.

9685745 EMBASE No: 95235537
Elevated circulating interleukin-7 levels in patients with systemic
juvenile rheumatoid arthritis
De Benedetti F.; Massa M.; Pignatti P.; Kelley M.; Faltynek C.R.; Martini
A.
Clinica Pediatrica, IRCCS, Pol. S. Matteo, P.le Golgi 2, 27100 Pavia
Italy
Journal of Rheumatology (Canada) , 1995, 22/8 (1581-1585) CODEN: JRHUA
ISSN: 0315-162X
LANGUAGES: English SUMMARY LANGUAGES: English

3/3/58 (Item 23 from file: 72)
DIALOG(R)File 72:EMBASE
(c) 1997 Elsevier Science B.V. All rts. reserv.

9675733 EMBASE No: 95227193
Etiopathogenesis of reactive arthritis and ankylosing spondylitis
Careless D.J.; Inman R.D.
Toronto Hospital Arthritis Centre, 399 Bathurst Street, Toronto, Ont. M5T
2S8 Canada
Current Opinion in Rheumatology (USA) , 1995, 7/4 (290-298) CODEN: CORHE
ISSN: 1040-8711
LANGUAGES: English SUMMARY LANGUAGES: English

3/3/59 (Item 24 from file: 72)
DIALOG(R)File 72:EMBASE
(c) 1997 Elsevier Science B.V. All rts. reserv.

9658135 EMBASE No: 95213487
Biological therapies: A novel approach to the treatment of autoimmune
disease
Fox D.A.
Division of Rheumatology, Department of Internal Medicine, Univ. of
Michigan Medical Center, Ann Arbor, MI 48109-0358 USA
American Journal of Medicine (USA) , 1995, 99/1 (82-88) CODEN: AJMEA
ISSN: 0002-9343
LANGUAGES: English SUMMARY LANGUAGES: English

3/3/60 (Item 25 from file: 72)
DIALOG(R)File 72:EMBASE
(c) 1997 Elsevier Science B.V. All rts. reserv.

9656683 EMBASE No: 95211861
Paediatric rheumatology: Original article inflammatory cytokine responses
in juvenile chronic arthritis

Rooney M.; David J.; Symons J.; Di Giovine F.; Varsani H.; Woo P.
UCLMS, 46 Cleveland Street, London W1P 6DB United Kingdom
British Journal of Rheumatology (United Kingdom) , 1995, 34/5 (454-460)
CODEN: BJRHD ISSN: 0263-7103
LANGUAGES: English SUMMARY LANGUAGES: English

3/3/61 (Item 26 from file: 72)
DIALOG(R)File 72:EMBASE
(c) 1997 Elsevier Science B.V. All rts. reserv.

9629778 EMBASE No: 95188270
Thalidomide: Rationale for renewed use in immunological disorders
Schuler U.; Ehninger G.
Medizinische Klinik I, Fetscherstrasse 74, 01307 Dresden Germany
Drug Safety (New Zealand) , 1995, 12/6 (364-369) CODEN: DRSAE ISSN:
0114-5916
LANGUAGES: English SUMMARY LANGUAGES: English

3/3/62 (Item 27 from file: 72)
DIALOG(R)File 72:EMBASE
(c) 1997 Elsevier Science B.V. All rts. reserv.

9614005 EMBASE No: 95172702
Correlations between PAF-acether and tumor necrosis factor in rheumatoid
arthritis. Influence of parenteral corticosteroids
Hilliquin P.; Houbaba H.; Aissa J.; Benveniste J.; Menkes C.J.
Service Rhumatologie A, Hopital Cochin, 27 Fabourg Saint-Jacques, F-75014
Paris France
Scandinavian Journal of Rheumatology (Norway) , 1995, 24/3 (169-173)
CODEN: SJRHA ISSN: 0300-9742
LANGUAGES: English SUMMARY LANGUAGES: English

3/3/63 (Item 28 from file: 72)
DIALOG(R)File 72:EMBASE
(c) 1997 Elsevier Science B.V. All rts. reserv..

9588949 EMBASE No: 95153573
Cell adhesion molecules in rheumatoid arthritis
Haskard D.O.
Department of Medicine, Royal Postgraduate Medical School, Hammersmith
Hospital, Du Cane Road, W12 ONN London United Kingdom
Current Opinion in Rheumatology (USA) , 1995, 7/3 (229-234) CODEN: CORHE
ISSN: 1040-8711
LANGUAGES: English SUMMARY LANGUAGES: English

3/3/64 (Item 29 from file: 72)
DIALOG(R)File 72:EMBASE
(c) 1997 Elsevier Science B.V. All rts. reserv.

9588943 EMBASE No: 95153567
Biologic agents in the treatment of inflammatory rheumatic diseases
Kalden J.R.; Manger B.
Department of Internal Medicine III, Clin. Immunology/Rheumatology Inst.,
University of Erlangen-Nuremberg, Krankenhausstr 12, D-91054 Erlangen

Germany

Current Opinion in Rheumatology (USA) , 1995, 7/3 (191-197) CODEN: CORHE
ISSN: 1040-8711

LANGUAGES: English SUMMARY LANGUAGES: English

3/3/65 (Item 30 from file: 72)

DIALOG(R)File 72:EMBASE

(c) 1997 Elsevier Science B.V. All rts. reserv.

9588940 EMBASE No: 95153564

Disease-modifying antirheumatic drugs, including methotrexate, gold, antimalarials, and D-penicillamine

Conaghan P.G.; Brooks P.

University of New South Wales, St. Vincent's Hospital, Victoria Street, Darlinghurst, NSW 2010 Australia

Current Opinion in Rheumatology (USA) , 1995, 7/3 (167-173) CODEN: CORHE
ISSN: 1040-8711

LANGUAGES: English SUMMARY LANGUAGES: English

3/3/66 (Item 31 from file: 72)

DIALOG(R)File 72:EMBASE

(c) 1997 Elsevier Science B.V. All rts. reserv.

9575949 EMBASE No: 95137770

Long term treatment of rheumatoid arthritis with high doses of intravenous immunoglobulins: Effects on disease activity and serum cytokines

Muscat C.; Bertotto A.; Ercolani R.; Bistoni O.; Agea E.; Cesarotti M.; Fiorucci G.; Spinozzi F.; Gerli R.

Institute of Internal Medicine, University of Perugia, Policlinico di Montelupe, I-06100 Perugia Italy

Annals of the Rheumatic Diseases (United Kingdom) , 1995, 54/5 (382-385)

CODEN: ARDIA ISSN: 0003-4967

LANGUAGES: English SUMMARY LANGUAGES: English

3/3/67 (Item 32 from file: 72)

DIALOG(R)File 72:EMBASE

(c) 1997 Elsevier Science B.V. All rts. reserv.

9542805 EMBASE No: 95102299

Soluble receptors for tumor necrosis factor and interleukin-2 in serum and synovial fluid of patients with rheumatoid arthritis, reactive arthritis and osteoarthritis

Steiner G.; Studnicka-Benke A.; Witzmann G.; Hofler E.; Smolen J.

Ludwig Boltzman Inst. Rheumatology, 2nd Department of Medicine, Lainz Hospital, Wolkerbergengasse 1, A-1130 Vienna Austria

Journal of Rheumatology (Canada) , 1995, 22/3 (406-412) CODEN: JRHUA

ISSN: 0315-162X

LANGUAGES: English SUMMARY LANGUAGES: English

3/3/68 (Item 33 from file: 72)

DIALOG(R)File 72:EMBASE

(c) 1997 Elsevier Science B.V. All rts. reserv.

9531324 EMBASE No: 95081003

Regulatory effects of IL-13 on synovial fluid macrophages and blood monocytes from patients with inflammatory arthritis

Hart P.H.; Ahern M.J.; Smith M.D.; Finlay-Jones J.J.

Dept. Microbiology/Infectious Dis., School of Medicine, Flinders Univ. of South Australia, GPO Box 2100, Adelaide, SA 5001 Australia

Clinical and Experimental Immunology (United Kingdom) , 1995, 99/3 (331-337) CODEN: CEXIA ISSN: 0009-9104

LANGUAGES: English SUMMARY LANGUAGES: English

3/3/69 (Item 34 from file: 72)

DIALOG(R)File 72:EMBASE

(c) 1997 Elsevier Science B.V. All rts. reserv.

9495670 EMBASE No: 95064067

Pulmonary involvement in rheumatoid arthritis

Anaya J.-M.; Diethelm L.; Ortiz L.A.; Gutierrez M.; Citera G.; Welsh R.A.; Espinoza L.R.

Division of Clinical Immunology, UTHSC, 7703 Floyd Curl Dr, San Antonio, TX 78284-7874 USA

Seminars in Arthritis and Rheumatism (USA) , 1995, 24/4 (242-254)

CODEN: SAHRB ISSN: 0049-0172

LANGUAGES: English SUMMARY LANGUAGES: English

3/3/70 (Item 35 from file: 72)

DIALOG(R)File 72:EMBASE

(c) 1997 Elsevier Science B.V. All rts. reserv.

9477163 EMBASE No: 95049183

Novel drug therapies in inflammatory bowel disease

Debinski H.S.; Kamm M.A.

St Mark's Hospital, City Road, London EC1V 2PS United Kingdom

EUR. J. GASTROENTEROL. HEPATOL. (United Kingdom) , 1995, 7/2 (169-182)

CODEN: EJGHE ISSN: 0954-691X

LANGUAGES: English SUMMARY LANGUAGES: English

3/3/71 (Item 36 from file: 72)

DIALOG(R)File 72:EMBASE

(c) 1997 Elsevier Science B.V. All rts. reserv.

9477080 EMBASE No: 95049081

Update of immunomodulatory therapy for inflammatory bowel disease

Bernstein C.N.

Section of Gastroenterology, GB443 Health Sciences Centre, 820 Sherbrook Street, Winnipeg, Man. R3A 1R9 Canada

CAN. J. GASTROENTEROL. (Canada) , 1994, 8/7 (413-416) CODEN: CJGAE

ISSN: 0835-7900

LANGUAGES: English SUMMARY LANGUAGES: English; French

3/3/72 (Item 37 from file: 72)

DIALOG(R)File 72:EMBASE

(c) 1997 Elsevier Science B.V. All rts. reserv.

9476519 EMBASE No: 95048253

Advances in understanding and novel therapeutic targets in inflammatory arthritis

FitzGerald O.

Department of Rheumatology, St Vincents Hospital, Dublin 4 Ireland

IR. J. MED. SCI. (Ireland) , 1995, 164/1 (4-11) CODEN: IJMSA ISSN: 0021-1265

LANGUAGES: English

3/3/73 (Item 38 from file: 72)

DIALOG(R)File 72:EMBASE

(c) 1997 Elsevier Science B.V. All rts. reserv.

9407105 EMBASE No: 94355211

Preliminary report of radical multiple synovectomy in rheumatoid arthritis

Yoshino S.; Koiwa M.; Kowada M.; Nagashima S.; Nishioka K.

Department of Joint Disease, Nippon Medical School, Chiyoda-ku, Tokyo Japan

RYUMACHI (Japan) , 1994, 34/5 (908-913) CODEN: RYMCA ISSN: 0300-9157

LANGUAGES: Japanese SUMMARY LANGUAGES: English

3/3/74 (Item 39 from file: 72)

DIALOG(R)File 72:EMBASE

(c) 1997 Elsevier Science B.V. All rts. reserv.

9389690 EMBASE No: 94339223

Gold sodium thiomalate down-regulates intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 expression on vascular endothelial cells

Koike R.; Miki I.; Otoshi M.; Totsuka T.; Inoue H.; Kase H.; Saito I.; Miyasaka N.

Division of Immunological Diseases, Medical Research Institute, Tokyo Medical and Dental University, 1-5-45, Yushima, Bunkyo-ku, Tokyo Japan

MOL. PHARMACOL. (USA) , 1994, 46/4 (599-604) CODEN: MOPMA ISSN: 0026-895X

LANGUAGES: English SUMMARY LANGUAGES: English

3/3/75 (Item 40 from file: 72)

DIALOG(R)File 72:EMBASE

(c) 1997 Elsevier Science B.V. All rts. reserv.

9378839 EMBASE No: 94323839

Systemic cytokine measurements: Their role in monitoring the response to therapy in patients with rheumatoid arthritis

Luqmani R.; Sheeran T.; Robinson M.; Richardson K.; Winkles J.; Emery P.

Department of Rheumatology, University of Birmingham, Edgbaston, Birmingham B15 2TT United Kingdom

CLIN. EXP. RHEUMATOL. (Italy) , 1994, 12/5 (503-508) CODEN: CERHD ISSN: 0392-856X

LANGUAGES: English SUMMARY LANGUAGES: English

3/3/76 (Item 41 from file: 72)

DIALOG(R)File 72:EMBASE

(c) 1997 Elsevier Science B.V. All rts. reserv.

9375821 EMBASE No: 94318125

Type VI collagen-specific messenger RNA is expressed constitutively by cultured human synovial fibroblasts and is suppressed by interleukin-1

Bathon J.M.; Hwang J.J.; Shin L.H.; Precht P.A.; Towns M.C.; Horton W.E. Jr.

Johns Hopkins Asthma/Allergy Center, 5501 Hopkins Bayview Circle, Baltimore, MD 21224 USA

ARTHRITIS RHEUM. (USA) , 1994, 37/9 (1350-1356) CODEN: ARHEA ISSN: 0004-3591

LANGUAGES: English SUMMARY LANGUAGES: English

3/3/77 (Item 42 from file: 72)

DIALOG(R)File 72:EMBASE

(c) 1997 Elsevier Science B.V. All rts. reserv.

9375507 EMBASE No: 94320449

Prostaglandin and tumor necrosis factor secretion by peritoneal macrophages isolated from normal and arthritic rats treated with liposomal methotrexate

Williams A.S.; Camilleri J.P.; Topley N.; Williams B.D.

Rheumatology Research Laboratory, Univ. of Wales College of Medicine, Heath Park, Cardiff, CF4 4XN United Kingdom

J. PHARMACOL. TOXICOL. METHODS (USA) , 1994, 32/1 (53-58) CODEN: JPTME ISSN: 1056-8719

LANGUAGES: English SUMMARY LANGUAGES: English

3/3/78 (Item 43 from file: 72)

DIALOG(R)File 72:EMBASE

(c) 1997 Elsevier Science B.V. All rts. reserv.

9312845 EMBASE No: 94259688

Circadian rhythm of serum interleukin-6 in rheumatoid arthritis

Arvidson N.G.; Gudbjornsson B.; Elfman L.; Ryden A.-C.; Totterman T.H.; Hallgren R.

Section of Rheumatology, Department of Medicine, Uppsala University Hospital, S-751 85 Uppsala Sweden

ANN. RHEUM. DIS. (United Kingdom) , 1994, 53/8 (521-524) CODEN: ARDIA ISSN: 0003-4967

LANGUAGES: English SUMMARY LANGUAGES: English

3/3/79 (Item 44 from file: 72)

DIALOG(R)File 72:EMBASE

(c) 1997 Elsevier Science B.V. All rts. reserv.

9308370 EMBASE No: 94250587

Augmented expression of inflammatory cytokines and adhesion molecules in accelerated nodulosis during methotrexate therapy (5)

Miyasaka N.; Saito I.; Uemura T.; Kashiwazaki S.

Division of Immunological Diseases, Medical Research Institute, Tokyo Medical/Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113 Japan

ANN. RHEUM. DIS. (United Kingdom) , 1994, 53/7 (480-481) CODEN: ARDIA ISSN: 0003-4967

LANGUAGES: English

3/3/80 (Item 45 from file: 72)
DIALOG(R)File 72:EMBASE
(c) 1997 Elsevier Science B.V. All rts. reserv.

9305445 EMBASE No: 94253153
Pediatric rheumatic diseases
Warren R.W.; Perez M.D.; Wilking A.P.; Myones B.L.
Department of Pediatrics, Baylor College of Medicine, One Baylor Plaza,
Houston, TX 77030 USA
PEDIATR. CLIN. NORTH AM. (USA) , 1994, 41/4 (783-818) CODEN: PCNAA
ISSN: 0031-3955
LANGUAGES: English SUMMARY LANGUAGES: English

3/3/81 (Item 46 from file: 72)
DIALOG(R)File 72:EMBASE
(c) 1997 Elsevier Science B.V. All rts. reserv.

9290606 EMBASE No: 94236066
Research in pediatric rheumatology
Glass D.N.; Nepom B.S.; White P.H.; Shulman L.E.
Children's Hospital Medical Center, Cincinnati Univ. College of Medicine,
Cincinnati, OH 45229-3039 USA
J. RHEUMATOL. (Canada) , 1994, 21/7 (1347-1351) CODEN: JRHUA ISSN:
0315-162X
LANGUAGES: English

3/3/82 (Item 47 from file: 72)
DIALOG(R)File 72:EMBASE
(c) 1997 Elsevier Science B.V. All rts. reserv.

9198964 EMBASE No: 94145017
Monoclonal antibodies in the treatment of rheumatoid arthritis
Delafuente J.C.; Resman-Targoff B.H.
Department of Pharmacy Practice, University of Florida, PO Box 100486,
Gainesville, FL 32610 USA
ANN. PHARMACOTHER. (USA) , 1994, 28/5 (650-655) CODEN: APHRE ISSN:
1060-0280
LANGUAGES: English

3/3/83 (Item 48 from file: 72)
DIALOG(R)File 72:EMBASE
(c) 1997 Elsevier Science B.V. All rts. reserv.

9173141 EMBASE No: 94113521
Basic drugs in the treatment of rheumatic diseases and new approaches
with immunomodulating agents
BASISTHERAPEUTIKA BEI RHEUMA UND NEUE ANSATZE MIT IMMUNMODULATOREN
Metz G.
Auf dem Rucken 29, 89143 Blaubeuren Germany
PHARM. ZTG. (Germany) , 1994, 139/14 (9-18) CODEN: PZSED ISSN:
0031-7136
LANGUAGES: German SUMMARY LANGUAGES: German

3/3/84 (Item 49 from file: 72)
DIALOG(R)File 72:EMBASE
(c) 1997 Elsevier Science B.V. All rts. reserv.

9162404 EMBASE No: 94110945
Immunosuppression in the treatment of disease
Dickler H.B.; Albright J.F.
National Institutes of Health, Solar Building, Bethesda, MD 20892 USA
J. ALLERGY CLIN. IMMUNOL. (USA) , 1994, 93/3 (669-676) CODEN: JACIB
ISSN: 0091-6749
LANGUAGES: English

3/3/85 (Item 50 from file: 72)
DIALOG(R)File 72:EMBASE
(c) 1997 Elsevier Science B.V. All rts. reserv.

9121613 EMBASE No: 94070548
Novel immunosuppressive and antiinflammatory drugs: A 1993 perspective
Allison A.C.
Dawa Corporation, Belmont, CA USA
ANN. NEW YORK ACAD. SCI. (USA) , 1993, 696/- (XI-XX) CODEN: ANYAA
ISSN: 0077-8923
LANGUAGES: English SUMMARY LANGUAGES: English

3/3/86 (Item 51 from file: 72)
DIALOG(R)File 72:EMBASE
(c) 1997 Elsevier Science B.V. All rts. reserv.

9087118 EMBASE No: 94035282
Granulocyte colony-stimulating factor induction of improved
leukocytopenia with inflammatory flare in a Felty's syndrome patient
Yasuda M.; Kihara T.; Wada T.; Shiokawa S.; Furuta E.; Suenagu Y.; Nonaka
S.; Nobunaga M.; Yoshioka K.; Isayama T.
Medical Institute of Bioregulation, Kyushu University, Beppu Japan
ARTHRITIS RHEUM. (USA) , 1994, 37/1 (145-146) CODEN: ARHEA ISSN:
0004-3591
LANGUAGES: English

3/3/87 (Item 52 from file: 72)
DIALOG(R)File 72:EMBASE
(c) 1997 Elsevier Science B.V. All rts. reserv.

9084440 EMBASE No: 94014905
The current and future therapy strategies of rheumatoid arthritis (RA)
GEGENWARTIGE UND ZUKUNFTIGE THERAPIESTRATEGIEN DER RHEUMATOIDEN ARTHRITIS
(RA)
Schacht E.
Hauptabteilung Med. Wissenschaften, E. Tosse und Co. GmbH,
Friedrich-Ebert-Damm 101, 22047 Hamburg Germany
Z. RHEUMATOL. (Germany) , 1993, 52/6 (365-382) CODEN: ZRHMB ISSN:
0340-1855
LANGUAGES: German SUMMARY LANGUAGES: German; English

3/3/88 (Item 53 from file: 72)

DIALOG(R)File 72:EMBASE
(c) 1997 Elsevier Science B.V. All rts. reserv.

8985535 EMBASE No: 93289267
Interleukin-1 receptor antagonist
Arend W.P.
Division of Rheumatology, Department of Medicine, Colorado Univ. Health
Sciences Ctr., Denver, CO 80262 USA
ADV. IMMUNOL. (USA) , 1993, 54/- (167-227) CODEN: ADIMA ISSN:
0065-2776
LANGUAGES: English SUMMARY LANGUAGES: English

3/3/89 (Item 54 from file: 72)
DIALOG(R)File 72:EMBASE
(c) 1997 Elsevier Science B.V. All rts. reserv.

8982997 EMBASE No: 93284230
Future aspects of new therapeutic possibilities of rheumatic diseases
NEUE THERAPEUTISCHE MOGLICHKEITEN. ZUKUNFTSASPEKTE
Rubbert A.; Burmester G.-R.
Inst. fur Klin. Immunol./Rheumatol., Medizinische Klinik III, Universitat
Erlangen-Nurnberg, Krankenhausstrasse 12, D-91054 Erlangen Germany
INTERNIST (Germany) , 1993, 34/9 (841-851) CODEN: INTEA ISSN:
0020-9554 ADONIS ORDER NUMBER: 002095549300127M
LANGUAGES: German SUMMARY LANGUAGES: German

3/3/90 (Item 55 from file: 72)
DIALOG(R)File 72:EMBASE
(c) 1997 Elsevier Science B.V. All rts. reserv.

8914186 EMBASE No: 93218147
Synovial mononuclear phagocytes in rheumatoid arthritis and
osteoarthritis: Quantitative and functional aspects
Weinberg J.B.; Wortham T.S.; Misukonis M.A.; Patton K.L.; Chitneni S.R.
Duke University Medical Center, 508 Fulton Street, Durham, NC 27705 USA
IMMUNOL. INVESTIG. (USA) , 1993, 22/5 (365-374) CODEN: IMINE ISSN:
0882-0139
LANGUAGES: English SUMMARY LANGUAGES: English

3/3/91 (Item 56 from file: 72)
DIALOG(R)File 72:EMBASE
(c) 1997 Elsevier Science B.V. All rts. reserv.

8872009 EMBASE No: 93175822
Rheumatoid arthritis: New science, new treatment
Miller-Blair D.J.; Robbins D.L.
Kaiser-Permanente Medical Center, South Sacramento, CA USA
GERIATRICS (USA) , 1993, 48/6 (28-38) CODEN: GERIA ISSN: 0016-867X
LANGUAGES: English SUMMARY LANGUAGES: English

3/3/92 (Item 57 from file: 72)
DIALOG(R)File 72:EMBASE
(c) 1997 Elsevier Science B.V. All rts. reserv.

8809709 EMBASE No: 93110017

Immunosuppressive therapy for autoimmune diseases

Hoffman G.S.

Cleveland Clinic Foundation, 9500 Euclid Ave, Cleveland, OH 44195 USA

ANN. ALLERGY (USA) , 1993, 70/4 (263-274) CODEN: ANAEA ISSN: 0003-4738

LANGUAGES: English

3/3/93 (Item 58 from file: 72)

DIALOG(R)File 72:EMBASE

(c) 1997 Elsevier Science B.V. All rts. reserv.

8806250 EMBASE No: 93110018

CME examination

ANN. ALLERGY (USA) , 1993, 70/4 (274-275) CODEN: ANAEA ISSN: 0003-4738

LANGUAGES: English

3/3/94 (Item 59 from file: 72)

DIALOG(R)File 72:EMBASE

(c) 1997 Elsevier Science B.V. All rts. reserv.

8675094 EMBASE No: 92355604

Use of monoclonal antibodies in vivo as a therapeutic strategy for alloimmune or autoimmune reactivity: The Besancon experience

Herve P.; Racadot E.; Wendling D.; Rumbach L.; Tiberghien P.; Cahn J.Y.; Flesch M.; Wijdenes J.

Centre Reg. de Transfusion Sanguine, 1 Boulevard Fleming, 25020 Besancon France

IMMUNOL. REV. (Denmark) , 1992, -/129 (31-55) CODEN: IMRED ISSN: 0105-2896 ADONIS ORDER NUMBER: 010528969200043S

LANGUAGES: English

3/3/95 (Item 60 from file: 72)

DIALOG(R)File 72:EMBASE

(c) 1997 Elsevier Science B.V. All rts. reserv.

8621094 EMBASE No: 92297268

Is there a disease-modifying drug for juvenile chronic arthritis?

Rooney M.

Molecular Rheumatology Section, MRC Clinical Research Centre, Watford Road, Harrow, Middlesex HA1 3UJ United Kingdom

BR. J. RHEUMATOL. (United Kingdom) , 1992, 31/9 (635-641) CODEN: BJRHD ISSN: 0263-7103

LANGUAGES: English

3/3/96 (Item 61 from file: 72)

DIALOG(R)File 72:EMBASE

(c) 1997 Elsevier Science B.V. All rts. reserv.

8542432 EMBASE No: 92218309

Profile of cytokines in synovial fluid specimens from patients with arthritis. Interleukin 8 (IL-8) and IL-6 correlate with inflammatory arthritides

Remick D.G.; DeForge L.E.; Sullivan J.F.; Showell H.J.

1301 Catherine Road, Ann Arbor, MI 48109-0602 USA

IMMUNOL. INVESTIG. (USA) , 1992, 21/4 (321-327) CODEN: IMINE ISSN: 0882-0139

LANGUAGES: English SUMMARY LANGUAGES: English

3/3/97 (Item 62 from file: 72)

DIALOG(R)File 72:EMBASE

(c) 1997 Elsevier Science B.V. All rts. reserv.

8355207 EMBASE No: 92020818

Interaction(s) between essential fatty acids, eicosanoids, cytokines, growth factors and free radicals: Relevance to new therapeutic strategies in rheumatoid arthritis and other collagen vascular diseases

Das U.N.

Department of Medicine, Nizam's Institute of Medical Sciences, Hyderabad 500482 India

PROSTAGLANDINS LEUKOTRIENES ESSENT. FATTY ACIDS (United Kingdom) , 1991, 44/4 (201-210) CODEN: PLEAE ISSN: 0952-3278 ADONIS ORDER NUMBER: 095232789100121B

LANGUAGES: English SUMMARY LANGUAGES: English

3/3/98 (Item 63 from file: 72)

DIALOG(R)File 72:EMBASE

(c) 1997 Elsevier Science B.V. All rts. reserv.

8344235 EMBASE No: 92021049

Cytokines and drugs workshop

Hom J.T.; Simon P.L.

Lilly Research Laboratories, Indianapolis IN 46285 USA

AGENTS ACTIONS (Switzerland) , 1991, 35/SUPPL. (147-150) CODEN: AGACB ISSN: 0065-4299

LANGUAGES: English

3/3/99 (Item 64 from file: 72)

DIALOG(R)File 72:EMBASE

(c) 1997 Elsevier Science B.V. All rts. reserv.

8124745 EMBASE No: 91154846

Synovial angiogenesis

Liote F.

Clinique de Rhumatologie, Centre Viggo Petersen, 6, Rue Guy-Patin, 75010 Paris France

REV. RHUM. MAL. OSTEO-ARTICULAIRES (France) , 1991, 58/3 BIS (51-59S) CODEN: RRMOA ISSN: 0035-2659

LANGUAGES: French

3/3/100 (Item 65 from file: 72)

DIALOG(R)File 72:EMBASE

(c) 1997 Elsevier Science B.V. All rts. reserv.

8108738 EMBASE No: 91137004

Osteoporosis associated with rheumatoid arthritis: Pathogenesis and management

Joffe I.; Epstein S.

Division of Endocrinology and Metabolism, Albert Einstein Medical Center,

5401 Old York Rd, Philadelphia, PA 19141 USA
. SEMIN. ARTHRITIS RHEUM. (USA) , 1991, 20/4 (256-272) CODEN: SAHRB
ISSN: 0049-0172
LANGUAGES: English

3/3/101 (Item 66 from file: 72)
DIALOG(R)File 72:EMBASE
(c) 1997 Elsevier Science B.V. All rts. reserv.

8041608 EMBASE No: 91071603
The effects of some anti-arthritic drugs and cytokines on the shape and function of rodent macrophages
Haynes D.R.; Whitehouse M.W.; Vernon-Roberts B.
Department of Pathology, University of Adelaide, GPO Box 498, Adelaide, SA 5001 Australia
INT. J. EXP. PATHOL. (United Kingdom) , 1991, 72/1 (9-22) CODEN: IJEPE
ISSN: 0959-9673 ADONIS ORDER NUMBER: 095996739100002R
LANGUAGES: English

3/3/102 (Item 67 from file: 72)
DIALOG(R)File 72:EMBASE
(c) 1997 Elsevier Science B.V. All rts. reserv.

7923223 EMBASE No: 90357842
Development of angiogenesis inhibitors for clinical applications
Maione T.E.; Sharpe R.J.
Repligen Corporation, One Kendall Square, Cambridge, MA 02139 USA
TRENDS PHARMACOL. SCI. (United Kingdom) , 1990, 11/11 (457-461) CODEN: TPHSD
ISSN: 0165-6147
LANGUAGES: English

3/3/103 (Item 1 from file: 154)
DIALOG(R)File 154:MEDLINE(R)
(c) format only 1997 Knight-Ridder Info. All rts. reserv.

09785762 96307362
[Combination regimens in rheumatoid arthritis (editorial)]
Association des traitements de fond dans la polyarthrite rhumatoide.
Bologna C; Sany J
Presse Med (FRANCE) Jun 1 1996, 25 (19) p876-8, ISSN 0755-4982
Journal Code: PMT
Languages: FRENCH Summary Languages: ENGLISH
Document type: EDITORIAL English Abstract

3/3/104 (Item 2 from file: 154)
DIALOG(R)File 154:MEDLINE(R)
(c) format only 1997 Knight-Ridder Info. All rts. reserv.

09677693 96199293
Management of osteoarthritis and rheumatoid arthritis: prospects and possibilities.
Blackburn WD
Division of Immunology/Rheumatology, University of Alabama at Birmingham, Alabama 35233, USA.

Am J Med (UNITED STATES) Feb 26 1996, 100 (2A) p24S-30S, ISSN
0002-9343 Journal Code: 3JU
Languages: ENGLISH
Document type: JOURNAL ARTICLE; REVIEW; REVIEW, TUTORIAL

3/3/105 (Item 3 from file: 154)
DIALOG(R)File 154:MEDLINE(R)
(c) format only 1997 Knight-Ridder Info. All rts. reserv.

08509728 93219728
[If I had chronic polyarthritis--current ideas on basic therapy]
Wenn ich eine chronische Polyarthritis hatte--Neue Ideen zur
Basistherapie.
Hasler F
FMH Innere Medizin, speziell Rheumaerkrankungen, Chur.
Schweiz Rundsch Med Prax (SWITZERLAND) Mar 23 1993, 82 (12) p349-52,
ISSN 0369-8394 Journal Code: SRM
Languages: GERMAN Summary Languages: ENGLISH
Document type: JOURNAL ARTICLE English Abstract

3/3/106 (Item 4 from file: 154)
DIALOG(R)File 154:MEDLINE(R)
(c) format only 1997 Knight-Ridder Info. All rts. reserv.

08101632 92239632
Angiogenesis and its inhibition: potential new therapies in oncology and
non-neoplastic diseases.
Billington DC
Institut de Recherches Servier, Suresnes, France.
Drug Des Discov (SWITZERLAND) Nov 1991, 8 (1) p3-35, ISSN 1055-9612
Journal Code: A5B
Languages: ENGLISH
Document type: JOURNAL ARTICLE; REVIEW; REVIEW, TUTORIAL

3/3/107 (Item 1 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 1997 American Chemical Society. All rts. reserv.

120200274 CA: 120(16)200274a JOURNAL
Effect of liposomally encapsulated MTX-DMPE conjugates upon TNF.alpha.
and PGE2 release by lipopolysaccharide stimulated rat peritoneal
macrophages
AUTHOR(S): Williams, Anwen S.; Topley, N.; Williams, B. D.
LOCATION: Rheumatology Research Laboratory, University of Wales College
of Medicine, Heath Park, Cardiff, UK, CF4 4XN
JOURNAL: Biochim. Biophys. Acta DATE: 1994 VOLUME: 1225 NUMBER: 2
PAGES: 217-22 CODEN: BBACQ ISSN: 0006-3002 LANGUAGE: English

3/3/108 (Item 1 from file: 351)
DIALOG(R)File 351:DERWENT WPI
(c)1997 Derwent Info Ltd. All rts. reserv.

010035215 WPI Acc No: 94-302928/37
XRAM Acc No: C94-138132

Image available

Use of tripterinin, a diterpene from medicinal plant sources - in autoimmune disease, e.g., arthritis, and tissue transplant rejection

Patent Assignee: (PHAR-) PHARMAGENESIS INC

Author (Inventor): WIEDMANN T W; XU R S

Patent Family:

CC Number	Kind	Date	Week	
WO 9420488	A1	940915	9437	(Basic)
AU 9464002	A	940926	9503	
US 5468772	A	951121	9601	

Priority Data (CC No Date): US 31288 (930310)

Applications (CC,No,Date): WO 94US2540 (940308); AU 9464002 (940308)

?

5/3/1 (Item 1 from file: 55)

DIALOG(R)File 55:BIOSIS PREVIEWS(R)

(c) 1997 BIOSIS. All rts. reserv.

13223416 BIOSIS Number: 99223416

Methotrexate (MTX) treatment reduces inflammatory cell numbers and expression of monokines and adhesion molecules in synovial tissue of patients with rheumatoid arthritis (RA)

Dolhain R J E M; Tak P P; Dijkmans B A C; De Kuiper P; Breedveld F C; Miltenburg A M M

Dep. Rheumatol., Univ. Hosp., Leiden, Netherlands

Arthritis & Rheumatism 39 (9 SUPPL.). 1996. S102.

Full Journal Title: 60th National Scientific Meeting of the American College of Rheumatology and the 31st National Scientific Meeting of the Association of Rheumatology Health Professionals, Orlando, Florida, USA, October 18-22, 1996. Arthritis & Rheumatism

ISSN: 0004-3591

Language: ENGLISH

Document Type: CONFERENCE PAPER

Print Number: Biological Abstracts/RRM Vol. 048 Iss. 011 Ref. 202537

5/3/2 (Item 2 from file: 55)

DIALOG(R)File 55:BIOSIS PREVIEWS(R)

(c) 1997 BIOSIS. All rts. reserv.

13195603 BIOSIS Number: 99195603

Interleukin 1 (IL-1) receptor antagonist, soluble tumor necrosis factor receptors, IL-1-beta, and IL-8-markers of remission in rheumatoid arthritis during treatment with methotrexate

Seitz M; Loetscher P; Dewald B; Towbin H; Rordorf C; Gallati H; Gerber N J

Dep. Rheumatol., Univ. Hosp., Inselspital, CH-3010 Berne, Switzerland

Journal of Rheumatology 23 (9). 1996. 1512-1516.

Full Journal Title: Journal of Rheumatology

ISSN: 0315-162X

Language: ENGLISH

Print Number: Biological Abstracts Vol. 102 Iss. 009 Ref. 127610

5/3/3 (Item 3 from file: 55)

DIALOG(R)File 55:BIOSIS PREVIEWS(R)

(c) 1997 BIOSIS. All rts. reserv.

12173087 BIOSIS Number: 98773087
Inflammatory bowel disease (IBD): Therapeutic actualities
Florent C H
Hopital Saint Antoine, Paris, France
Acta Endoscopica 25 (5 SUPPL.). 1995. 571-574.
Full Journal Title: Acta Endoscopica
ISSN: 0240-642X
Language: FRENCH ENGLISH
Print Number: Biological Abstracts Vol. 101 Iss. 010 Ref. 140279

5/3/4 (Item 4 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)
(c) 1997 BIOSIS. All rts. reserv.

12122694 BIOSIS Number: 98722694
Nitric oxide: An important articular free radical
Murrell G A C; Dolan M M; Jang D; Szabo C; Warren R F; Hannafin J A
Dep. Orthopaedic Surg., St. George Hosp., Kogarah, Sydney, NSW 2217,
Australia
Journal of Bone and Joint Surgery American Volume 78 (2). 1996. 265-274.
Full Journal Title: Journal of Bone and Joint Surgery American Volume
ISSN: 0021-9355
Language: ENGLISH
Print Number: Biological Abstracts Vol. 101 Iss. 008 Ref. 106969

5/3/5 (Item 5 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)
(c) 1997 BIOSIS. All rts. reserv.

12093694 BIOSIS Number: 98693694
A system for assessment of monokine gene expression using human whole
blood
Joyce D A; Steer J H; Beilharz M W; Stranger R
Sir Charles Gairdner Hosp., Nedlands 6009, Western Australia
Genetic Analysis Techniques and Applications 12 (1). 1995. 39-43.
Full Journal Title: Genetic Analysis Techniques and Applications
ISSN: 1050-3862
Language: ENGLISH
Print Number: Biological Abstracts Vol. 101 Iss. 007 Ref. 093975

5/3/6 (Item 6 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)
(c) 1997 BIOSIS. All rts. reserv.

12080296 BIOSIS Number: 98680296
Trends in rheumatoid arthritis research
Emilie D; Russo-Marie F
INSERM U. 322, 22 rue Mechain, 75014 Paris, France
M-S (Medecine Sciences) 11 (11). 1995. 1577-1580.
Full Journal Title: M-S (Medecine Sciences)
ISSN: 0767-0974
Language: FRENCH
Print Number: Biological Abstracts Vol. 101 Iss. 006 Ref. 080577

5/3/7 (Item 7 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)
(c) 1997 BIOSIS. All rts. reserv.

11990492 BIOSIS Number: 98590492
Therapy of chronic inflammatory bowel
Levy P
Strasbourg, France
Acta Endoscopica 25 (2 SUPPL.). 1995. 219-222.
Full Journal Title: Acta Endoscopica
ISSN: 0240-642X
Language: FRENCH
Document Type: MEETING REPORT
Print Number: Biological Abstracts Vol. 101 Iss. 002 Ref. 018197

5/3/8 (Item 8 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)
(c) 1997 BIOSIS. All rts. reserv.

11935486 BIOSIS Number: 98535486
Suppression of tumor necrosis factor (TNF) and TNF-mediated effector
mechanisms by methotrexate (MTX) in patients with rheumatoid arthritis
Fenner H; Zueger S; Taylor D; Sander O; Herborn G; Rau R
Swiss Fed. Inst. Technol., CH-8057 Zurich, Switzerland
Arthritis & Rheumatism 38 (9 SUPPL.). 1995. S266.
Full Journal Title: 59th National Scientific Meeting of the American
College of Rheumatology and the 30th National Scientific Meeting of the
Association of Rheumatology Health Professionals, San Francisco,
California, USA, October 21-26, 1995. Arthritis & Rheumatism
ISSN: 0004-3591
Language: ENGLISH
Document Type: CONFERENCE PAPER
Print Number: Biological Abstracts/RRM Vol. 047 Iss. 012 Ref. 205361

5/3/9 (Item 9 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)
(c) 1997 BIOSIS. All rts. reserv.

11935485 BIOSIS Number: 98535485
Tumor necrosis factor alpha (TNF) blockade enhances methotrexate (MTX)
response in patients with rheumatoid arthritis (RA)
Sander O; Herborn G; Rau R
Rheumatol. Unit, Evangelisches Krankenhaus, D-40882 Ratingen, Germany
Arthritis & Rheumatism 38 (9 SUPPL.). 1995. S266.
Full Journal Title: 59th National Scientific Meeting of the American
College of Rheumatology and the 30th National Scientific Meeting of the
Association of Rheumatology Health Professionals, San Francisco,
California, USA, October 21-26, 1995. Arthritis & Rheumatism
ISSN: 0004-3591
Language: ENGLISH
Document Type: CONFERENCE PAPER
Print Number: Biological Abstracts/RRM Vol. 047 Iss. 012 Ref. 205360

5/3/10 (Item 10 from file: 55)

.DIALOG(R)File 55:BIOSIS PREVIEWS(R)
(c) 1997 BIOSIS. All rts. reserv.

11935481 BIOSIS Number: 98535481

Differential effects of methotrexate (MTX) on the proliferation and proinflammatory cytokine production of an in vitro model for human proliferative synovitis

Ohya N; Yamada H; Takahashi K; Ishii O; Kikugawa T; Mizushima Y; Ichikawa Y

St. Marianna Univ. Sch. Med., Kawasaki 216, Japan

Arthritis & Rheumatism 38 (9 SUPPL.). 1995. S265.

Full Journal Title: 59th National Scientific Meeting of the American College of Rheumatology and the 30th National Scientific Meeting of the Association of Rheumatology Health Professionals, San Francisco, California, USA, October 21-26, 1995. Arthritis & Rheumatism

ISSN: 0004-3591

Language: ENGLISH

Document Type: CONFERENCE PAPER

Print Number: Biological Abstracts/RRM Vol. 047 Iss. 012 Ref. 205356

5/3/11 (Item 11 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)
(c) 1997 BIOSIS. All rts. reserv.

11873246 BIOSIS Number: 98473246

Methotrexate action in rheumatoid arthritis: Stimulation of cytokine inhibitor and inhibition of chemokine production by peripheral blood mononuclear cells

Seitz M; Loetscher P; Dewald B; Towbin H; Rordorf C; Gallati H; Baggiolini M; Gerber N J

Div. Rheumatol., Univ. Hosp., Inselspital, CH-3010 Bern, Switzerland

British Journal of Rheumatology 34 (7). 1995. 602-609.

Full Journal Title: British Journal of Rheumatology

ISSN: 0263-7103

Language: ENGLISH

Print Number: Biological Abstracts Vol. 100 Iss. 009 Ref. 139303

5/3/12 (Item 12 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)
(c) 1997 BIOSIS. All rts. reserv.

11857705 BIOSIS Number: 98457705

The antiinflammatory effects of an adenosine kinase inhibitor are mediated by adenosine

Cronstein B N; Naime D; Firestein G

New York Univ. Med. Cent., New York, NY, USA

Arthritis & Rheumatism 38 (8). 1995. 1040-1045.

Full Journal Title: Arthritis & Rheumatism

ISSN: 0004-3591

Language: ENGLISH

Print Number: Biological Abstracts Vol. 100 Iss. 008 Ref. 123762

5/3/13 (Item 13 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)
(c) 1997 BIOSIS. All rts. reserv.

11829085 BIOSIS Number: 98429085

Increased spontaneous production of IL-8 in peripheral blood monocytes from the psoriatic patient: Relation to focal infection and response to treatments

Teranishi Y; Mizutani H; Murata M; Shimizu M; Matsushima K

Dep. Dermatol., Mie Univ., Fac. Med., 2-174 Edobashi, Tsu, Mie 514, Japan

Journal of Dermatological Science 10 (1). 1995. 8-15.

Full Journal Title: Journal of Dermatological Science

ISSN: 0923-1811

Language: ENGLISH

Print Number: Biological Abstracts Vol. 100 Iss. 007 Ref. 106677

5/3/14 (Item 14 from file: 55)

DIALOG(R)File 55:BIOSIS PREVIEWS(R)

(c) 1997 BIOSIS. All rts. reserv.

11729019 BIOSIS Number: 98329019

Autoimmunity, nutrition and old age

Florez-Tascon Sixto F J; Goya J; Sanchez-Escribano F; Serrano S; Garay J

Lab. MEGALAB, C/Alfonso XII 42, Madrid, Spain

Geriatrka (Madrid) 11 (1). 1995. 18-20, 22-24, 26-27.

Full Journal Title: Geriatrka (Madrid)

ISSN: 0212-9744

Language: SPANISH

Print Number: Biological Abstracts Vol. 100 Iss. 003 Ref. 036743

5/3/15 (Item 15 from file: 55)

DIALOG(R)File 55:BIOSIS PREVIEWS(R)

(c) 1997 BIOSIS. All rts. reserv.

11717869 BIOSIS Number: 98317869

The effect of liposomally conjugated methotrexate upon mediator release from human peripheral blood monocytes

Williams A S; Pun N Y L; Amos N; Cooper A M; Williams B D

Rheumatol. Res. Lab., Univ. Wales Coll. Med., Heath Park, Cardiff CF4 4XN, UK

British Journal of Rheumatology 34 (3). 1995. 241-245.

Full Journal Title: British Journal of Rheumatology

ISSN: 0263-7103

Language: ENGLISH

Print Number: Biological Abstracts Vol. 100 Iss. 002 Ref. 025593

5/3/16 (Item 16 from file: 55)

DIALOG(R)File 55:BIOSIS PREVIEWS(R)

(c) 1997 BIOSIS. All rts. reserv.

10945560 BIOSIS Number: 97145560

Serum levels of interleukin-6 and tumour-necrosis-factor-alpha are not correlated to disease activity in patients with rheumatoid arthritis after treatment with low-dose methotrexate

Wascher T C; Hermann J; Brezinschek R; Brezinschek H P; Wilders-Truschling M; Rainer F; Krejs G J

Dep. Med., Auenbruggerpl. 15, A-8036 Graz, AUS

European Journal of Clinical Investigation 24 (1). 1994. 73-75.

Full Journal Title: European Journal of Clinical Investigation
ISSN: 0014-2972
Language: ENGLISH
Print Number: Biological Abstracts Vol. 097 Iss. 007 Ref. 095435

5/3/17 (Item 17 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)
(c) 1997 BIOSIS. All rts. reserv.

10842177 BIOSIS Number: 97042177
Elevated levels of TNF in the joints of adjuvant arthritic rats
Smith-Oliver T; Noel L S; Stimpson S S; Yarnall D P; Connolly K M
Dep. Immunology, Glaxo Res. Inst., Five Moore Drive, Research Triangle
Park, NC 27709, USA
Cytokine 5 (4). 1993. 298-304.
Full Journal Title: Cytokine
ISSN: 1043-4666
Language: ENGLISH
Print Number: Biological Abstracts Vol. 097 Iss. 003 Ref. 026524

5/3/18 (Item 18 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)
(c) 1997 BIOSIS. All rts. reserv.

10020722 BIOSIS Number: 95020722
DEGRADATION OF ENDOGENOUS BACTERIAL CELL WALL POLYMERS BY THE MURALYTIC
ENZYME MUTANOLYSIN PREVENTS HEPATOBILIARY INJURY IN GENETICALLY SUSCEPTIBLE
RATS WITH EXPERIMENTAL INTESTINAL BACTERIAL OVERGROWTH
LICHTMAN S N; OKORUWA E E; KEKU J; SCHWAB J H; SARTOR R B
ROOM 310, BURNETT WOMACK BUILDING, CB 7220, DEP. PEDIATRIC
GASTROENTEROLOGY, UNIV. NORTH CAROLINA, CHAPEL HILL, NC 27599-7220.
J CLIN INVEST 90 (4). 1992. 1313-1322. CODEN: JCINA
Full Journal Title: Journal of Clinical Investigation
Language: ENGLISH

5/3/19 (Item 19 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)
(c) 1997 BIOSIS. All rts. reserv.

8368514 BIOSIS Number: 41052514
THE EFFECT OF PREDNISOLONE 5 AMINOSALICYLIC ACID 6 MERCAPTOPURINE AND
METHOTREXATE ON MONOCYTE-DERIVED INFLAMMATORY CYTOKINE EXPRESSION OF HUMAN
MONONUCLEAR CELLS
DIELEMAN L A; BEAGLEY K W; ELSON C O
DIV. GASTROENTEROL., UNIV. ALA., BIRMINGHAM, ALA. 35294.
DIGESTIVE DISEASE WEEK AND THE 92ND ANNUAL MEETING OF THE AMERICAN
GASTROENTEROLOGICAL ASSOCIATION, NEW ORLEANS, LOUISIANA, USA, MAY 19-22,
1991. GASTROENTEROLOGY 100 (5 PART 2). 1991. A575. CODEN: GASTA
Language: ENGLISH
Document Type: CONFERENCE PAPER

5/3/20 (Item 20 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)
(c) 1997 BIOSIS. All rts. reserv.

8339671 BIOSIS Number: 41023671

IMMUNOLOGY OF INFLAMMATORY BOWEL DISEASE SUMMARY OF THE PROCEEDINGS OF
THE SUBCOMMITTEE ON IMMUNOSUPPRESSIVE USE IN IBD

MARKOWITZ J; DAUM F; COHEN S A; GLASSMAN M; HOLMES R D; PICCOLI D; ROSSI
T M; TREEM W R; ULSHEN M H; WINTER H S

DEP. PEDIATRICS, NORTH SHORE UNIV. HOSP., CORNELL UNIV. MED. COLL., 300
COMMUNITY DR., MANHASSET, N.Y. 11030, USA.

J PEDIATR GASTROENTEROL NUTR 12 (4). 1991. 411-423. CODEN: JPGND

Full Journal Title: Journal of Pediatric Gastroenterology and Nutrition

Language: ENGLISH

Document Type: CONFERENCE PROCEEDINGS

5/3/21 (Item 21 from file: 55)

DIALOG(R)File 55:BIOSIS PREVIEWS(R)

(c) 1997 BIOSIS. All rts. reserv.

6823206 BIOSIS Number: 37017585

ELEVATION OF AN IMPORTANT LYMPHOKINE IL-2 AND MONOKINE TNF IN THE SERUM
OF PATIENTS WITH PRIMARY BILIARY CIRRHOSIS AUTOIMMUNITY

DEMPSEY R A; MILLER L C; CASTRACANE J M; DINARELLO C A

ENDOGEN INC., BOSTON, MASS., USA.

73RD ANNUAL MEETING OF THE FEDERATION OF AMERICAN SOCIETIES FOR
EXPERIMENTAL BIOLOGY, NEW ORLEANS, LOUISIANA, USA, MARCH 19-23, 1989. FASEB
(FED AM SOC EXP BIOL) J 3 (4). 1989. A1121. CODEN: FAJOE

Language: ENGLISH

Document Type: CONFERENCE PAPER

5/3/22 (Item 1 from file: 72)

DIALOG(R)File 72:EMBASE

(c) 1997 Elsevier Science B.V. All rts. reserv.

10201979 EMBASE No: 97010160

Short term immunosuppressive therapy and long term immunoregulation:
Promises and problems

Isaacs J.; Dick A.

United Kingdom

British Journal of Ophthalmology (United Kingdom) , 1996, 80/12
(1035-1036) CODEN: BJOPA ISSN: 0007-1161

DOCUMENT TYPE: Journal

LANGUAGES: English

NUMBER OF REFERENCES: 14

5/3/23 (Item 2 from file: 72)

DIALOG(R)File 72:EMBASE

(c) 1997 Elsevier Science B.V. All rts. reserv.

10166244 EMBASE No: 96338065

Cytokine-suppressive anti-inflammatory drugs. Status of development in
rheumatoid arthritis

Huizinga T.W.J.; Breedveld F.C.

Department of Rheumatology, University Hospital, Postbus 9600, 2300 RC
Leiden Netherlands

Clinical Immunotherapeutics (New Zealand) , 1996, 6/5 (395-404) CODEN:
CIMME ISSN: 1172-7039

LANGUAGES: English SUMMARY LANGUAGES: English

5/3/24 (Item 3 from file: 72)

DIALOG(R)File 72:EMBASE

(c) 1997 Elsevier Science B.V. All rts. reserv.

10135749 EMBASE No: 96313827

The effects of immunosuppressive agents on cytokines

Elson C.O.

Div. Gastroenterology/Hepatology, Department of Medicine, University of Alabama, UAB Station, Birmingham, AL 35294-0007 USA

Alimentary Pharmacology and Therapeutics, Supplement (United Kingdom) , 1996, 10/2 (100-105) CODEN: ATSLE ISSN: 0953-0673

LANGUAGES: English SUMMARY LANGUAGES: English

5/3/25 (Item 4 from file: 72)

DIALOG(R)File 72:EMBASE

(c) 1997 Elsevier Science B.V. All rts. reserv.

10007980 EMBASE No: 96188022

Interferon-beta(1b) treatment decreases tumor necrosis factor-alpha and increases interleukin-6 production in multiple sclerosis

Brod S.A.; Marshall Jr. G.D.; Henninger E.M.; Sriram S.; Khan M.; Wolinsky J.S.

Department of Neurology, Texas Univ. Health Science Center, P.O. Box 20708, Houston, TX 77225 USA

Neurology (USA) , 1996, 46/6 (1633-1638) CODEN: NEURA ISSN: 0028-3878

LANGUAGES: English SUMMARY LANGUAGES: English

5/3/26 (Item 5 from file: 72)

DIALOG(R)File 72:EMBASE

(c) 1997 Elsevier Science B.V. All rts. reserv.

9994652 EMBASE No: 96160387

Recent developments in the treatment of encephalomyelitis

Liu X.; Mashour G.A.; Kurtz A.

Georgetown University, Department of Neurosurgery, 3970 Reservoir Road, Washington, DC 20007 USA

Expert Opinion on Therapeutic Patents (United Kingdom) , 1996, 6/5 (457-470) CODEN: EOTPE ISSN: 1354-3776

LANGUAGES: English SUMMARY LANGUAGES: English

5/3/27 (Item 6 from file: 72)

DIALOG(R)File 72:EMBASE

(c) 1997 Elsevier Science B.V. All rts. reserv.

9989014 EMBASE No: 96156814

Ibuprofen inhibits pyrogen-dependent expression of VCAM-1 and ICAM-1 on human endothelial cells

Kapiotis S.; Sengoelge G.; Sperr W.R.; Baghestanian M.; Quehenberger P.; Bevec D.; Li S.R.; Menzel E.J.; Muhl A.; Zapolska D.; Virgolini I.; Valent P.; Speiser W.

Clin Inst Med./Chem. Lab Diagnostics, University of Vienna, Vienna 1090 Austria

Life Sciences (USA) , 1996, 58/23 (2167-2181) CODEN: LIFSA ISSN: 0024-3205

LANGUAGES: English SUMMARY LANGUAGES: English

5/3/28 (Item 7 from file: 72)

DIALOG(R)File 72:EMBASE

(c) 1997 Elsevier Science B.V. All rts. reserv.

9979333 EMBASE No: 96166734

Experimental immunotherapies for multiple sclerosis

Martin R.; McFarland H.

Neuroimmunology Branch, Natl Inst Neurological Disord Stroke, National Institutes of Health, Bethesda, MD 20892 USA

Springer Seminars in Immunopathology (Germany) , 1996, 18/1 (1-24)

CODEN: SSIMD ISSN: 0344-4325

LANGUAGES: English SUMMARY LANGUAGES: English

5/3/29 (Item 8 from file: 72)

DIALOG(R)File 72:EMBASE

(c) 1997 Elsevier Science B.V. All rts. reserv.

9937049 EMBASE No: 96122714

Cicatricial pemphigoid: Diagnosis and treatment

Quan Dong Nguyen; Foster C.S.

Department of Ophthalmology, Massachusetts Eye and Ear Infirmary, Harvard Medical School, 243 Charles Street, Boston, MA 02114 USA

International Ophthalmology Clinics (USA) , 1996, 36/1 (41-60) CODEN: IOPCA

ISSN: 0020-8167

LANGUAGES: English SUMMARY LANGUAGES: English

5/3/30 (Item 9 from file: 72)

DIALOG(R)File 72:EMBASE

(c) 1997 Elsevier Science B.V. All rts. reserv.

9916826 EMBASE No: 96086319

Management of osteoarthritis and rheumatoid arthritis: Prospects and possibilities

Blackburn Jr. W.D.

Division of Immunology/Rheumatology, University of Alabama, Birmingham, AL 35233 USA

American Journal of Medicine (USA) , 1996, 100/2 A (2A24S-2A30S) CODEN: AJMEA

ISSN: 0002-9343

LANGUAGES: English SUMMARY LANGUAGES: English

5/3/31 (Item 10 from file: 72)

DIALOG(R)File 72:EMBASE

(c) 1997 Elsevier Science B.V. All rts. reserv.

9916740 EMBASE No: 96085529

The future use of biologic therapies in combination for the treatment of rheumatoid arthritis

Strand V.

546-29th Street, San Francisco, CA 94131 USA

Journal of Rheumatology (Canada) , 1996, 23/SUPPL. 44 (91-96) CODEN:

JRHUA ISSN: 0315-162X

LANGUAGES: English SUMMARY LANGUAGES: English

5/3/32 (Item 11 from file: 72)

DIALOG(R)File 72:EMBASE

(c) 1997 Elsevier Science B.V. All rts. reserv.

9882885 EMBASE No: 96067087

Association of generalized pustular psoriasis, Sjogren syndrome, and Hashimoto's thyroiditis

Yamamoto T.; Yokoyama A.; Yamamoto T.

Department of Dermatology, School of Medicine, Tokyo Medical and Dental University, 1-5-45, Bunkyo-ku, Yushima, Tokyo 113 Japan

Journal of Dermatology (Japan) , 1996, 23/1 (64-65) CODEN: JDMYA

ISSN: 0385-2407

LANGUAGES: English

5/3/33 (Item 12 from file: 72)

DIALOG(R)File 72:EMBASE

(c) 1997 Elsevier Science B.V. All rts. reserv.

9860716 EMBASE No: 96044870

Inhibitors of haemopoiesis and their potential clinical relevance

Parker A.N.; Pragnell I.B.

Beatson Institute Cancer Research, Garscube Estate, Switchback Road, Bearsden, Glasgow G61 1BD United Kingdom

Blood Reviews (United Kingdom) , 1995, 9/4 (226-233) CODEN: BLORE

ISSN: 0268-960X

LANGUAGES: English SUMMARY LANGUAGES: English

5/3/34 (Item 13 from file: 72)

DIALOG(R)File 72:EMBASE

(c) 1997 Elsevier Science B.V. All rts. reserv.

9851158 EMBASE No: 96032527

Maintenance strategies in Crohn's disease

Sachar D.B.

Division of Gastroenterology, Mount Sinai Medical Center, Mount Sinai School of Medicine, New York, NY USA

Hospital Practice (USA) , 1996, 31/1 (99-106) CODEN: HOPRB ISSN: 8750-2836

LANGUAGES: English SUMMARY LANGUAGES: English

5/3/35 (Item 14 from file: 72)

DIALOG(R)File 72:EMBASE

(c) 1997 Elsevier Science B.V. All rts. reserv.

9832395 EMBASE No: 96009693

Angiogenesis

Swerlick R.A.

Department of Dermatology, Emory University, WMB 5014, Atlanta, GA 30322 USA

Journal of Dermatology (Japan) , 1995, 22/11 (845-852) CODEN: JDMYA

ISSN: 0385-2407

LANGUAGES: English SUMMARY LANGUAGES: English

5/3/36 (Item 15 from file: 72)

DIALOG(R)File 72:EMBASE

(c) 1997 Elsevier Science B.V. All rts. reserv.

9825251 EMBASE No: 96002297

Increased levels of soluble interleukin-2 receptor in veno-occlusive disease of the liver after allogenic bone marrow transplantation

Remberger M.; Ringden O.

Division of Clinical Immunology, Huddinge Hospital, S-14186 Huddinge Sweden

Transplantation (USA) , 1995, 60/11 (1293-1299) CODEN: TRPLA ISSN: 0041-1337

LANGUAGES: English SUMMARY LANGUAGES: English

5/3/37 (Item 16 from file: 72)

DIALOG(R)File 72:EMBASE

(c) 1997 Elsevier Science B.V. All rts. reserv.

9787618 EMBASE No: 95351542

Combination therapy

Borigini M.J.; Paulus H.E.

Division of Rheumatology, UCLA School of Medicine, 32-48 Rehabilitation, 1000 Veterans Avenue, Los Angeles, CA 90024 USA

Bailliere's Clinical Rheumatology (United Kingdom) , 1995, 9/4 (689-710)

CODEN: BCRHE ISSN: 0950-3579

LANGUAGES: English SUMMARY LANGUAGES: English

5/3/38 (Item 17 from file: 72)

DIALOG(R)File 72:EMBASE

(c) 1997 Elsevier Science B.V. All rts. reserv.

9782760 EMBASE No: 95334809

A review on the strategies for the development and application of new anti-arthritic agents

Lewis A.J.; Keft A.F.

Wyeth Ayerst Research, Princeton, NJ USA

Immunopharmacology and Immunotoxicology (USA) , 1995, 17/4 (607-663)

CODEN: IITOE ISSN: 0892-3973

LANGUAGES: English

5/3/39 (Item 18 from file: 72)

DIALOG(R)File 72:EMBASE

(c) 1997 Elsevier Science B.V. All rts. reserv.

9772322 EMBASE No: 95329534

New IBD markers: Definition of disease heterogeneity

Targan S.R.

Cedars Sinai Medical Centre, Inflammatory Bowel Disease Centre, 8700 Beverly Boulevard, Los Angeles, CA 90048 USA

Canadian Journal of Gastroenterology (Canada) , 1995, 9/6 (301-304)

CODEN: CJGAE ISSN: 0835-7900

LANGUAGES: English SUMMARY LANGUAGES: English; French

5/3/40 (Item 19 from file: 72)
DIALOG(R)File 72:EMBASE
(c) 1997 Elsevier Science B.V. All rts. reserv.

9716625 EMBASE No: 95273067
Juvenile rheumatoid arthritis and spondyloarthropathies
Lindsley C.B.
Department of Pediatrics, University of Kansas Medical Center, 3901
Rainbow Boulevard, Kansas City, KS 66160-7330 USA
Current Opinion in Rheumatology (USA) , 1995, 7/5 (425-429) CODEN: CORHE
ISSN: 1040-8711
LANGUAGES: English SUMMARY LANGUAGES: English

5/3/41 (Item 20 from file: 72)
DIALOG(R)File 72:EMBASE
(c) 1997 Elsevier Science B.V. All rts. reserv.

9675733 EMBASE No: 95227193
Etiopathogenesis of reactive arthritis and ankylosing spondylitis
Careless D.J.; Inman R.D.
Toronto Hospital Arthritis Centre, 399 Bathurst Street, Toronto, Ont. M5T
2S8 Canada
Current Opinion in Rheumatology (USA) , 1995, 7/4 (290-298) CODEN: CORHE
ISSN: 1040-8711
LANGUAGES: English SUMMARY LANGUAGES: English

5/3/42 (Item 21 from file: 72)
DIALOG(R)File 72:EMBASE
(c) 1997 Elsevier Science B.V. All rts. reserv.

9658135 EMBASE No: 95213487
Biological therapies: A novel approach to the treatment of autoimmune
disease
Fox D.A.
Division of Rheumatology, Department of Internal Medicine, Univ. of
Michigan Medical Center, Ann Arbor, MI 48109-0358 USA
American Journal of Medicine (USA) , 1995, 99/1 (82-88) CODEN: AJMEA
ISSN: 0002-9343
LANGUAGES: English SUMMARY LANGUAGES: English

5/3/43 (Item 22 from file: 72)
DIALOG(R)File 72:EMBASE
(c) 1997 Elsevier Science B.V. All rts. reserv.

9656683 EMBASE No: 95211861
Paediatric rheumatology: Original article inflammatory cytokine responses
in juvenile chronic arthritis.
Rooney M.; David J.; Symons J.; Di Giovine F.; Varsani H.; Woo P.
UCLMS, 46 Cleveland Street, London W1P 6DB s methotrexate and
(immunosuppress?)
United Kingdom
British Journal of Rheumatology (United Kingdom) , 1995, 34/5 (454-460)
CODEN: BJRHD ISSN: 0263-7103

LANGUAGES: English SUMMARY LANGUAGES: English

5/3/44 (Item 23 from file: 72)
DIALOG(R)File 72:EMBASE
(c) 1997 Elsevier Science B.V. All rts. reserv.

9588949 EMBASE No: 95153573
Cell adhesion molecules in rheumatoid arthritis
Haskard D.O.
Department of Medicine, Royal Postgraduate Medical School, Hammersmith
Hospital, Du Cane Road, W12 ONN London United Kingdom
Current Opinion in Rheumatology (USA) , 1995, 7/3 (229-234) CODEN: CORHE
ISSN: 1040-8711
LANGUAGES: English SUMMARY LANGUAGES: English

5/3/45 (Item 24 from file: 72)
DIALOG(R)File 72:EMBASE
(c) 1997 Elsevier Science B.V. All rts. reserv.

9588943 EMBASE No: 95153567
Biologic agents in the treatment of inflammatory rheumatic diseases
Kalden J.R.; Manger B.
Department of Internal Medicine III, Clin. Immunology/Rheumatology Inst.,
University of Erlangen-Nuremberg, Krankenhausstr 12, D-91054 Erlangen
Germany
Current Opinion in Rheumatology (USA) , 1995, 7/3 (191-197) CODEN: CORHE
ISSN: 1040-8711
LANGUAGES: English SUMMARY LANGUAGES: English

5/3/46 (Item 25 from file: 72)
DIALOG(R)File 72:EMBASE
(c) 1997 Elsevier Science B.V. All rts. reserv.

9575949 EMBASE No: 95137770
Long term treatment of rheumatoid arthritis with high doses of
intravenous immunoglobulins: Effects on disease activity and serum
cytokines
Muscat C.; Bertotto A.; Ercolani R.; Bistoni O.; Agea E.; Cesarotti M.;
Fiorucci G.; Spinozzi F.; Gerli R.
Institute of Internal Medicine, University of Perugia, Policlinico di
Montelucente, I-06100 Perugia Italy
Annals of the Rheumatic Diseases (United Kingdom) , 1995, 54/5 (382-385)
CODEN: ARDIA ISSN: 0003-4967
LANGUAGES: English SUMMARY LANGUAGES: English

5/3/47 (Item 26 from file: 72)
DIALOG(R)File 72:EMBASE
(c) 1997 Elsevier Science B.V. All rts. reserv.

9537654 EMBASE No: 95106038
Signal transduction pathways in epidermal proliferation and cutaneous
inflammation
Van Ruissen F.; Van de Kerkhof P.C.M.; Schalkwijk J.
Department of Dermatology, University Hospital Nijmegen, PO Box 9101,

6500 HB Nijmegen Netherlands
Clinics in Dermatology (USA) , 1995, 13/2 (161-190) CODEN: CLDEE
ISSN: 0738-081X
LANGUAGES: English

5/3/48 (Item 27 from file: 72)
DIALOG(R)File 72:EMBASE
(c) 1997 Elsevier Science B.V. All rts. reserv.

9531324 EMBASE No: 95081003
Regulatory effects of IL-13 on synovial fluid macrophages and blood monocytes from patients with inflammatory arthritis
Hart P.H.; Ahern M.J.; Smith M.D.; Finlay-Jones J.J.
Dept. Microbiology/Infectious Dis., School of Medicine, Flinders Univ. of South Australia, GPO Box 2100, Adelaide, SA 5001 Australia
Clinical and Experimental Immunology (United Kingdom) , 1995, 99/3 (331-337) CODEN: CEXIA ISSN: 0009-9104
LANGUAGES: English SUMMARY LANGUAGES: English

5/3/49 (Item 28 from file: 72)
DIALOG(R)File 72:EMBASE
(c) 1997 Elsevier Science B.V. All rts. reserv.

9490525 EMBASE No: 95062493
Therapy for multiple sclerosis
Weiner H.L.; Hohol M.J.; Khoury S.J.; Dawson D.M.; Hafler D.A.
221 Longwood Ave., Boston, MA 02115 USA
NEUROL. CLIN. (USA) , 1995, 13/1 (173-196) CODEN: NECLE ISSN: 0733-8619
LANGUAGES: English SUMMARY LANGUAGES: English

5/3/50 (Item 29 from file: 72)
DIALOG(R)File 72:EMBASE
(c) 1997 Elsevier Science B.V. All rts. reserv.

9477163 EMBASE No: 95049183
Novel drug therapies in inflammatory bowel disease
Debinski H.S.; Kamm M.A.
St Mark's Hospital, City Road, London EC1V 2PS United Kingdom
EUR. J. GASTROENTEROL. HEPATOL. (United Kingdom) , 1995, 7/2 (169-182)
CODEN: EJJGHE ISSN: 0954-691X
LANGUAGES: English SUMMARY LANGUAGES: English

5/3/51 (Item 30 from file: 72)
DIALOG(R)File 72:EMBASE
(c) 1997 Elsevier Science B.V. All rts. reserv.

9477080 EMBASE No: 95049081
Update of immunomodulatory therapy for inflammatory bowel disease
Bernstein C.N.
Section of Gastroenterology, GB443 Health Sciences Centre, 820 Sherbrook Street, Winnipeg, Man. R3A 1R9 Canada
CAN. J. GASTROENTEROL. (Canada) , 1994, 8/7 (413-416) CODEN: CJGAE
ISSN: 0835-7900

LANGUAGES: English SUMMARY LANGUAGES: English; French

5/3/52 (Item 31 from file: 72)

DIALOG(R)File 72:EMBASE

(c) 1997 Elsevier Science B.V. All rts. reserv.

9476519 EMBASE No: 95048253

Advances in understanding and novel therapeutic targets in inflammatory arthritis

FitzGerald O.

Department of Rheumatology, St Vincents Hospital, Dublin 4 Ireland

IR. J. MED. SCI. (Ireland) , 1995, 164/1 (4-11) CODEN: IJMSA ISSN: 0021-1265

LANGUAGES: English

5/3/53 (Item 32 from file: 72)

DIALOG(R)File 72:EMBASE

(c) 1997 Elsevier Science B.V. All rts. reserv.

9389690 EMBASE No: 94339223

Gold sodium thiomalate down-regulates intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 expression on vascular endothelial cells

Koike R.; Miki I.; Otoshi M.; Totsuka T.; Inoue H.; Kase H.; Saito I.; Miyasaka N.

Division of Immunological Diseases, Medical Research Institute, Tokyo Medical and Dental University, 1-5-45, Yushima, Bunkyo-ku, Tokyo Japan

MOL. PHARMACOL. (USA) , 1994, 46/4 (599-604) CODEN: MOPMA ISSN: 0026-895X

LANGUAGES: English SUMMARY LANGUAGES: English

5/3/54 (Item 33 from file: 72)

DIALOG(R)File 72:EMBASE

(c) 1997 Elsevier Science B.V. All rts. reserv.

9372940 EMBASE No: 94316706

Pyridinyl imidazoles inhibit the inflammatory phase of delayed type hypersensitivity reactions without affecting T-dependent immune responses

Reddy M.P.; Webb E.F.; Cassatt D.; Maley D.; Lee J.C.; Griswold D.E.; Truneh A.

Department of Molecular Immunology, SmithKline Beecham Pharmaceuticals, P. O. Box 1539, King of Prussia, PA 19406 USA

INT. J. IMMUNOPHARMACOL. (United Kingdom) , 1994, 16/10 (795-804) CODEN: IJIMD ISSN: 0192-0561

LANGUAGES: English SUMMARY LANGUAGES: English

5/3/55 (Item 34 from file: 72)

DIALOG(R)File 72:EMBASE

(c) 1997 Elsevier Science B.V. All rts. reserv.

9312845 EMBASE No: 94259688

Circadian rhythm of serum interleukin-6 in rheumatoid arthritis

Arvidson N.G.; Gudbjornsson B.; Elfman L.; Ryden A.-C.; Totterman T.H.; Hallgren R.

Section of Rheumatology, Department of Medicine, Uppsala University
Hospital, S-751 85 Uppsala Sweden

ANN. RHEUM. DIS. (United Kingdom) , 1994, 53/8 (521-524) CODEN: ARDIA
ISSN: 0003-4967

LANGUAGES: English SUMMARY LANGUAGES: English

5/3/56 (Item 35 from file: 72)

DIALOG(R)File 72:EMBASE

(c) 1997 Elsevier Science B.V. All rts. reserv.

9308370 EMBASE No: 94250587

Augmented expression of inflammatory cytokines and adhesion molecules in
accelerated nodulosis during methotrexate therapy (5)

Miyasaka N.; Saito I.; Uemura T.; Kashiwazaki S.

Division of Immunological Diseases, Medical Research Institute, Tokyo
Medical/Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113 Japan

ANN. RHEUM. DIS. (United Kingdom) , 1994, 53/7 (480-481) CODEN: ARDIA
ISSN: 0003-4967

LANGUAGES: English

5/3/57 (Item 36 from file: 72)

DIALOG(R)File 72:EMBASE

(c) 1997 Elsevier Science B.V. All rts. reserv.

9290606 EMBASE No: 94236066

Research in pediatric rheumatology

Glass D.N.; Nepom B.S.; White P.H.; Shulman L.E.

Children's Hospital Medical Center, Cincinnati Univ. College of Medicine,
Cincinnati, OH 45229-3039 USA

J. RHEUMATOL. (Canada) , 1994, 21/7 (1347-1351) CODEN: JRHUA ISSN:
0315-162X

LANGUAGES: English

5/3/58 (Item 37 from file: 72)

DIALOG(R)File 72:EMBASE

(c) 1997 Elsevier Science B.V. All rts. reserv.

9162404 EMBASE No: 94110945

Immunosuppression in the treatment of disease

Dickler H.B.; Albright J.F.

National Institutes of Health, Solar Building, Bethesda, MD 20892 USA

J. ALLERGY CLIN. IMMUNOL. (USA) , 1994, 93/3 (669-676) CODEN: JACIB
ISSN: 0091-6749

LANGUAGES: English

5/3/59 (Item 38 from file: 72)

DIALOG(R)File 72:EMBASE

(c) 1997 Elsevier Science B.V. All rts. reserv.

9121613 EMBASE No: 94070548

Novel immunosuppressive and antiinflammatory drugs: A 1993 perspective
Allison A.C.

Dawa Corporation, Belmont, CA USA

ANN. NEW YORK ACAD. SCI. (USA) , 1993, 696/- (XI-XX) CODEN: ANYAA

ISSN: 0077-8923

LANGUAGES: English SUMMARY LANGUAGES: English

5/3/60 (Item 39 from file: 72)

DIALOG(R)File 72:EMBASE

(c) 1997 Elsevier Science B.V. All rts. reserv.

9121292 EMBASE No: 94061927

Inflammatory bowel disease

DOENCA INFLAMATORIA INTESTINAL IDIOPATICA

Damiao A.O.; De Moraes Filho J.P.

Departamento de Gastroenterologia, FMUSP, Sao Paulo Brazil

REV. BRAS. MED. (Brazil) , 1993/94, 50/SPEC. ISS. DEC. (7-21) CODEN:

RBMEA ISSN: 0034-7264

LANGUAGES: Portuguese

5/3/61 (Item 40 from file: 72)

DIALOG(R)File 72:EMBASE

(c) 1997 Elsevier Science B.V. All rts. reserv.

9087118 EMBASE No: 94035282

Granulocyte colony-stimulating factor induction of improved leukocytopenia with inflammatory flare in a Felty's syndrome patient

Yasuda M.; Kihara T.; Wada T.; Shiokawa S.; Furuta E.; Suenagu Y.; Nonaka S.; Nobunaga M.; Yoshioka K.; Isayama T.

Medical Institute of Bioregulation, Kyushu University, Beppu Japan

ARTHRITIS RHEUM. (USA) , 1994, 37/1 (145-146) CODEN: ARHEA ISSN: 0004-3591

LANGUAGES: English

5/3/62 (Item 41 from file: 72)

DIALOG(R)File 72:EMBASE

(c) 1997 Elsevier Science B.V. All rts. reserv.

9084440 EMBASE No: 94014905

The current and future therapy strategies of rheumatoid arthritis (RA)

GEGENWARTIGE UND ZUKUNFTIGE THERAPIESTRATEGIEN DER RHEUMATOIDEN ARTHRITIS (RA)

Schacht E.

Hauptabteilung Med. Wissenschaften, E. Tosse und Co. GmbH, Friedrich-Ebert-Damm 101, 22047 Hamburg Germany

Z. RHEUMATOL. (Germany) , 1993, 52/6 (365-382) CODEN: ZRHMB ISSN: 0340-1855

LANGUAGES: German SUMMARY LANGUAGES: German; English

5/3/63 (Item 42 from file: 72)

DIALOG(R)File 72:EMBASE

(c) 1997 Elsevier Science B.V. All rts. reserv.

9071836 EMBASE No: 94010175

Myositis and myopathies: Editorial overview

Kagen L.J.

Department of Medicine, Hospital for Special Surgery, 535 East 70th Street, New York, NY 10021 USA

CURR. OPIN. RHEUMATOL. (USA) , 1993, 5/6 (691-694) CODEN: CORHE ISSN: 1040-8711

LANGUAGES: English

5/3/64 (Item 43 from file: 72)

DIALOG(R)File 72:EMBASE

(c) 1997 Elsevier Science B.V. All rts. reserv.

9036884 EMBASE No: 93340614

Inducible nitric oxide synthase activity in hepatocytes is dependent on the coinduction of tetrahydrobiopterin synthesis

Di Silvio M.; Geller D.A.; Gross S.S.; Nussler A.; Freeswick P.; Simmons R.L.; Billiar T.R.

Department of Surgery, University of Pittsburgh, Pittsburgh, PA 15261
USA

ADV. EXP. MED. BIOL. (USA) , 1993, 338/- (305-308) CODEN: AEMBA ISSN: 0065-2598

LANGUAGES: English

5/3/65 (Item 44 from file: 72)

DIALOG(R)File 72:EMBASE

(c) 1997 Elsevier Science B.V. All rts. reserv.

9030054 EMBASE No: 93333782

Graft-versus-host disease: Host and donor views

Deeg H.J.; Yolken; Rostami; Nelson; Pahwa; Schaffer; Boxer

Fred Hutchinson Cancer Research Ctr., 1124 Columbia St, Seattle, WA 98104

USA

SEMIN. HEMATOL. (USA) , 1993, 30/4 SUPPL. 4 (110-118) CODEN: SEHEA

ISSN: 0037-1963

LANGUAGES: English SUMMARY LANGUAGES: English

5/3/66 (Item 45 from file: 72)

DIALOG(R)File 72:EMBASE

(c) 1997 Elsevier Science B.V. All rts. reserv.

8985535 EMBASE No: 93289267

Interleukin-1 receptor antagonist

Arend W.P.

Division of Rheumatology, Department of Medicine, Colorado Univ. Health Sciences Ctr., Denver, CO 80262 USA

ADV. IMMUNOL. (USA) , 1993, 54/- (167-227) CODEN: ADIMA ISSN: 0065-2776

LANGUAGES: English SUMMARY LANGUAGES: English

5/3/67 (Item 46 from file: 72)

DIALOG(R)File 72:EMBASE

(c) 1997 Elsevier Science B.V. All rts. reserv.

8914186 EMBASE No: 93218147

Synovial mononuclear phagocytes in rheumatoid arthritis and osteoarthritis: Quantitative and functional aspects

Weinberg J.B.; Wortham T.S.; Misukonis M.A.; Patton K.L.; Chitneni S.R.

Duke University Medical Center, 508 Fulton Street, Durham, NC 27705 USA

IMMUNOL. INVESTIG. (USA) , 1993, 22/5 (365-374) CODEN: IMINE ISSN: 0882-0139

LANGUAGES: English SUMMARY LANGUAGES: English

5/3/68 (Item 47 from file: 72)

DIALOG(R)File 72:EMBASE

(c) 1997 Elsevier Science B.V. All rts. reserv.

8872009 EMBASE No: 93175822

Rheumatoid arthritis: New science, new treatment

Miller-Blair D.J.; Robbins D.L.

Kaiser-Permanente Medical Center, South Sacramento, CA USA

GERIATRICS (USA) , 1993, 48/6 (28-38) CODEN: GERIA ISSN: 0016-867X

LANGUAGES: English SUMMARY LANGUAGES: English

5/3/69 (Item 48 from file: 72)

DIALOG(R)File 72:EMBASE

(c) 1997 Elsevier Science B.V. All rts. reserv.

8852420 EMBASE No: 93156138

The role of cytokines in psoriatic inflammation

DIE ROLLE VON ZYTOKINEN FUR DIE PATHOGENESE DER PSORIASIS

Kapp A.

Funktionsbereich Allergologie, Hautklinik, Albert-Ludwigs-Universitat,
Hauptstrasse 7, W-7800 Freiburg Germany

HAUTARZT (Germany) , 1993, 44/4 (201-207) CODEN: HAUTA ISSN: 0017-8470

LANGUAGES: German SUMMARY LANGUAGES: German; English

5/3/70 (Item 49 from file: 72)

DIALOG(R)File 72:EMBASE

(c) 1997 Elsevier Science B.V. All rts. reserv.

8831742 EMBASE No: 93135727

Therapeutic applications of photopheresis

Rook A.H.; Cohen J.H.; Lessin S.R.; Vowels B.R.

Department of Dermatology, Hospital University of Pennsylvania, 3400
Spruce Street, Philadelphia, PA 19104 USA

DERMATOL. CLIN. (USA) , 1993, 11/2 (339-347) CODEN: DRMCD ISSN: 0733-8635

LANGUAGES: English SUMMARY LANGUAGES: English

5/3/71 (Item 50 from file: 72)

DIALOG(R)File 72:EMBASE

(c) 1997 Elsevier Science B.V. All rts. reserv.

8809709 EMBASE No: 93110017

Immunosuppressive therapy for autoimmune diseases

Hoffman G.S.

Cleveland Clinic Foundation, 9500 Euclid Ave, Cleveland, OH 44195 USA

ANN. ALLERGY (USA) , 1993, 70/4 (263-274) CODEN: ANAEA ISSN: 0003-4738

LANGUAGES: English

5/3/72 (Item 51 from file: 72)

DIALOG(R)File 72:EMBASE
(c) 1997 Elsevier Science B.V. All rts. reserv.

8807982 EMBASE No: 93111770
Acute and chronic graft-versus-host disease
Vogelsang G.B.
Johns Hopkins Oncology Center, 600 North Wolfe Street, Baltimore, MD
21287-8985 USA
CURR. OPIN. ONCOL. (USA) , 1993, 5/2 (276-281) CODEN: CUOOE ISSN:
1040-8746
LANGUAGES: English SUMMARY LANGUAGES: English

5/3/73 (Item 52 from file: 72)
DIALOG(R)File 72:EMBASE
(c) 1997 Elsevier Science B.V. All rts. reserv.

8806250 EMBASE No: 93110018
CME examination
ANN. ALLERGY (USA) , 1993, 70/4 (274-275) CODEN: ANAEA ISSN: 0003-4738
LANGUAGES: English

5/3/74 (Item 53 from file: 72)
DIALOG(R)File 72:EMBASE
(c) 1997 Elsevier Science B.V. All rts. reserv.

8730141 EMBASE No: 93034093
Wegener's granulomatosis
Hoffman G.S.
Rheumatic/Immunologic Diseases Dept., Cleveland Clinic Foundation, 9500
Euclid Avenue, Cleveland, OH 44195 USA
CURR. OPIN. RHEUMATOL. (USA) , 1993, 5/1 (11-17) CODEN: CORHE ISSN:
1040-8711
LANGUAGES: English SUMMARY LANGUAGES: English

5/3/75 (Item 54 from file: 72)
DIALOG(R)File 72:EMBASE
(c) 1997 Elsevier Science B.V. All rts. reserv.

8675094 EMBASE No: 92355604
Use of monoclonal antibodies in vivo as a therapeutic strategy for
alloimmune or autoimmune reactivity: The Besancon experience
Herve P.; Racadot E.; Wendling D.; Rumbach L.; Tiberghien P.; Cahn J.Y.;
Flesch M.; Wijdenes J.
Centre Reg. de Transfusion Sanguine, 1 Boulevard Fleming, 25020 Besancon
France
IMMUNOL. REV. (Denmark) , 1992, -/129 (31-55) CODEN: IMRED ISSN:
0105-2896 ADONIS ORDER NUMBER: 010528969200043S
LANGUAGES: English

5/3/76 (Item 55 from file: 72)
DIALOG(R)File 72:EMBASE
(c) 1997 Elsevier Science B.V. All rts. reserv.

8574752 EMBASE No: 92250773

Supportive care in marrow transplantation
Bensinger W.I.

Clinical Research Division, Fred Hutchinson Cancer Research Ctr., 1124
Columbia Street, Seattle, WA 98104 USA

CURR. OPIN. ONCOL. (USA) , 1992, 4/4 (614-623) CODEN: CUOOE ISSN:
1040-8746

LANGUAGES: English SUMMARY LANGUAGES: English

5/3/77 (Item 56 from file: 72)

DIALOG(R)File 72:EMBASE

(c) 1997 Elsevier Science B.V. All rts. reserv.

8542432 EMBASE No: 92218309

Profile of cytokines in synovial fluid specimens from patients with
arthritis. Interleukin 8 (IL-8) and IL-6 correlate with inflammatory
arthritides

Remick D.G.; DeForge L.E.; Sullivan J.F.; Showell H.J.

I301 Catherine Road, Ann Arbor, MI 48109-0602 USA

IMMUNOL. INVESTIG. (USA) , 1992, 21/4 (321-327) CODEN: IMINE ISSN:
0882-0139

LANGUAGES: English SUMMARY LANGUAGES: English

5/3/78 (Item 57 from file: 72)

DIALOG(R)File 72:EMBASE

(c) 1997 Elsevier Science B.V. All rts. reserv.

8355207 EMBASE No: 92020818

Interaction(s) between essential fatty acids, eicosanoids, cytokines,
growth factors and free radicals: Relevance to new therapeutic strategies
in rheumatoid arthritis and other collagen vascular diseases

Das U.N.

Department of Medicine, Nizam's Institute of Medical Sciences, Hyderabad
500482 India

PROSTAGLANDINS LEUKOTRIENES ESSENT. FATTY ACIDS (United Kingdom) , 1991,
44/4 (201-210) CODEN: PLEAE ISSN: 0952-3278 ADONIS ORDER NUMBER:
095232789100121B

LANGUAGES: English SUMMARY LANGUAGES: English

5/3/79 (Item 58 from file: 72)

DIALOG(R)File 72:EMBASE

(c) 1997 Elsevier Science B.V. All rts. reserv.

8344235 EMBASE No: 92021049

Cytokines and drugs workshop

Hom J.T.; Simon P.L.

Lilly Research Laboratories, Indianapolis IN 46285 USA

AGENTS ACTIONS (Switzerland) , 1991, 35/SUPPL. (147-150) CODEN: AGACB
ISSN: 0065-4299

LANGUAGES: English

5/3/80 (Item 59 from file: 72)

DIALOG(R)File 72:EMBASE

(c) 1997 Elsevier Science B.V. All rts. reserv.

8290316 EMBASE No: 91320042

Phase I-II trial of pentoxifylline for the prevention of
transplant-related toxicities following bone marrow transplantation

Bianco J.A.; Appelbaum F.R.; Nemunaitis J.; Almgren J.; Andrews F.;
Kettner P.; Shields A.; Singer J.W.

Marrow Transplant Unit, 111-ONC, Veterans Affairs Medical Center, 1660 S
Columbian Way, Seattle, WA 98108 USA

BLOOD (USA) , 1991, 78/5 (1205-1211) CODEN: BLOOA ISSN: 0006-4971

LANGUAGES: English

5/3/81 (Item 60 from file: 72)

DIALOG(R)File 72:EMBASE

(c) 1997 Elsevier Science B.V. All rts. reserv.

8124745 EMBASE No: 91154846

Synovial angiogenesis

Liote F.

Clinique de Rhumatologie, Centre Viggo Petersen, 6, Rue Guy-Patin, 75010
Paris France

REV. RHUM. MAL. OSTEO-ARTICULAIRES (France) , 1991, 58/3 BIS (51-59S)

CODEN: RRMOA ISSN: 0035-2659

LANGUAGES: French

5/3/82 (Item 61 from file: 72)

DIALOG(R)File 72:EMBASE

(c) 1997 Elsevier Science B.V. All rts. reserv.

8110893 EMBASE No: 91141395

Methotrexate: Mechanism of action in rheumatoid arthritis

Segal R.; Yaron M.; Tartakovsky B.

Department of Rheumatology, Ichilov Hospital, Tel-Aviv 64239 Israel

SEMIN. ARTHRITIS RHEUM. (USA) , 1990, 20/3 (190-200) CODEN: SAHRB
ISSN: 0049-0172

LANGUAGES: English

5/3/83 (Item 62 from file: 72)

DIALOG(R)File 72:EMBASE

(c) 1997 Elsevier Science B.V. All rts. reserv.

8108738 EMBASE No: 91137004

Osteoporosis associated with rheumatoid arthritis: Pathogenesis and
management

Joffe I.; Epstein S.

Division of Endocrinology and Metabolism, Albert Einstein Medical Center,
5401 Old York Rd, Philadelphia, PA 19141 USA

SEMIN. ARTHRITIS RHEUM. (USA) , 1991, 20/4 (256-272) CODEN: SAHRB
ISSN: 0049-0172

LANGUAGES: English

5/3/84 (Item 63 from file: 72)

DIALOG(R)File 72:EMBASE

(c) 1997 Elsevier Science B.V. All rts. reserv.

8041608 EMBASE No: 91071603

The effects of some anti-arthritic drugs and cytokines on the shape and function of rodent macrophages

Haynes D.R.; Whitehouse M.W.; Vernon-Roberts B.

Department of Pathology, University of Adelaide, GPO Box 498, Adelaide, SA 5001 Australia

INT. J. EXP. PATHOL. (United Kingdom) , 1991, 72/1 (9-22) CODEN: IJEPE
ISSN: 0959-9673 ADONIS ORDER NUMBER: 095996739100002R

LANGUAGES: English

5/3/85 (Item 1 from file: 154)

DIALOG(R)File 154:MEDLINE(R)

(c) format only 1997 Knight-Ridder Info. All rts. reserv.

09677693 96199293

Management of osteoarthritis and rheumatoid arthritis: prospects and possibilities.

Blackburn WD

Division of Immunology/Rheumatology, University of Alabama at Birmingham, Alabama 35233, USA.

Am J Med (UNITED STATES) Feb 26 1996, 100 (2A) p24S-30S, ISSN 0002-9343 Journal Code: 3JU

Languages: ENGLISH

Document type: JOURNAL ARTICLE; REVIEW; REVIEW, TUTORIAL

5/3/86 (Item 2 from file: 154)

DIALOG(R)File 154:MEDLINE(R)

(c) format only 1997 Knight-Ridder Info. All rts. reserv.

09402415 95332415

Circulating selectins, intercellular adhesion molecule-1, and vascular cell adhesion molecule-1 in hyperthyroidism.

Wenisch C; Myskiw D; Gessl A; Graninger W

Department of Infectious Diseases, University of Vienna, Austria.

J Clin Endocrinol Metab (UNITED STATES) Jul 1995, 80 (7) p2122-6, ISSN 0021-972X Journal Code: HRB

Languages: ENGLISH

Document type: JOURNAL ARTICLE

5/3/87 (Item 3 from file: 154)

DIALOG(R)File 154:MEDLINE(R)

(c) format only 1997 Knight-Ridder Info. All rts. reserv.

09377454 95307454

Effects of rhG-CSF on infection complications and impaired function of neutrophils secondary to chemotherapy for non-Hodgkin's lymphoma. Hokkaido Study Group of Malignant Lymphoma, and rhG-CSF, Japan.

Kuni-Eda Y; Okabe M; Kurosawa M; Maekawa I; Higuchi M; Kawamura M; Morioka M; Suzuki S; Ohmura T; Fujimoto N; et al

Third Department of Internal Medicine, Hokkaido University School of Medicine, Sapporo, Japan.

Leuk Lymphoma (SWITZERLAND) Feb 1995, 16 (5-6) p471-6, ISSN 1042-8194 Journal Code: BNQ

Languages: ENGLISH

Document type: JOURNAL ARTICLE; MULTICENTER STUDY

5/3/88 (Item 4 from file: 154)
DIALOG(R)File 154:MEDLINE(R)
(c) format only 1997 Knight-Ridder Info. All rts. reserv.

09188394 95118394
Rheumatoid arthritis treated with tenidap and piroxicam. Clinical associations with cytokine modulation by tenidap.
Littman BH; Drury CE; Zimmerer RO; Stack CB; Law CG
Central Research Division, Pfizer Inc., Groton, CT 06340.
Arthritis Rheum (UNITED STATES) Jan 1995, 38 (1) p29-37, ISSN 0004-3591 Journal Code: 90M
Languages: ENGLISH
Document type: CLINICAL TRIAL; JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL

5/3/89 (Item 5 from file: 154)
DIALOG(R)File 154:MEDLINE(R)
(c) format only 1997 Knight-Ridder Info. All rts. reserv.

08509728 93219728
[If I had chronic polyarthritis--current ideas on basic therapy]
Wenn ich eine chronische Polyarthritis hatte--Neue Ideen zur Basistherapie.
Hasler F
FMH Innere Medizin, speziell Rheumaerkrankungen, Chur.
Schweiz Rundsch Med Prax (SWITZERLAND) Mar 23 1993, 82 (12) p349-52, ISSN 0369-8394 Journal Code: SRM
Languages: GERMAN Summary Languages: ENGLISH
Document type: JOURNAL ARTICLE English Abstract

5/3/90 (Item 6 from file: 154)
DIALOG(R)File 154:MEDLINE(R)
(c) format only 1997 Knight-Ridder Info. All rts. reserv.

08300316 93010316
The effect of slow-acting anti-rheumatic drugs (SAARDs) and combinations of SAARDs on monokine production in vitro.
Danis VA; Franic GM; Brooks PM
Kolling Institute, Royal North Shore Hospital, St. Leonards, NSW, Australia.
Drugs Exp Clin Res (SWITZERLAND) 1991, 17 (12) p549-54, ISSN 0378-6501 Journal Code: EBM
Languages: ENGLISH
Document type: JOURNAL ARTICLE

5/3/91 (Item 7 from file: 154)
DIALOG(R)File 154:MEDLINE(R)
(c) format only 1997 Knight-Ridder Info. All rts. reserv.

08101632 92239632
Angiogenesis and its inhibition: potential new therapies in oncology and non-neoplastic diseases.
Billington DC
Institut de Recherches Servier, Suresnes, France.

Drug Des Discov (SWITZERLAND) Nov 1991, 8 (1) p3-35, ISSN 1055-9612
Journal Code: A5B
Languages: ENGLISH
Document type: JOURNAL ARTICLE; REVIEW; REVIEW, TUTORIAL

5/3/92 (Item 1 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 1997 American Chemical Society. All rts. reserv.

121263477 CA: 121(22)263477k JOURNAL
Prostaglandin and tumor necrosis factor secretion by peritoneal
macrophages isolated from normal and arthritic rats treated with liposomal
methotrexate
AUTHOR(S): Williams, Anwen S.; Camilleri, J. P.; Topley, N.; Williams, B.
D.
LOCATION: Dep. of Rheumatology, Univ. of Wales College of Medicine,
Cardiff, UK,
JOURNAL: J. Pharmacol. Toxicol. Methods DATE: 1994 VOLUME: 32 NUMBER:
1 PAGES: 53-8 CODEN: JPTMEZ ISSN: 1056-8719 LANGUAGE: English
MEETING DATE: 940930

5/3/93 (Item 1 from file: 351)
DIALOG(R)File 351:DERWENT WPI
(c)1997 Derwent Info Ltd. All rts. reserv.

010035215 WPI Acc No: 94-302928/37
XRAM Acc No: C94-138132

Image available

Use of tripterinin, a diterpene from medicinal plant sources - in
autoimmune disease, e.g., arthritis, and tissue transplant rejection

Patent Assignee: (PHAR-) PHARMAGENESIS INC

Author (Inventor): WIEDMANN T W; XU R S

Patent Family:

CC Number	Kind	Date	Week	
WO 9420488	A1	940915	9437	(Basic)
AU 9464002	A	940926	9503	
US 5468772	A	951121	9601	

Priority Data (CC No Date): US 31288 (930310)

Applications (CC,No,Date): WO 94US2540 (940308); AU 9464002 (940308)

53587 METHOTREXATE
145836 IMMUNOSUPPRESS?
S10 4279 METHOTREXATE AND (IMMUNOSUPPRESS?)
?s s10 and crohn?

4279 S10
23664 CROHN?
S11 119 S10 AND CROHN?
?rd s11

>>>Duplicate detection is not supported for File 351.

>>>Records from unsupported files will be retained in the RD set.

...examined 50 records (50)
...examined 50 records (100)
...completed examining records
S12 95 RD S11 (unique items)
?s s12 and review?

95 S12
1929787 REVIEW?
S13 52 S12 AND REVIEW?
?t s13/3/all

13/3/1 (Item 1 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)
(c) 1997 BIOSIS. All rts. reserv.

13324148 BIOSIS Number: 99324148
Immunosuppressive drugs in inflammatory bowel diseases
Reimund J M; Wittersheim C; Duclos B; Baumann R
Serv. Hepato-Gastroenterol. Assistance Nutr., Hop. Univ. Strasbourg, Hop.
Hautepierre, Ave. Moliere, 67098 Strasbourg Cedex, France
Semaine des Hopitaux 72 (27-28). 1996. 868-879.
Full Journal Title: Semaine des Hopitaux
ISSN: 0037-1777
Language: FRENCH
Print Number: Biological Abstracts Vol. 103 Iss. 002 Ref. 027262.

13/3/2 (Item 2 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)
(c) 1997 BIOSIS. All rts. reserv.

13247635 BIOSIS Number: 99247635
Therapeutic strategies for pediatric Crohn disease
Grand R J; Ramakrishna J; Calenda K A
New England Medical Cent., 750 Washington St., PO Box 213, Boston, MA,
USA
Clinical and Investigative Medicine 19 (5). 1996. 373-380.
Full Journal Title: Clinical and Investigative Medicine
ISSN: 0147-958X
Language: ENGLISH
Print Number: Biological Abstracts Vol. 102 Iss. 011 Ref. 163265

13/3/3 (Item 3 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)
(c) 1997 BIOSIS. All rts. reserv.

12181077 BIOSIS Number: 98781077
Review article: The medical management of Crohn's disease
Elton E; Hanauer S B
Section Gastroenterology, Dep. Med., Univ. Chicago, 5841 S. Maryland
Avenue, Chicago, IL 60637, USA
Alimentary Pharmacology & Therapeutics 10 (1). 1996. 1-22.
Full Journal Title: Alimentary Pharmacology & Therapeutics
ISSN: 0269-2813
Language: ENGLISH
Print Number: Biological Abstracts Vol. 101 Iss. 010 Ref. 148269

13/3/4 (Item 4 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)
(c) 1997 BIOSIS. All rts. reserv.

12173116 BIOSIS Number: 98773116
A review of immune modifier therapy for inflammatory bowel disease:
Azathioprine, 6-mercaptopurine, cyclosporine, and methotrexate
Sandborn W J
Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
American Journal of Gastroenterology 91 (3). 1996. 423-433.
Full Journal Title: American Journal of Gastroenterology
ISSN: 0002-9270
Language: ENGLISH
Print Number: Biological Abstracts Vol. 101 Iss. 010 Ref. 140308

13/3/5 (Item 5 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)
(c) 1997 BIOSIS. All rts. reserv.

11990481 BIOSIS Number: 98590481
Management of severe acute colitis in the adult patient
Carbonnel F; Lemann M; Rambaud J-C
Serv. Gastroenterol. Nutr., Hopital Rothschild, 33 boulevard de Picpus,
F-75571 Paris Cedex 12, France
Gastroenterologie Clinique et Biologique 19 (5 SUPPL.). 1995. B15-B22.
Full Journal Title: Gastroenterologie Clinique et Biologique
ISSN: 0399-8320
Language: FRENCH
Print Number: Biological Abstracts Vol. 101 Iss. 002 Ref. 018186

13/3/6 (Item 6 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)
(c) 1997 BIOSIS. All rts. reserv.

11869473 BIOSIS Number: 98469473
Bacterial translocation of endogenous bacteria
Hedouin V; Neut C; Lescut D; Bazin B; Rambaud J-C; Colombel J-F
Service des Maladies de l'Appareil Digestif et de la Nutrition, Hopital
Huriez, CHRU, F-59037 Lille, France
Gastroenterologie Clinique et Biologique 19 (4). 1995. 393-401.

Full Journal Title: Gastroenterologie Clinique et Biologique
ISSN: 0399-8320
Language: FRENCH
Print Number: Biological Abstracts Vol. 100 Iss. 009 Ref. 135530

13/3/7 (Item 7 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)
(c) 1997 BIOSIS. All rts. reserv.

11458563 BIOSIS Number: 98058563
Medical therapy of inflammatory bowel disease
Hanauer S B; Baert F
Univ. Chicago Med. Cent., 5841 S. Maryland Ave., MC 4076, Chicago, IL
60637, USA
Medical Clinics of North America 78 (6). 1994. 1413-1426.
Full Journal Title: Medical Clinics of North America
ISSN: 0025-7125
Language: ENGLISH
Print Number: Biological Abstracts/RRM Vol. 047 Iss. 002 Ref. 019205

13/3/8 (Item 8 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)
(c) 1997 BIOSIS. All rts. reserv.

10928234 BIOSIS Number: 97128234
Pharmacotherapy of inflammatory bowel disease
Reynolds P D; Hunter J O
Dep. Gastroenterology, Addenbrooke's Hosp., Hills Road, Cambridge CB2
2QQ, UK
Digestive Diseases 11 (6). 1993. 334-342.
Full Journal Title: Digestive Diseases
ISSN: 0257-2753
Language: ENGLISH
Print Number: Biological Abstracts Vol. 097 Iss. 006 Ref. 078109

13/3/9 (Item 9 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)
(c) 1997 BIOSIS. All rts. reserv.

10879528 BIOSIS Number: 97079528
Maintenance of symptomatic remission in patients with Crohn's disease
Stark M E; Tremaine W J
Div. Gastroenterol., Mayo Clin. Rochester, 200 First Street SW,
Rochester, MN 55905, USA
Mayo Clinic Proceedings 68 (12). 1993. 1183-1190.
Full Journal Title: Mayo Clinic Proceedings
ISSN: 0025-6196
Language: ENGLISH
Print Number: Biological Abstracts Vol. 097 Iss. 004 Ref. 047033

13/3/10 (Item 10 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)
(c) 1997 BIOSIS. All rts. reserv.

10827864 BIOSIS Number: 97027864
Rolling review: Inflammatory bowel disease
Carpani De Kaski M; Hodgson H J F
Dep. Gastroenterol., Royal Postgraduate Med. Sch., Hammersmith Hosp.,
London W12 0NN, UK
Alimentary Pharmacology & Therapeutics 7 (5). 1993. 567-579.
Full Journal Title: Alimentary Pharmacology & Therapeutics
ISSN: 0269-2813
Language: ENGLISH
Print Number: Biological Abstracts Vol. 097 Iss. 002 Ref. 014401

13/3/11 (Item 11 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)
(c) 1997 BIOSIS. All rts. reserv.

9873091 BIOSIS Number: 44123091
REVIEW ARTICLE IMMUNOSUPPRESSIVE THERAPY FOR INFLAMMATORY BOWEL DISEASE
KOZAREK R A
VIRGINIA MASON CLINIC, P.O. BOX 900, SEATTLE, WA 98101, USA.
ALIMENT PHARMACOL THER 7 (2). 1993. 117-123. CODEN: APTHE
Full Journal Title: Alimentary Pharmacology & Therapeutics
Language: ENGLISH

13/3/12 (Item 12 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)
(c) 1997 BIOSIS. All rts. reserv.

9630695 BIOSIS Number: 94135695
NEW THERAPEUTIC AGENTS IN THE TREATMENT OF INFLAMMATORY BOWEL DISEASE
GEIER D L; MINER P B JR
DEP. MED., UNIV. KANSAS MED. CENT., KANSAS CITY, KANSAS 66103.
AM J MED 93 (2). 1992. 199-208. CODEN: AJMEA
Full Journal Title: American Journal of Medicine
Language: ENGLISH

13/3/13 (Item 13 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)
(c) 1997 BIOSIS. All rts. reserv.

9339901 BIOSIS Number: 43084901
IMMUNOSUPPRESSANTS
MARSH J W; VEHE K L; WHITE H M
QUEENY TOWER, SUITE 6107, ONE BARNES HOSPITAL PLAZA, ST. LOUIS, MO.
63110.
GASTROENTEROL CLIN NORTH AM 21 (3). 1992. 679-693. CODEN: GCNAE
Full Journal Title: Gastroenterology Clinics of North America
Language: ENGLISH

13/3/14 (Item 1 from file: 72)
DIALOG(R)File 72:EMBASE
(c) 1997 Elsevier Science B.V. All rts. reserv.

10173210 EMBASE No: 96361144
Inflammatory bowel disease

Millar A.; Kulhalli V.
Dept Gastroentology Haemotology, Royal Free Hospital, London United
Kingdom
Pharmaceutical Journal (United Kingdom) , 1996, 257/6918 (723-728)
CODEN: PHJOA ISSN: 0031-6873
LANGUAGES: English SUMMARY LANGUAGES: English

13/3/15 (Item 2 from file: 72)
DIALOG(R)File 72:EMBASE
(c) 1997 Elsevier Science B.V. All rts. reserv.

10169566 EMBASE No: 96352940
Biomedical and psychosocial factors in the development and course of
inflammatory bowel diseases: A review
DER EINFLUSS SOMATISCHER UND PSYCHOSOZIALER FAKTOREN AUF ENTSTEHUNG UND
VERLAUF CHRONISCH-ENTZUNDLICHER DARMERKRANKUNGEN. EINE LITERATURUBERSICHT
Faller H.; Kraus M.R.
Inst. Psychotherapie/Med. Psychol., Universitat Wurzburg, Klinikstrasse
3, D-97070 Wurzburg Germany
Psychotherapeut (Germany) , 1996, 41/6 (339-354) CODEN: PYCHE ISSN:
0935-6185
LANGUAGES: German SUMMARY LANGUAGES: English; German

13/3/16 (Item 3 from file: 72)
DIALOG(R)File 72:EMBASE
(c) 1997 Elsevier Science B.V. All rts. reserv.

10136368 EMBASE No: 96315831
Treatment of Crohn's disease
LE TRAITEMENT DE LA MALADIE DE CROHN
Carre-Auger E.; Roubille R.
13, Rue des Dahlias, 69003 Lyon France
Lyon Pharmaceutique (France) , 1996, 47/6 (315-321) CODEN: LYPHA
ISSN: 0024-7804
LANGUAGES: French SUMMARY LANGUAGES: English; French

13/3/17 (Item 4 from file: 72)
DIALOG(R)File 72:EMBASE
(c) 1997 Elsevier Science B.V. All rts. reserv.

10105849 EMBASE No: 96299045
Newer treatments for inflammatory bowel disease
Stotland B.R.; Lichtenstein G.R.
Division of Gastroenterology, Department of Medicine, Pennsylvania Univ.
Sch. of Medicine, 3400 Spruce Street, Philadelphia, PA 19104-4283 USA
Primary Care - Clinics in Office Practice (USA) , 1996, 23/3 (577-608)
CODEN: PRCAD ISSN: 0095-4543
LANGUAGES: English SUMMARY LANGUAGES: English

13/3/18 (Item 5 from file: 72)
DIALOG(R)File 72:EMBASE
(c) 1997 Elsevier Science B.V. All rts. reserv.

10095012 EMBASE No: 96275960

Position of corticoids and immunosuppressives in the treatment of inflammatory bowel diseases

POSTAVENI KORTIKOIDU A IMUNOSUPRESIV V TERAPII IDIOPATICKYCH STREVNICH ZANETU

Lukas M.

II Interni Klinika, VFN, U nemocnice 2, 128 08 Praha 2 Czech Republic
Ceska a Slovenska Gastroenterologie (Czech Republic) , 1996, 50/4
(111-115) CODEN: CSGAE ISSN: 1210-7824

LANGUAGES: Czech SUMMARY LANGUAGES: English; Czech

13/3/19 (Item 6 from file: 72)

DIALOG(R)File 72:EMBASE

(c) 1997 Elsevier Science B.V. All rts. reserv.

9998530 EMBASE No: 96178578

Current medical therapy for inflammatory bowel disease

Bonner G.F.

Cleveland Clinic Florida, 3000 W Cypress Creek Rd., Fort Lauderdale, FL
33309 USA

Southern Medical Journal (USA) , 1996, 89/6 (556-566) CODEN: SMJOA
ISSN: 0038-4348

LANGUAGES: English SUMMARY LANGUAGES: English

13/3/20 (Item 7 from file: 72)

DIALOG(R)File 72:EMBASE

(c) 1997 Elsevier Science B.V. All rts. reserv.

9951933 EMBASE No: 96138421

Episcleritis and scleritis: Diagnosis and therapy

Soukiasian S.H.

Lahey Eye Institute, 1 Essex Center Dr, Peabody, MA 01960 USA
Seminars in Ophthalmology (USA) , 1996, 11/1 (79-92) CODEN: SEOPE
ISSN: 0882-0538

LANGUAGES: English SUMMARY LANGUAGES: English

13/3/21 (Item 8 from file: 72)

DIALOG(R)File 72:EMBASE

(c) 1997 Elsevier Science B.V. All rts. reserv.

9920230 EMBASE No: 96102221

Medical management of colorectal Crohn's disease

Barnett J.L.

University Michigan Medical Center, Gastroenterology Division, 3912
Taubman Center, Ann Arbor, MI 48109 0362 USA

Current Opinion in Gastroenterology (USA) , 1996, 12/1 (26-31) CODEN:
COGAE ISSN: 0267-1379

LANGUAGES: English SUMMARY LANGUAGES: English

13/3/22 (Item 9 from file: 72)

DIALOG(R)File 72:EMBASE

(c) 1997 Elsevier Science B.V. All rts. reserv.

9899272 EMBASE No: 96070300

Present orientation of medical therapy for Crohn's disease

MODERNI ORIENTAMENTI DI TERAPIA MEDICA DEL MORBO DI CROHN
Grassi M.; Raffa S.; Damiani V.C.; Gurgo A.M.; Messini F.
Universita degli Studi 'La Sapienza', Istituto di Idrologia Medica, Rome
Italy
Clinica Terapeutica (Italy) , 1995, 146/11 (737-745) CODEN: CLTEA
ISSN: 0009-9074
LANGUAGES: Italian SUMMARY LANGUAGES: English; Italian

13/3/23 (Item 10 from file: 72)
DIALOG(R)File 72:EMBASE
(c) 1997 Elsevier Science B.V. All rts. reserv.

9892729 EMBASE No: 96066012
Review article: Refractory distal colitis-explanations and options
Griffin M.G.; Miner P.B.
Department of Medicine, University of Kansas Medical Center, 3901 Rainbow
Boulevard, Kansas City, KS 66160-7350 USA
Alimentary Pharmacology and Therapeutics (United Kingdom) , 1996, 10/1
(39-48) CODEN: APTHE ISSN: 0269-2813
LANGUAGES: English SUMMARY LANGUAGES: English

13/3/24 (Item 11 from file: 72)
DIALOG(R)File 72:EMBASE
(c) 1997 Elsevier Science B.V. All rts. reserv.

9865012 EMBASE No: 96040779
Effects of cigarette smoking on the long-term course of Crohn's disease
Cosnes J.; Carbonnel F.; Beaugerie L.; Quintrec Y.L.; Gendre J.P.
Hopital Rothschild, 33 Bd de Picpus, 75571 Paris Cedex 12 France
Gastroenterology (USA) , 1996, 110/2 (424-431) CODEN: GASTA ISSN:
0016-5085
LANGUAGES: English SUMMARY LANGUAGES: English

13/3/25 (Item 12 from file: 72)
DIALOG(R)File 72:EMBASE
(c) 1997 Elsevier Science B.V. All rts. reserv.

9724111 EMBASE No: 95280745
Medical management of specific clinical presentations
Bitton A.; Peppercorn M.A.
Division of Gastroenterology, Beth Israel Hospital, 330 Brookline Avenue,
Boston, MA 02215 USA
Gastroenterology Clinics of North America (USA) , 1995, 24/3 (541-558)
CODEN: GCNAE ISSN: 0889-8553
LANGUAGES: English SUMMARY LANGUAGES: English

13/3/26 (Item 13 from file: 72)
DIALOG(R)File 72:EMBASE
(c) 1997 Elsevier Science B.V. All rts. reserv.

9724110 EMBASE No: 95280744
New therapeutic approaches
Hanauer S.B.; Schulman M.I.
University of Chicago Medical Center, 5841 S Maryland Avenue, Chicago, IL

60637 USA

Gastroenterology Clinics of North America (USA) , 1995, 24/3 (523-540)
CODEN: GCNAE ISSN: 0889-8553
LANGUAGES: English SUMMARY LANGUAGES: English

13/3/27 (Item 14 from file: 72)
DIALOG(R)File 72:EMBASE
(c) 1997 Elsevier Science B.V. All rts. reserv.

9666929 EMBASE No: 95195674
Inflammatory bowel disease therapy: An update
Shah S.A.; Peppercorn M.A.
Division of Gastroenterology, Department of Medicine, Beth Israel
Hospital, 330 Brookline Avenue, Boston, MA 02215 USA
Comprehensive Therapy (USA) , 1995, 21/6 (296-302) CODEN: COTHD ISSN:
0098-8243
LANGUAGES: English SUMMARY LANGUAGES: English

13/3/28 (Item 15 from file: 72)
DIALOG(R)File 72:EMBASE
(c) 1997 Elsevier Science B.V. All rts. reserv.

9638871 EMBASE No: 95184236
Immunosuppressive therapy of inflammatory bowel disease: A historical
perspective
Korelitz B.I.
Section of Gastroenterology, Department of Medicine, Lenox Hill Hospital,
New York, NY 10021 USA
Gastroenterologist (USA) , 1995, 3/2 (141-152) CODEN: GASTF ISSN:
1065-2477
LANGUAGES: English SUMMARY LANGUAGES: English

13/3/29 (Item 16 from file: 72)
DIALOG(R)File 72:EMBASE
(c) 1997 Elsevier Science B.V. All rts. reserv.

9615750 EMBASE No: 95173118
Clinical treatment of inflammatory bowel disease related to the severity
of the complaint
TRATAMIENTO CLINICO DE LAS ENFERMEDADES INTESTINALES INFLAMATORIAS SEGUN
LA GRAVEDAD DEL CUADRO. NUEVOS AGENTES FARMACOLOGICOS TOPICOS Y SISTEMICOS
Rios H.R.; Siccardi R.B.
Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires
Argentina
Prensa Medica Argentina (Argentina) , 1995, 82/3 (247-265) CODEN: PMARA
ISSN: 0032-745X
LANGUAGES: Spanish SUMMARY LANGUAGES: English; Spanish

13/3/30 (Item 17 from file: 72)
DIALOG(R)File 72:EMBASE
(c) 1997 Elsevier Science B.V. All rts. reserv.

9538360 EMBASE No: 95101213
Immunosuppressive therapy in inflammatory bowel disease

Hoang P.; Fontaine P.; Dalton H.R.; Gehenot M.; Sibille C.; Schoonbroodt D.; Vanheuverzwyn R.

Cliniques Saint-Luc, Service de Gastroenterologie, Av. Hippocrate 10, 1200 Bruxelles Belgium

Acta Gastro-Enterologica Belgica (Belgium) , 1994, 57/5-6 (333-338)

CODEN: AGEBA ISSN: 0001-5644

LANGUAGES: English SUMMARY LANGUAGES: English

13/3/31 (Item 18 from file: 72)

DIALOG(R)File 72:EMBASE

(c) 1997 Elsevier Science B.V. All rts. reserv.

9396174 EMBASE No: 94326077

Treatment of adult Crohn's disease

TRAITEMENT DE LA MALADIE DE CROHN DE L'ADULTE

Bellanger J.; Cosnes J.; Gendre J.P.; Beaugerie L.; Malafosse M.; Le Quintrec Y.

Service de Gastroenterologie, de Nutrition, Hopital Rothschild, 33, Boulevard de Picpus, 75012 Paris France

REV. MED. INTERNE (France) , 1994, 15/10 (676-689) CODEN: RMEID ISSN: 0248-8663

LANGUAGES: French SUMMARY LANGUAGES: French; English

13/3/32 (Item 19 from file: 72)

DIALOG(R)File 72:EMBASE

(c) 1997 Elsevier Science B.V. All rts. reserv.

9358722 EMBASE No: 94292976

Update in medical treatment of inflammatory bowel disease

Papatheodoridis G.V.; Karamanolis D.G.

Greece

HELL. J. GASTROENTEROL. (Greece) , 1994, 7/2 (149-162) CODEN: ELGAE
ISSN: 1012-0424

LANGUAGES: Greek SUMMARY LANGUAGES: Greek; English

13/3/33 (Item 20 from file: 72)

DIALOG(R)File 72:EMBASE

(c) 1997 Elsevier Science B.V. All rts. reserv.

9220992 EMBASE No: 94159335

Therapy of chronic enteritis. Part II. Indications for therapy

THERAPIE CHRONISCH ENTZUNDLICHER DARMERKRANKUNGEN (TEIL II) NEUES RICHTIG INDIZIERT!

Press A.G.; Ramadori G.

Medizinische Klinik, Abt. Gastroenterol./Endokrinologie, Georg-August-Universitat, Postfach 3742, 37070 Gottingen Germany

THERAPIEWOCHE (Germany) , 1994, 44/17 (962-970) CODEN: THEWA ISSN: 0040-5973

LANGUAGES: German SUMMARY LANGUAGES: German; English

13/3/34 (Item 21 from file: 72)

DIALOG(R)File 72:EMBASE

(c) 1997 Elsevier Science B.V. All rts. reserv.

9112349 EMBASE No: 94061551

Salicylates, steroids and immunosuppressants in Crohn's disease

Buckley M.; O'Morain C.

Department of Gastroenterology, Meath-Adelaide Hospitals, Trinity College, Dublin Ireland

EUR. J. GASTROENTEROL. HEPATOL. (United Kingdom) , 1994, 6/2 (85-92)

CODEN: EJGHE ISSN: 0954-691X

LANGUAGES: English SUMMARY LANGUAGES: English

13/3/35 (Item 22 from file: 72)

DIALOG(R)File 72:EMBASE

(c) 1997 Elsevier Science B.V. All rts. reserv.

9076461 EMBASE No: 94001187

Review on inflammatory bowel disease: Crohn disease and ulcero-hemorrhagic recto-colitis

MISE AU POINT ACTUALISEE SUR LES MALADIES INTESTINALES INFLAMMATOIRES (MII): MALADIE DE CROHN ET RECTO-COLITE ULCERO-HEMORRAGIQUE

Fontaine F.; Brassinne A.; Delforge M.; Demoulin J.C.; Dreze C.; Gillard V.; Bastens B.

Ctr. Hosp. Saint-Joseph-Esperance, Rue de Hesbaye, 75, 4000 Liege Belgium

REV. MED. LIEGE (Belgium) , 1993, 48/11 (593-618) CODEN: RMLIA ISSN: 0035-3663

LANGUAGES: French SUMMARY LANGUAGES: French

13/3/36 (Item 23 from file: 72)

DIALOG(R)File 72:EMBASE

(c) 1997 Elsevier Science B.V. All rts. reserv.

9034434 EMBASE No: 93336906

A pathogenetically substantiated treatment for chronic inflammatory bowel disease - Does it come into view?

IST EINE PATHOGENETISCHE BEGRUNDETE THERAPIE DER CHRONISCH-ENTZUNDLICHEN DARMERKRANKUNGEN IN SICHT?

Miller B.

Medizinische Klinik II, St. Johannes-Hospital, An der Abtei 7-11, D-47166 Duisburg Germany

Z. GASTROENTEROL. (Germany) , 1993, 31/SUPPL. 5 (30-34) CODEN: ZGASA ISSN: 0044-2771

LANGUAGES: German

13/3/37 (Item 24 from file: 72)

DIALOG(R)File 72:EMBASE

(c) 1997 Elsevier Science B.V. All rts. reserv.

8984119 EMBASE No: 93287851

Treatment of inflammatory bowel disease: Present status and perspectives

TRAITEMENT DES MALADIES INFLAMMATOIRES: ETAT ACTUEL ET PERSPECTIVES

Lemann M.

Service de Gastro-Enterologie, Hopital Saint-Louis, 1, Rue Claude-Vellefaux, 75010 Paris France

MED. SCI. (France) , 1993, 9/8-9 (875-883) CODEN: MSMSE ISSN: 0767-0974

LANGUAGES: French SUMMARY LANGUAGES: French; English

13/3/38 (Item 25 from file: 72)
DIALOG(R)File 72:EMBASE
(c) 1997 Elsevier Science B.V. All rts. reserv.

8870463 EMBASE No: 93174194
The treatment of inflammatory bowel disease (IBD)
TERAPIA DELLE MALATTIE INFIAMMATORIE INTESTINALI
Impicciatore P.
RIC. PRAT. (Italy) , 1993, -/50 (43-49) CODEN: RIPRE ISSN: 1120-379X
LANGUAGES: Italian SUMMARY LANGUAGES: English

13/3/39 (Item 26 from file: 72)
DIALOG(R)File 72:EMBASE
(c) 1997 Elsevier Science B.V. All rts. reserv.

8827007 EMBASE No: 93130723
Diagnosis and medical management of Crohn's disease and ulcerative
colitis in children
Kirschner B.S.
Department of Pediatrics, Wyler Children's Hospital, University of
Chicago, 5825 South Maryland Avenue, Chicago, IL 60637 USA
PROBL. GEN. SURG. (USA) , 1993, 10/1 (16-32) CODEN: PGSUE ISSN:
0739-8328
LANGUAGES: English SUMMARY LANGUAGES: English

13/3/40 (Item 27 from file: 72)
DIALOG(R)File 72:EMBASE
(c) 1997 Elsevier Science B.V. All rts. reserv.

8688690 EMBASE No: 92369306
Medical therapy in Crohn's disease
Rogers A.I.; Coelho-Borges S.
Veterans Affairs Medical Center, 1201 NW 16th St, Miami, FL 33125 USA
POSTGRAD. MED. (USA) , 1992, 92/8 (169-171+173+177-178+186) CODEN: POMDA
ISSN: 0032-5481
LANGUAGES: English

13/3/41 (Item 28 from file: 72)
DIALOG(R)File 72:EMBASE
(c) 1997 Elsevier Science B.V. All rts. reserv.

8629716 EMBASE No: 92305625
Drug therapy of inflammatory bowel disease, part II: Patient management
recommendations
Peppercorn M.A.
Division of Gastroenterology, Inflammatory Bowel Disease Center, Beth
Israel Hospital, Boston, MA USA
DRUG THER. (USA) , 1992, 22/9 (43-48+53) CODEN: DRTHE ISSN: 0001-7094
LANGUAGES: English SUMMARY LANGUAGES: English

13/3/42 (Item 29 from file: 72)
DIALOG(R)File 72:EMBASE

(c) 1997 Elsevier Science B.V. All rts. reserv.

8629715 EMBASE No: 92305624

Drug therapy of inflammatory bowel disease, part I: Newer therapeutic agents

Peppercorn M.A.

Division of Gastroenterology, Inflammatory Bowel Disease Center, Beth Israel Hospital, Boston, MA USA

DRUG THER. (USA) , 1992, 22/9 (23-24+36-48+41-42) CODEN: DRTHE ISSN: 0001-7094

LANGUAGES: English SUMMARY LANGUAGES: English

13/3/43 (Item 30 from file: 72)

DIALOG(R)File 72:EMBASE

(c) 1997 Elsevier Science B.V. All rts. reserv.

8607019 EMBASE No: 92283129

New developments in the pharmacotherapy of inflammatory bowel disease
Harting J.W.

Oosterschelde Hospital Foundation, Goes Netherlands

PHARM. WEEKBL. SCI. ED. (Netherlands) , 1992, 14/4 A (275-286) CODEN: PWSED ISSN: 0167-6555

LANGUAGES: English SUMMARY LANGUAGES: English

13/3/44 (Item 31 from file: 72)

DIALOG(R)File 72:EMBASE

(c) 1997 Elsevier Science B.V. All rts. reserv.

8584285 EMBASE No: 92260203

Drug therapy for inflammatory bowel disease: Part II

Linn F.V.; Peppercorn M.A.

Gastroenterology Division, Department of Medicine, Beth Israel Hospital, 330 Brookline Avenue, Boston, MA 02215 USA

AM. J. SURG. (USA) , 1992, 164/2 (178-185) CODEN: AJSUA ISSN: 0002-9610

LANGUAGES: English SUMMARY LANGUAGES: English

13/3/45 (Item 32 from file: 72)

DIALOG(R)File 72:EMBASE

(c) 1997 Elsevier Science B.V. All rts. reserv.

8545482 EMBASE No: 92221362

Medical treatment of inflammatory bowel disease

Campieri M.; Gionchetti P.; Belluzzi A.; Brignola C.; Miglioli M.; Barbara L.

Ist Clinica Medica Gastroenterologia, University of Bologna, Policlinico S. Orsola, via Massarenti 9, 40138 Bologna Italy

CURR. OPIN. GASTROENTEROL. (United Kingdom) , 1992, 8/4 (663-675)
CODEN: COGAE ISSN: 0267-1379

LANGUAGES: English SUMMARY LANGUAGES: English

13/3/46 (Item 33 from file: 72)

DIALOG(R)File 72:EMBASE

(c) 1997 Elsevier Science B.V. All rts. reserv.

8174552 EMBASE No: 91203864
Risk-benefit assessment of drugs used in the treatment of inflammatory
bowel disease
Hanauer S.B.; Stathopoulos G.
Section of Gastroenterology, Department of Medicine, University of
Chicago Medical Center, 5841 South Maryland Avenue, Chicago, IL 60637 USA
DRUG SAF. (New Zealand) , 1991, 6/3 (192-219) CODEN: DRSAE ISSN:
0114-5916
LANGUAGES: English

13/3/47 (Item 34 from file: 72)
DIALOG(R)File 72:EMBASE
(c) 1997 Elsevier Science B.V. All rts. reserv.

7603845 EMBASE No: 90030920
Newer pharmacologic agents for the therapy of inflammatory bowel disease
Ruderman W.B.
Department of Gastroenterology, Cleveland Clinic Florida, 3000 W. Cypress
Creek Road, Fort Lauderdale, FL 33309 USA
MED. CLIN. NORTH AM. (USA) , 1990, 74/1 (133-153+viii) CODEN: MCNAA
ISSN: 0025-7125
LANGUAGES: English

13/3/48 (Item 35 from file: 72)
DIALOG(R)File 72:EMBASE
(c) 1997 Elsevier Science B.V. All rts. reserv.

7597758 EMBASE No: 90026712
Advances in drug therapy for inflammatory bowel disease
Peppercorn M.A.
Beth Israel Hospital, 330 Brookline Avenue, Boston, MA 02115 USA
ANN. INTERN. MED. (USA) , 1990, 112/1 (50-60) CODEN: AIMEA ISSN:
0003-4819
LANGUAGES: English

13/3/49 (Item 36 from file: 72)
DIALOG(R)File 72:EMBASE
(c) 1997 Elsevier Science B.V. All rts. reserv.

6217267 EMBASE No: 86212330
Interim report of clinical studies presented at the International
Symposium on Ciclosporin in Auto-Immune Diseases, Basel, March 18-20, 1985
Schmitz-Schumann M.
Hochebirgsklinik, CH-7265 Davos-Wolfgang SWITZERLAND
PROG. ALLERGY (SWITZERLAND) , 1986, VOL. 38 (436-446) CODEN: PRALA
LANGUAGES: ENGLISH

13/3/50 (Item 1 from file: 154)
DIALOG(R)File 154:MEDLINE(R)
(c) format only 1997 Knight-Ridder Info. All rts. reserv.

09612048 96133648
Methotrexate for inflammatory bowel disease: pharmacology and preliminary

results [see comments]

Egan LJ; Sandborn WJ

Inflammatory Bowel Disease Clinic, Mayo Clinic Rochester, MN 55905, USA.

Mayo Clin Proc (UNITED STATES) Jan 1996, 71 (1) p69-80, ISSN

0025-6196 Journal Code: LLY

Comment in Mayo Clin Proc 1996 Jan;71(1):104-5

Languages: ENGLISH

Document type: JOURNAL ARTICLE; REVIEW; REVIEW, TUTORIAL

13/3/51 (Item 2 from file: 154)

DIALOG(R)File 154:MEDLINE(R)

(c) format only 1997 Knight-Ridder Info. All rts. reserv.

09500222 96021822

[Methotrexate treatment in non-cancerous disorders]

Traitement par methotrexate en dehors des affections cancéreuses.

Cogan E

Service de Medecine Interne, Hopital Erasme, Bruxelles.

Rev Med Brux (BELGIUM) Jul-Aug 1995, 16 (4) p300-3, ISSN 0035-3639

Journal Code: SLK

Languages: FRENCH Summary Languages: ENGLISH

Document type: JOURNAL ARTICLE English Abstract

13/3/52 (Item 3 from file: 154)

DIALOG(R)File 154:MEDLINE(R)

(c) format only 1997 Knight-Ridder Info. All rts. reserv.

09149181 95079181

Immunosuppressive drugs in Crohn's disease.

Kornbluth A; George J; Sachar DB

Mount Sinai School of Medicine, City University, New York, NY.

Gastroenterologist (UNITED STATES) Sep 1994, 2 (3) p239-46, ISSN

1065-2477 Journal Code: B3Q

Languages: ENGLISH

Document type: JOURNAL ARTICLE; REVIEW; REVIEW, TUTORIAL

?

PLEASE ENTER A COMMAND OR BE LOGGED OFF IN 5 MINUTES

?ds

Set	Items	Description
S1	426	METHOTREXATE AND (TNF OR TUMOR(W) NECROSIS(W) FACTOR?)
S2	145	S1 AND (CROHN? OR ARTHRITIS)
S3	108	RD S2 (unique items)
S4	116	S1 AND (INFLAMMAT? OR AUTOIMMUN?)
S5	93	RD S4 (unique items)
S6	39	(S3 OR S5) AND REVIEW?
S7	39	RD S6 (unique items)
S8	10	S3 AND PY=1991
S9	10	RD S8 (unique items)
S10	4279	METHOTREXATE AND (IMMUNOSUPPRESS?)
S11	119	S10 AND CROHN?
S12	95	RD S11 (unique items)
S13	52	S12 AND REVIEW?
?		

?ds

Set	Items	Description
S1	426	METHOTREXATE AND (TNF OR TUMOR(W) NECROSIS(W) FACTOR?)
S2	145	S1 AND (CROHN? OR ARTHRITIS)
S3	108	RD S2 (unique items)
S4	116	S1 AND (INFLAMMAT? OR AUTOIMMUN?)
S5	93	RD S4 (unique items)
S6	39	(S3 OR S5) AND REVIEW?
S7	39	RD S6. (unique items)
S8	10	S3 AND PY=1991
S9	10	RD S8 (unique items)
S10	4279	METHOTREXATE AND (IMMUNOSUPPRESS?)
S11	119	S10 AND CROHN?
S12	95	RD S11 (unique items)
S13	52	S12 AND REVIEW?

?

PLEASE ENTER A COMMAND OR BE LOGGED OFF IN 5 MINUTES

?s methotraxate and autoimmun?

16 METHOTRAXATE
99100 AUTOIMMUN?

S14 0 METHOTRAXATE AND AUTOIMMUN?

?s methotraxate and arthritis

16 METHOTRAXATE
134379 ARTHRITIS

S15 1 METHOTRAXATE AND ARTHRITIS

?t s15/3/all

15/3/1 (Item 1 from file: 154)

DIALOG(R)File 154:MEDLINE(R)

(c) format only 1997 Knight-Ridder Info. All rts. reserv.

08131483 92269483

[Current concept of the management of rheumatoid arthritis based on the pathogenesis]

Nishioka K

Rheumatology Division, St. Marianna University.

Nippon Rinsho (JAPAN) Mar 1992, 50 (3) p629-36, ISSN 0047-1852

Journal Code: KIM

Languages: JAPANESE Summary Languages: ENGLISH

Document type: JOURNAL ARTICLE; REVIEW; REVIEW, TUTORIAL English

Abstract

?t s15/7/all

15/7/1 (Item 1 from file: 154)

DIALOG(R)File 154:MEDLINE(R)

(c) format only 1997 Knight-Ridder Info. All rts. reserv.

08131483 92269483

[Current concept of the management of rheumatoid arthritis based on the pathogenesis]

Nishioka K

Rheumatology Division, St. Marianna University.

Nippon Rinsho (JAPAN) Mar 1992, 50 (3) p629-36, ISSN 0047-1852
Journal Code: KIM

Languages: JAPANESE Summary Languages: ENGLISH

Document type: JOURNAL ARTICLE; REVIEW; REVIEW, TUTORIAL English
Abstract

A new therapeutic concept for the management of rheumatoid arthritis (RA) is strongly required since most traditional methods have failed to introduce remission. This paper attempted to review over novel therapeutic approaches based on the advanced program especially on early stage of RA. Clinical improvement has been observed with tripple combined therapy using such as bucillamine, methotraxate, and sufphasulzopyridine. However, more basic therapeutic program would be required based on the pathogenesis of RA. Here the future development of therapeutic approach including targetting immunosuppression or gene targetting on proliferated synovium has been discussed. (23 Refs.)

?